https://www.iqanda-cme.com/ 2026-02-10T20:26:56+0000 weekly 1 https://www.iqanda-cme.com/about-iqanda-nipt-in-twin-pregnancies 2018-12-20T03:18:14+0000 weekly 0.8 https://www.iqanda-cme.com/primary-care 2019-07-11T22:57:09+0000 weekly 0.8 https://www.iqanda-cme.com/test 2019-08-14T01:02:26+0000 weekly 0.8 https://www.iqanda-cme.com/genomisches-profiling-genomic-profiling-german 2019-06-06T17:44:36+0000 weekly 0.8 https://www.iqanda-cme.com/iqanda-glycemic-regulation 2019-09-07T01:00:12+0000 weekly 0.8 https://www.iqanda-cme.com/test2 2024-12-18T22:08:53+0000 weekly 0.8 https://www.iqanda-cme.com/about-iqanda-ngs-and-genomic-profiling 2018-12-20T03:17:10+0000 weekly 0.8 https://www.iqanda-cme.com/iqanda-genomic-profiling 2019-07-11T22:28:57+0000 weekly 0.8 https://www.iqanda-cme.com/profilazione-genomica-genomic-profiling-italian 2019-01-05T02:33:04+0000 weekly 0.8 https://www.iqanda-cme.com/about-iqanda-interventional-cardiology 2019-08-02T00:24:57+0000 weekly 0.8 https://www.iqanda-cme.com/iqanda-arthritis 2019-07-11T21:48:41+0000 weekly 0.8 https://www.iqanda-cme.com/submit-a-question 2019-05-08T19:49:10+0000 weekly 0.8 https://www.iqanda-cme.com/perfil-gen-mico-genomic-profiling-portuguese 2019-01-05T02:34:18+0000 weekly 0.8 https://www.iqanda-cme.com/ngs-and-genomic-profiling 2019-09-07T01:11:02+0000 weekly 0.8 https://www.iqanda-cme.com/iqanda-cardiovascular 2019-07-11T22:01:32+0000 weekly 0.8 https://www.iqanda-cme.com/iqanda-diabetes 2019-07-11T22:01:58+0000 weekly 0.8 https://www.iqanda-cme.com/perfil-gen-mico-genomic-profiling-spanish 2019-01-05T02:35:19+0000 weekly 0.8 https://www.iqanda-cme.com/about-iqanda-rheumatoid-arthritis 2018-12-20T03:19:33+0000 weekly 0.8 https://www.iqanda-cme.com/iqanda-diagnostic-medicine 2019-07-11T22:28:21+0000 weekly 0.8 https://www.iqanda-cme.com/biosimilars-for-ra 2019-06-07T03:54:28+0000 weekly 0.8 https://www.iqanda-cme.com/iqanda-pain-management 2019-09-07T00:59:19+0000 weekly 0.8 https://www.iqanda-cme.com/iqanda-cancer 2025-04-10T19:46:57+0000 weekly 0.8 https://www.iqanda-cme.com/prenatal-screening 2019-06-01T17:12:11+0000 weekly 0.8 https://www.iqanda-cme.com/pcsk9-use-in-diabetes-management 2019-03-29T23:07:34+0000 weekly 0.8 https://www.iqanda-cme.com/about-iqanda-prenatal-screening 2018-12-20T03:19:08+0000 weekly 0.8 https://www.iqanda-cme.com/about-iqanda-genomics-in-cancer 2018-12-20T03:16:19+0000 weekly 0.8 https://www.iqanda-cme.com/prenatal-screening1 2019-07-11T22:55:54+0000 weekly 0.8 https://www.iqanda-cme.com/interventional-cardiology 2019-06-06T17:45:01+0000 weekly 0.8 https://www.iqanda-cme.com/nipt-in-twin-pregnancies 2019-01-05T02:26:12+0000 weekly 0.8 https://www.iqanda-cme.com/iqanda-cardiology 2019-12-11T20:51:37+0000 weekly 0.8 https://www.iqanda-cme.com/about-iqanda-genomic-profiling 2018-12-20T03:15:53+0000 weekly 0.8 https://www.iqanda-cme.com/rheumatiod-arthritis 2019-08-29T22:19:45+0000 weekly 0.8 https://www.iqanda-cme.com/iqanda-genomics-in-cancer 2019-06-06T17:44:25+0000 weekly 0.8 https://www.iqanda-cme.com/about-iqanda-pain-management 2019-08-19T15:49:15+0000 weekly 0.8 https://www.iqanda-cme.com/thrombosis 2019-07-11T22:59:08+0000 weekly 0.8 https://www.iqanda-cme.com/about-iqanda-biosimilars-for-ra 2019-03-19T23:38:12+0000 weekly 0.8 https://www.iqanda-cme.com/biologics 2025-04-10T19:51:42+0000 weekly 0.8 https://www.iqanda-cme.com/dermatology 2025-04-10T19:47:35+0000 weekly 0.8 https://www.iqanda-cme.com/about-iqanda-t2d-and-cv-outcomes 2019-03-08T00:51:02+0000 weekly 0.8 https://www.iqanda-cme.com/pulmonology 2026-02-10T20:25:20+0000 weekly 0.8 https://www.iqanda-cme.com/about-iqanda-glycemic-regulation 2018-12-20T03:16:45+0000 weekly 0.8 https://www.iqanda-cme.com/iqanda-genomic-profiling-english 2019-09-07T01:13:10+0000 weekly 0.8 https://www.iqanda-cme.com/t2d-and-cv-outcomes 2019-09-07T01:10:00+0000 weekly 0.8 https://www.iqanda-cme.com/videos/which-patients-in-your-view-based-on-the-odyssey-outcomes-and-fourier-trials-do-you-want-to-drive-below-the-ldl-c-threshold-of-70-mg/dl-what-is-your-rationale-and-how-do-you-select-your-patients-and-achieve-your-targets-in-the-real-world 2019-03-19T18:45:03+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-you-see-the-benefit/safety-risk-equation-shaping-up-for-pcsk9-inhibitors-based-on-the-fourier-and-most-recently-the-odyssey-outcomes-trial 2019-03-20T16:44:04+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-your-analysis-of-the-two-major-cv-outcome-trials-and-from-a-mortality-end-point-perspective-in-what-way-do-mortality-outcome-end-points/results-distinguish-the-odyssey-outcomes-trial-with-alirocumab 2019-03-19T05:46:53+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-patients-requiring-down-titration-of-their-statins-due-to-muscle-discomfort/pain-what-is-the-trigger-point-for-moving-beyond-statins-to-consider-pcsk9-inhibitors 2019-03-19T19:22:34+0000 weekly 0.8 https://www.iqanda-cme.com/videos/given-the-new-aha-guidelines-and-the-anticipation-of-new-esc-guidelines-in-2019-what-is-your-view-about-ldl-c-level-target-thresholds-vs-degree-of-ldl-c-reduction-what-level-do-you-consider-optimal-in-high-risk-patients-with-progressive- 2019-03-19T17:26:17+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-the-perspective-of-a-lipid-specialist-especially-in-light-of-the-associated-all-cause-mortality-reductions-reported-in-odyssey-outcomes-how-should-the-clinician-be-thinking-about-pcsk9-inhibitors-as-a-tool-in-their-day-to-day-practi 2019-03-20T00:58:16+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-the-subpopulation-of-high-risk-patients-individuals-with-post-acs-patients-with-diabetes-post-pci-and-others-is-there-enough-compelling-evidence-from-the-pcsk9-trials-that-the-ldl-hypothesis-is-a-proven-fact 2019-03-19T23:28:52+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-true-incidence-of-statin-intolerance-and-how-do-you-diagnose-it-and-what-is-your-approach-to-re-challenge-and-titration-with-other-statins-and-where-do-alirocumab-and-evolocumab-fit-into-the-statin-intolerance-treatment-plan3 2019-03-19T22:38:15+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-is-down-titration-from-a-high-intensity-statin-dose-potentially-problematic-and-what-are-the-pragmatic-implications-as-they-relate-to-pcsk9-inhibitor-use-in-patients-who-cannot-achieve-optimal-cv-reduction-with-statin-therapy 2019-03-20T16:19:07+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-the-setting-of-a-medical-cardiology-practice-to-what-extent-is-statin-induced-muscle-intolerance-an-important-cause-of-poor-statin-adherence-increased-healthcare-costs-and-increased-cardiac-event-rates 2019-03-20T16:22:44+0000 weekly 0.8 https://www.iqanda-cme.com/videos/do-you-use-different-ldl-c-levels-in-persons-with-diabetes-to-justify-initiation-of-pcsk9-inhibitors-is-the-presence-of-acs-required-or-symptomatic-ascvd-required-to-triage-them-into-pcsk9-based-treatment 2019-03-20T01:09:20+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-unmet-need-for-residual-cv-risk-reduction-in-post-acs-patients-with-t2d-in-your-role-as-a-member-of-the-ldl-guideline-group-for-aace-what-were-the-implications-of-treating-diabetic-patients-with-so-called-extreme-risk 2019-03-19T20:31:07+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-should-the-2018-aha-guidelines-for-ldl-c-that-specify-target-levels-for-high-risk-patients-impact-our-approach-to-selecting-therapies-including-pcsk9-inhibitors-that-have-the-potential-to-lower-ldl-c-to-levels-far-lower-than-those-re 2019-03-19T18:18:53+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-would-your-approach-be-to-a-57-year-old-man-with-an-ldl-c-of-70-mg/dl-who-has-recently-had-an-acs-event-and-now-develops-recurrent-acs-or-a-new-stent-thrombosis-does-odyssey-outcomes-provide-any-evidence-based-guidance 2019-03-19T23:35:14+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-have-the-trifecta-of-recent-developments-associated-all-cause-mortality-reduction-reported-in-odyssey-outcomes-price-reduction-of-pcsk9-inhibitors-and-new-aha-guidelines-affected-your-approach-to-deploying-these-agents-at-the-front-l 2019-03-20T16:12:19+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-did-we-learn-specifically-about-the-population-of-patients-with-post-acs-and-t2d-who-were-treated-with-alirocumab-in-the-odyssey-outcomes-trial 2019-03-19T05:48:36+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-a-lipid-medicine-and-preventive-cardiovascular-perspective-how-do-you-triage-the-diabetic-patient-with-acs-into-a-pcsk9-based-treatment-strategy-for-ldl-c-reduction 2019-03-20T01:05:24+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-a-lipid-specialist-s-perspective-do-the-results-from-the-odyssey-outcomes-trial-suggest-the-need-to-be-more-focused-on-achieving-absolute-target-levels-of-ldl-c-or-relative-percentage-reductions-in-ldl-c-levels 2019-03-20T21:21:03+0000 weekly 0.8 https://www.iqanda-cme.com/videos/the-iqanda-interactive-medical-intelligence-zone-for-diabetes-mangement 2019-05-22T23:14:36+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-current-challenges-and-protocols-in-europe-for-making-pcsk9-inhibitors-an-easily-reimbursable-mainstream-approach-to-managing-patients-with-require-secondary-prevention-for-their-high-risk-ascvd 2019-03-19T17:32:37+0000 weekly 0.8 https://www.iqanda-cme.com/videos/the-iqanda-interactive-medical-intelligence-zone-for-pain-management 2019-05-23T01:07:52+0000 weekly 0.8 https://www.iqanda-cme.com/videos/now-with-the-publication-of-odyssey-outcomes-which-demonstrated-an-associated-all-cause-mortality-reduction-benefit-how-do-you-view-the-foundational-role-of-pcsk9-inhibitors-in-the-cv-risk-treatment-plan-for-high-risk-patient-populations 2019-03-20T00:52:27+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-risks-of-failing-to-lower-ldl-c-levels-to-aha-or-esc-guideline-mandated-thresholds 2019-03-19T22:40:18+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-you-recommend-that-clinicians-directly-and-immediately-apply-the-results-of-the-cv-outcome-trials-with-alirocumab-and-evolocumab-directly-to-the-front-lines-of-medical-cardiology-practice 2019-03-19T23:02:45+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-a-safety-perspective-how-do-you-counsel-your-patients-in-whom-you-are-beginning-pcsk9-inhibitor-therapy 2019-03-20T16:46:18+0000 weekly 0.8 https://www.iqanda-cme.com/videos/you-have-identified-the-challenges-of-accessing-pcsk9-inhibitors-for-patients-whose-cv-risk-is-genetic-vs-those-whose-clinical-course-is-characterized-by-progressive-vascular-events-how-do-you-approach-each-subset-with-respect-to-ldl-c-m 2019-03-20T16:53:31+0000 weekly 0.8 https://www.iqanda-cme.com/videos/the-iqanda-interactive-medical-intelligence-zone-for-glycemic-regulation 2019-05-22T21:45:15+0000 weekly 0.8 https://www.iqanda-cme.com/videos/does-the-presence-of-a-stent-in-the-setting-of-acs-color-your-approach-to-the-degree-of-ldl-c-reduction-you-would-pursue 2019-03-19T17:21:06+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-your-framing-of-aggregate-ascvd-risk-as-a-stimulant-to-extremely-aggressive-ldl-c-lowering-what-clinical-signature-should-compel-the-general-cardiologist-to-translate-the-results-with-alirocumab-in-odyssey-outcomes-to-the-front-lines 2019-03-20T16:08:56+0000 weekly 0.8 https://www.iqanda-cme.com/videos/although-the-aha-guidelines-identify-a-70-mg/dl-threshold-target-for-patients-at-high-risk-for-recurrent-acs-do-you-believe-this-is-merely-a-starting-point-identifying-a-minimal-level-of-ldl-c-goal-attainment 2019-03-19T18:06:35+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-you-recommend-managing-the-patient-who-has-a-major-cv/thrombotic-event-a-recent-mi-who-is-on-a-statin-and-has-an-ldl-c-level-of-60-70-mg/dl-how-does-the-odyssey-outcome-trial-and/or-ivus-studies-help-you-assess-the-role-of-a-pcsk9 2019-03-20T16:25:14+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-large-is-the-subgroup-of-diabetic-patients-who-you-feel-are-likely-to-appropriate-candidates-for-pcsk9-inhibition-to-optimize-cv-risk-reduction-and-how-does-the-lack-of-a-safety-signal-influence-your-recommendations-for-this-group 2019-03-19T05:47:28+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-a-medical-cardiologist-s-perspective-which-patient-subgroups-in-your-practice-do-you-feel-represent-ideal-candidates-for-deployment-of-pcsk9-inhibitors-to-lower-ldl-c-levels-based-on-the-results-of-the-odyssey-outcomes-and-fourier-t 2019-03-20T16:31:08+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-does-the-pharmacoeconomic-landscape-currently-look-like-for-pcsk9-inhibition-especially-in-light-of-the-recent-price-reductions-for-alirocumab-and-evolocumab 2019-03-20T00:48:54+0000 weekly 0.8 https://www.iqanda-cme.com/videos/should-lipidologists-consider-other-markers-such-as-apob-as-well-as-ldl-c-for-reducing-cv-risk-in-diabetes-and-hypertriglyceridemia 2019-03-19T19:27:38+0000 weekly 0.8 https://www.iqanda-cme.com/videos/as-a-leading-authority-in-ldl-c-mediated-cv-risk-reduction-can-you-provide-us-with-your-perspective-on-the-evidence-for-pcsk9-inhibitors-as-a-foundational-approach-for-managing-a-broad-spectrum-of-patients-with-high-risk-coronary-heart-d 2019-03-19T17:07:36+0000 weekly 0.8 https://www.iqanda-cme.com/videos/to-what-degree-have-you-observed-statin-intolerance-or-resistance-in-patients-with-high-risk-cad-what-protocol-do-you-employ-to-mitigate-and/or-manage-statin-intolerance-where-does-the-pcsk9-inhibitor-fit-into-your-sequencing-strategy 2019-03-19T21:30:03+0000 weekly 0.8 https://www.iqanda-cme.com/videos/with-the-results-of-odyssey-outcomes-and-the-more-attractive-pricing-for-pcsk9-inhibitors-how-do-you-now-see-the-landscape-for-this-therapy-especially-in-the-context-of-the-lipid-medicine/atherosclerosis-specialist-and-the-preventive-car 2019-03-20T21:14:15+0000 weekly 0.8 https://www.iqanda-cme.com/videos/based-on-the-odyssey-outcomes-trial-which-enrolled-primarily-patients-with-post-acs-which-subset-of-patients-managed-in-a-medical-cardiology-practice-should-be-thoroughly-evaluated-for-cv-risk-reduction-benefits-accruing-to-pcsk9-inhibit 2019-03-19T23:08:51+0000 weekly 0.8 https://www.iqanda-cme.com/videos/the-iqanda-interactive-precision-cancer-intelligence-zone 2019-05-17T18:15:28+0000 weekly 0.8 https://www.iqanda-cme.com/videos/as-a-lead-investigator-for-both-fh-and-ascvd-focused-trials-evaluating-pcsk9-inhibitors-what-is-your-interpretation-of-the-data-confirming-regimen-adherence-and-compliance-with-these-injectable-agents 2019-03-19T23:56:24+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-a-medical-cardiologist-s-perspective-how-do-the-threshold-setting-targets-of-ldl-c-levels-of-70-mg/dl-apply-to-pcsk9-based-treatment-for-cv-risk-reduction-did-the-guidelines-emphasize-sufficiently-the-results-of-the-cv-outcome-trial 2019-03-19T23:14:25+0000 weekly 0.8 https://www.iqanda-cme.com/videos/based-on-the-results-of-odyssey-outcomes-and-fourier-do-you-recommend-that-clinicians-strive-in-selected-high-risk-populations-to-lower-ldl-c-significantly-lower-than-70-mg/dl 2019-03-20T00:31:49+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-describe-the-actual-clinical-phenotypes-actual-patients-referred-to-you-by-interventional-or-medical-cardiologists-in-which-pcsk9-inhibition-would-represent-a-foundational-approach-to-reduction-of-residual-cv-risk-burden 2019-03-19T05:08:47+0000 weekly 0.8 https://www.iqanda-cme.com/videos/iqanda-for-genomic-profiling 2019-05-28T19:09:35+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-have-recent-pcsk9-trials-affected-your-position-on-the-role-of-intensifying-ldl-c-reductions-to-new-target-levels-and-how-are-they-likely-to-affect-future-global/esc-2019-guidelines-for-ldl-mediated-cv-risk-reduction 2019-03-19T19:13:37+0000 weekly 0.8 https://www.iqanda-cme.com/videos/based-on-odyssey-outcomes-for-which-biological/metabolic-risk-markers-do-you-feel-that-cardiologists-and-atherosclerosis-specialists-should-strive-to-achieve-ldl-c-levels-even-more-aggressive-than-those-identified-in-the-aha-guidelines 2019-03-20T16:56:11+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-principal-concerns-related-to-cv-risk-reduction-in-patients-with-t2d-and-where-does-ldl-c-lowering-with-pcsk9-inhibitors-fit-into-the-clinical-strategy 2019-03-20T00:28:26+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-a-lipid-medicine-and-atherosclerosis-expert-s-perspective-when-you-look-at-the-odyssey-outcomes-and-fourier-trials-what-consistent-or-comparative-message-do-you-take-from-these-investigations-into-the-safety-and-efficacy-of-pcsk9-in 2019-03-19T18:55:05+0000 weekly 0.8 https://www.iqanda-cme.com/videos/based-on-the-odyssey-outcomes-trial-specifically-the-low-ldl-c-levels-achieved-without-adverse-consequences-what-target-level-of-ldl-c-do-you-recommend-in-medically-managed-patients-with-moderate-to-high-risk-features-of-ascvd 2019-03-20T16:32:51+0000 weekly 0.8 https://www.iqanda-cme.com/videos/within-the-context-of-a-medical-cardiology-practice-especially-navigating-among-patients-with-inadequate-responses-to-ezetimibe-and/or-statin-intolerance-or-resistance-how-do-you-sequence-pcsk9-inhibitors-in-your-ldl-c-lowering-treatment 2019-03-20T16:14:51+0000 weekly 0.8 https://www.iqanda-cme.com/videos/as-an-interventional-cardiologist-in-the-uk-what-do-the-results-from-the-odyssey-outcomes-trial-and-price-reductions-mean-to-the-clinician-at-the-front-lines-of-cardiology-care-as-far-as-access-to-and-triggers-for-deploying-a-pcsk9-inhib 2019-03-19T22:14:37+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-cite-specific-patient-types-where-you-are-strongly-inclined-to-use-a-pcsk9-inhibitor-because-achieving-both-significant-percentage-based-reductions-in-ldl-c-level-as-well-as-achieving-an-ldl-c-level-70mg/dl-are-of-critical-import 2019-03-19T18:49:34+0000 weekly 0.8 https://www.iqanda-cme.com/videos/as-a-medical-cardiologist-treating-patients-for-secondary-prevention-of-ascvd-can-you-share-with-us-the-outcomes-and-disease-course-of-patients-you-have-managed-with-pcsk9-inhibitors-has-the-cost-reductions-affected-your-appetite-for-the 2019-03-19T23:26:04+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-specific-ldl-c-related-endpoints-are-likely-to-undergo-review-and-revisions-based-on-the-publication-of-two-pcsk9-related-trials-odyssey-outcomes-and-fourier 2019-03-19T19:31:46+0000 weekly 0.8 https://www.iqanda-cme.com/videos/richard-carvajal-md 2024-12-18T06:28:57+0000 weekly 0.8 https://www.iqanda-cme.com/videos/with-the-odyssey-outcomes-trial-s-favorable-pharmacoeconomic-analysis-now-established-and-a-reduction-in-all-cause-mortality-with-alirocumab-where-do-you-see-the-evidence-based-opportunities-for-these-agents-in-your-practice-setting 2019-03-20T21:16:09+0000 weekly 0.8 https://www.iqanda-cme.com/videos/as-the-cost-and-institutional-barriers-to-deploying-pcsk9-inhibitors-become-less-onerous-which-patients-in-a-medical-cardiology-practice-represent-the-most-attractive-candidates-for-these-agents-and-their-profound-ldl-c-lowering-effects 2019-03-19T22:56:01+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-current-unmet-need-for-cv-risk-reduction-in-general-beyond-ldl-c-level-lowering 2019-03-19T17:34:39+0000 weekly 0.8 https://www.iqanda-cme.com/videos/given-the-new-guidelines-price-reductions-and-the-reduction-in-associated-all-cause-mortality-reported-with-alirocumab-in-odyssey-outcomes-which-patients-should-now-be-embraced-as-plausible-candidates-for-pcsk9-mediated-cv-risk-reduction 2019-03-19T18:28:32+0000 weekly 0.8 https://www.iqanda-cme.com/videos/assuming-the-community-cardiologist-is-able-to-obtain-reimbursement-for-pcsk9-inhibitors-in-what-segment-of-your-patient-population-do-you-think-this-therapy-is-most-under-utilized-how-do-price-reductions-for-these-agents-affect-your-app 2019-03-20T16:35:19+0000 weekly 0.8 https://www.iqanda-cme.com/videos/as-a-program-director-with-a-mandate-to-improve-quality-of-cv-care-how-do-you-see-role-of-pcsk9-inhibitors-in-subspecialty-groups-interventional-cardiologists-medical/preventive-cardiologists-lipidologists/ascvd-and-diabetes-specialists 2019-03-19T23:22:07+0000 weekly 0.8 https://www.iqanda-cme.com/videos/you-have-introduced-the-concept-of-progressive-atherosclerotic-burden-to-characterize-the-multiplicity-of-biologic-metabolic-and-clinical-markers-in-a-cv-risk-profile-how-do-you-apply-this-aggregated-risk-to-patient-selection-for-pcsk9-i 2019-03-20T21:12:27+0000 weekly 0.8 https://www.iqanda-cme.com/videos/given-the-results-of-odyssey-fourier-and-others-as-a-lipid/atherosclerosis-specialist-what-is-your-take-home-about-what-the-appetite-should-be-for-using-pcsk9-inhibitors-to-lower-ldl-c-levels-beyond-esc-and-aha-recommended-thresholds-of- 2019-03-20T00:08:48+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-rationale-for-a-new-category-called-extreme-risk-introduced-by-aace-in-which-they-designate-a-threshold-ldl-c-target-of-55-mg/dl 2019-03-19T05:46:38+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-a-medical-cardiologist-s-perspective-why-is-the-mandate-to-lower-ldl-c-level-so-important-for-reducing-cv-risk-how-low-do-recommend-lowering-the-ldl-c-level-where-do-the-pcsk9-inhibitors-fit-into-the-overall-sequencing-strategy 2019-03-20T00:21:30+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-you-think-you-will-use-the-combination-formulations-in-real-practice-how-will-you-titrate-these-agents 2019-05-22T21:36:07+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-a-patient-centric-clinical-profile-perspective-which-high-risk-burden-patient-populations-do-you-as-an-atherosclerosis-specialist-single-out-for-pcsk9-mediated-ldl-c-reduction 2019-03-19T18:16:39+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-should-the-lipid-specialist-approach-the-individual-with-diabetes-who-doesn-t-yet-have-ascvd 2019-03-19T21:18:19+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-your-lipid-practice-which-patients-with-ascvd-do-you-prioritize-for-pcsk9-mediated-lowering-of-ldl-c-based-on-odyssey-outcomes-what-do-we-know-about-the-subgroup-of-post-acs-patients-who-benefited-most-from-alirocumab 2019-03-20T00:42:41+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-have-the-results-of-odyssey-outcomes-especially-as-they-relate-to-progressive-cv-risk-reductions-in-patients-with-high-ldl-c-levels-who-achieve-target-levels-of-50-mg/dl-or-less-support-the-treat-to-target-approach-to-lipid-managemen 2019-03-19T23:23:59+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-you-see-the-future-of-access-affordability-and-general-utilization-of-pcsk9-inhibitors-as-a-result-of-the-price-reductions-and-results-from-cv-outcome-trials 2019-03-19T22:52:50+0000 weekly 0.8 https://www.iqanda-cme.com/videos/do-you-have-any-safety-concerns-about-driving-ldl-c-levels-to-less-than-50-mg/dl-with-pcsk9-inhibitors 2019-03-20T16:48:31+0000 weekly 0.8 https://www.iqanda-cme.com/videos/which-diabetic-patients-in-particular-should-be-prioritized-for-pcsk9-mediated-cv-risk-reduction 2019-03-20T00:10:17+0000 weekly 0.8 https://www.iqanda-cme.com/videos/the-pcsk9-trials-have-confirmed-a-the-absence-of-a-j-point-curve-for-ldl-c-lowering-and-b-continuing-cv-risk-reduction-even-when-lowering-ldl-c-from-100mg/dl-to-30mg/dl-in-light-of-this-how-should-the-lipid-specialist-deploy-pcsk9-inhibi 2019-03-20T21:18:44+0000 weekly 0.8 https://www.iqanda-cme.com/videos/assuming-optimization-of-patient-outcomes-rather-than-cost-is-the-primary-driver-governing-use-of-pcsk9-inhibitors-which-patients-in-a-medical-cardiology-practice-would-you-single-out-for-this-therapy-and-to-achieve-what-ldl-c-target-lev 2019-03-20T16:37:43+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-the-perspective-of-a-lipid-and-atherosclerosis-specialist-assuming-that-the-barriers-to-pcsk9-inhibitors-are-reduced-which-patients-at-risk-for-or-with-confirmed-ascvd-represent-the-best-risk-directed-candidates-for-ldl-c-lowering 2019-03-19T19:00:10+0000 weekly 0.8 https://www.iqanda-cme.com/videos/the-iqanda-interactive-rheumatoid-arthritis-intelligence 2019-05-22T22:16:20+0000 weekly 0.8 https://www.iqanda-cme.com/videos/at-your-institution-do-you-experience-any-significant-barriers-to-having-prescriptions-authorized-for-alirocumab-or-evolocumab-and-how-have-the-price-reductions-affected-either-your-perception-of-access-to-and/or-reimbursement-for-these- 2019-03-20T00:35:56+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-a-lipid-medicine-specialist-s-perspective-what-would-your-approach-be-to-a-post-acs-patient-with-two-stents-and-triple-vessel-disease-whose-ldl-c-level-is-70-mg/dl 2019-03-20T00:53:32+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-your-perspective-as-a-medical-cardiologist-what-impact-should-the-reductions-in-associated-overall-mortality-reported-with-alirocumab-in-the-odyssey-outcomes-trial-have-on-selecting-a-pcsk9-inhibitor 2019-03-19T23:18:56+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-your-mind-as-a-director-of-a-lipid-clinic-and-preventive-cardiology-center-how-do-you-apply-the-results-of-the-odyssey-outcomes-and-other-trials-in-terms-of-the-lack-of-safety-signals-when-lowering-ldl-c-to-levels-50-mg/dl 2019-03-20T00:53:28+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-specific-patient-types-that-you-manage-in-your-lipid-focused-practice-and-which-are-referred-to-you-for-potential-intervention-with-a-pcsk9-inhibitor-why-are-these-patients-being-referred-to-you-for-pcsk9-mediated-ldl-c-redu 2019-03-19T21:35:50+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-profile-of-the-diabetic-patient-in-whom-the-diabetes-specialist-should-strongly-consider-the-ldl-c-lowering-and-outcome-improving-effects-of-pcsk9-inhibitors-how-do-we-risk-stratify-populations-for-secondary-prevention 2019-03-19T05:47:07+0000 weekly 0.8 https://www.iqanda-cme.com/videos/when-is-70-mg/dl-not-good-enough-is-this-a-threshold-what-clinical-factors-suggest-lower-targets-are-better-what-is-happening-at-the-vascular-biology-level 2019-03-20T15:54:07+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-you-approach-younger-patients-with-known-advanced-subclinical-atherosclerosis 2019-03-19T18:33:09+0000 weekly 0.8 https://www.iqanda-cme.com/videos/where-did-the-70-mg/dl-ldl-c-target-goal-come-from-why-wasn-t-it-set-lower-in-the-guidelines-from-the-outset-for-patients-with-acs 2019-03-19T19:36:28+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-light-of-the-effectiveness-and-safety-in-post-acs-patients-of-the-ultra-low-levels-of-ldl-c-achieved-in-the-odyssey-outcomes-and-fourier-trials-how-has-that-shaped-your-clinical-perspective-on-the-role-of-pcsk9-inhibitors-in-high-risk 2019-03-19T19:18:13+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-should-the-lipid-and-atherosclerosis-disease-specialist-interpret-the-esc-and-aha-guideline-threshold-of-70-mg/dl-ldl-c-level-and-determine-whether-even-lower-levels-are-even-better-to-mitigate-residual-cv-risk 2019-03-20T00:50:34+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-the-lipid-clinic-setting-in-patients-you-have-treated-with-pcsk9-inhibitors-what-are-you-finding-as-far-as-regimen-adherence-toleration-and-patient-engagement/satisfaction-with-these-injectable-strategies 2019-03-19T21:24:02+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-provide-some-specific-examples-of-patients-in-your-general-cardiology-practice-in-whom-you-have-prescribed-pcsk9-inhibitors-and-your-rationale-and-the-evidentiary-basis-for-doing-so-when-does-statin-intolerance-play-a-role 2019-03-20T00:27:40+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-you-view-the-lack-of-current-safety-signals-encountered-in-cv-outcome-trials-with-pcsk9-inhibitors-what-are-the-implications-for-lifelong-use-of-these-agents 2019-03-19T22:49:11+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-percentage-of-patients-have-statin-muscle-intolerance-based-on-the-criteria-you-and-your-colleagues-have-developed-why-is-there-a-disconnect-between-the-prevalence-of-statin-muscle-intolerance-vs-the-results-reported-in-major-trials 2019-03-20T16:20:46+0000 weekly 0.8 https://www.iqanda-cme.com/videos/you-have-made-the-case-for-a-call-to-action-to-treat-ldl-c-very-aggressively-in-diabetic-patients-with-known-ascvd-what-is-your-rationale-for-this-and-how-do-the-recent-rials-support-your-recommendation-to-treat-diabetics-with-ascvd-aggr 2019-03-19T20:28:09+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-should-the-fact-that-cv-risk-is-not-binary-but-progressive-influence-the-decision-to-use-a-pcsk9-inhibitor 2019-03-19T22:11:28+0000 weekly 0.8 https://www.iqanda-cme.com/videos/iqanda-for-prenatal-screening 2019-05-24T18:40:10+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-share-with-us-a-specific-patient-who-has-had-an-acs-event-and-is-post-pci-and-how-you-optimize-cv-risk-reduction-in-the-age-of-pcsk9-mediated-ldl-c-risk-reduction-and-aggressive-ldl-c-lowering 2019-03-19T17:15:11+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-change-in-practice-based-on-the-all-cause-mortality-reduction-reported-in-odyssey-outcomes-do-you-believe-is-warranted-especially-as-these-results-might-impact-the-ldl-c-level-that-should-be-targeted-and-the-duration-of-therapy 2019-03-20T00:59:36+0000 weekly 0.8 https://www.iqanda-cme.com/videos/given-the-reduction-in-both-cv-outcomes-and-associated-all-cause-mortality-are-the-ldl-c-thresholds-currently-recommended-by-the-aha-and-esc-low-enough-and-what-are-the-implications-for-pcsk9-mediated-cv-risk-reduction 2019-03-20T00:57:42+0000 weekly 0.8 https://www.iqanda-cme.com/videos/you-have-noted-that-70-mg/dl-is-the-aha-guideline-threshold-for-the-ldl-c-level-in-high-risk-patients-but-when-in-your-view-is-more-aggressive-lowering-to-levels-such-as-those-observed-in-the-odyssey-outcomes-and-fourier-trials-justified 2019-03-20T16:03:58+0000 weekly 0.8 https://www.iqanda-cme.com/videos/are-you-finding-it-easier-to-get-authorization-for-reimbursement-and-approval-of-pcsk9-inhibitors-now-that-prices-have-come-down-and-we-have-seen-clear-outcome-benefits-in-both-major-trials 2019-03-20T16:50:47+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-are-current-genomic-testing-models-based-on-targeted-sequencing-hot-spot-unsustainable-and-less-effective-than-comprehensive-genomic-profiling-ggp-developed-by-foundationone 2019-05-22T02:29:41+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-you-stratify-your-patients-with-known-ascvd-to-determine-their-eligibility-for-pcsk9-inhibitors-and-are-there-some-patients-that-you-would-characterize-as-ultra-high-risk-and-therefore-requiring-ldl-c-lowering-to-less-than-70-mg/d 2019-03-20T16:42:05+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-a-lipid-specialist-perspective-how-do-you-navigate-the-risk-territory-of-ldl-c-levels-70-mg/dl-with-pcsk9-inhibitors-and-in-which-patient-subgroups-do-these-agents-offer-unique-outcome-related-benefits 2019-03-19T21:08:42+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-the-perspective-of-a-lipid-medicine-specialist-how-do-the-results-of-the-now-published-odyssey-outcomes-trial-and-related-trials-help-you-select-patients-for-pcsk9-mediated-ldl-c-reduction-and-what-targets-do-you-advocate 2019-03-19T21:13:20+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-paint-the-profile-of-the-post-acs-patient-with-t2d-in-whom-the-aggregate-cv-risk-exceeds-a-threshold-that-supports-a-strategy-of-pcsk9-mediated-ldl-c-reduction-in-order-to-achieve-levels-of-less-than-70-mg/dl-or-even-less-than-50 2019-03-20T01:07:53+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-which-of-your-patients-with-fh-do-you-feel-psck9-inhibitors-will-become-foundational-agents-in-conjunction-with-statins-when-tolerated 2019-03-20T00:37:32+0000 weekly 0.8 https://www.iqanda-cme.com/videos/a-confluence-of-events-has-reshaped-the-accessibility-evidence-basis-and-actionability-profile-for-pcsk9-inhibitors-as-an-atherosclerosis-specialist-how-have-these-developments-changed-the-equation-and-shaped-your-approach-to-cv-risk-red 2019-03-19T18:00:59+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-vigorous-should-we-be-in-trying-to-lower-ldl-c-in-patients-who-have-statin-intolerance-what-is-the-role-of-combined-so-called-backbone-statin-treatment-plus-pcsk9-inhibitor-therapy 2019-03-20T00:45:01+0000 weekly 0.8 https://www.iqanda-cme.com/videos/considering-that-younger-persons-are-vulnerable-to-carrying-a-lifelong-atherosclerosis-burden-when-their-ldl-c-levels-are-elevated-how-to-do-approach-them-management-wise 2019-03-20T00:03:52+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-your-experience-deploying-pcsk9-inhibitors-in-the-clinic-and-what-are-the-most-reliable-and-actionable-triggers-for-deploying-this-program-for-cv-risk-reduction-and-predictably-achieving-reimbursement-and-payor-support-for-this-t 2019-03-20T00:44:10+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-should-the-threshold-of-70-mg/dl-identified-in-the-aha-guidelines-mean-to-the-medical-or-preventive-cardiologist-in-his/her-aspiration-to-optimize-cv-risk-reduction-in-high-risk-patients-with-a-history-of-acs-or-related-high-risk-fe 2019-03-19T18:35:57+0000 weekly 0.8 https://www.iqanda-cme.com/videos/new-test-video 2025-11-25T00:44:10+0000 weekly 0.8 https://www.iqanda-cme.com/videos/since-odyssey-outcomes-demonstrated-a-reduction-in-adverse-cv-outcomes-as-well-as-a-decrease-in-associated-all-cause-mortality-in-post-acs-patients-what-is-your-view-on-treating-to-push-ldl-c-levels-to-even-lower-levels-than-the-70-mg/dl 2019-03-19T22:45:23+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-are-patients-who-should-clearly-be-on-a-pcsk9-inhibitor-not-being-treated-in-the-primary-cardiology-setting-but-rather-seeking-and-obtaining-this-treatment-in-the-lipid-clinic-environment 2019-03-20T16:06:10+0000 weekly 0.8 https://www.iqanda-cme.com/videos/have-studies-been-done-looking-at-pcsk9-inhibitors-as-monotherapy-in-post-acs-patients-with-elevated-ldl-c-levels 2019-03-19T23:10:00+0000 weekly 0.8 https://www.iqanda-cme.com/videos/as-a-thrombosis-specialist-and-cardiologist-how-do-respond-to-the-recent-aha-guidelines-identifying-70-mg/dl-as-a-threshold-target-for-high-risk-patients-is-this-target-a-starting-point-or-a-stopping-point-for-your-ldl-c-lowering-goals 2019-03-20T00:40:09+0000 weekly 0.8 https://www.iqanda-cme.com/videos/as-shown-in-the-odyssey-outcomes-trial-alirocumab-lowers-lp-a-fourier-also-demonstrated-similar-results-with-evolocumab-what-are-the-implications-of-these-findings-and-how-do-you-translate-the-results-into-medical-cardiology-practice 2019-03-20T16:39:47+0000 weekly 0.8 https://www.iqanda-cme.com/videos/which-patients-in-your-view-are-not-candidates-for-pcsk9-inhibition 2019-03-20T15:58:30+0000 weekly 0.8 https://www.iqanda-cme.com/videos/which-patient-subgroups-that-based-on-the-odyssey-outcomes-trial-could-benefit-significantly-from-a-pcsk9-inhibitor-in-your-observation-are-not-getting-treatment-consistently-enough-i-e-are-being-under-treated-with-these-agents 2019-03-19T19:40:39+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-available-evidence-supporting-the-rationale-for-comprehensive-molecular-profiling-across-a-broad-continuum-of-solid-tumor-subtypes 2019-05-17T18:14:30+0000 weekly 0.8 https://www.iqanda-cme.com/videos/nipt-technology-screens-for-sex-chromosome-abnormalities-sca-such-as-klinefelter-syndrome-and-turner-syndrome-how-accurate-is-nipt-for-identifying-sex-chromosome-abnormalities 2019-05-24T18:35:33+0000 weekly 0.8 https://www.iqanda-cme.com/videos/under-what-circumstances-do-you-use-monotherapy-with-methotrexate-and-when-do-you-use-combination-therapy-and-intensify-treatment-with-a-biologic-agent 2019-05-23T18:29:34+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-we-curate-the-results-of-ngs-based-genomic-profiles-how-do-we-prioritize-subsidiary-molecular-markers-especially-when-there-are-multiple-drivers-identified-and-determine-their-level-of-actionability 2019-05-17T18:14:31+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-results-of-the-primary-and-secondary-end-points-in-the-leader-trial-please-elaborate-on-cv-end-points-as-well-as-microvascular-disease-outcomes-especially-nephropathic-changes 2019-05-22T22:30:04+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-discuss-the-esc-guidelines-for-ldl-c-targets-and-the-recent-aha-guidelines-designating-a-target-threshold-of-70-mg/dl-is-this-low-enough-what-is-your-recommendation-for-pcsk9-inhibition-in-the-high-risk-acs-patient-who-has-underg 2019-03-12T18:26:10+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-what-kind-of-solid-tumors-can-comprehensive-genomic-profiling/ngs-make-a-difference-in-identifying-patients-with-egfr-and-other-mutations-that-may-be-missed-by-hotspot-tests-korean 2019-05-21T22:41:15+0000 weekly 0.8 https://www.iqanda-cme.com/videos/since-both-pcsk9-outcome-trials-demonstrated-impressive-safety-when-ldl-c-levels-are-lowered-into-ranges-much-lower-than-70-mg/dl-what-should-be-the-approach-of-the-interventional-and-medical-cardiologist-to-achieving-ldl-c-levels-in-thi 2019-03-12T18:22:24+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-what-types-of-solid-tumors-has-genomic-alteration-directed-therapy-guided-by-ngs-been-shown-to-improve-patient-outcomes-including-progression-free-survival-and-overall-os-portuguese 2020-08-11T00:03:54+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-common-mutations-and-rearrangements-among-them-egfr-alk-her2-braf-ras-met-ret-and-ros-present-in-tumors-represent-the-best-molecular-targets-for-cancer-therapy 2019-05-21T23:47:31+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-has-been-your-clinical-experience-with-respect-to-the-comparative-toleration-of-statins-vs-pcsk9-inhibitors 2019-03-12T18:27:35+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-an-ic-perspective-in-a-patient-who-is-post-pci/post-stent-insertion-for-acs-when-is-the-aggregated-risk-of-the-patient-sufficiently-alarming-for-you-to-consider-intensive-lowering-of-ldl-c-to-a-level-50-mg/dl-with-a-pcsk9-inhibitor 2019-04-13T15:22:20+0000 weekly 0.8 https://www.iqanda-cme.com/videos/ic-and-lipid-specialists-are-challenged-to-maximize-cv-risk-reduction-in-high-risk-populations-how-should-they-approach-the-70-mg/dl-ldl-c-target-identified-in-the-aha-guidelines-and-when-is-the-30-mg/dl-70-mg/dl-even-more-desirable1 2019-03-19T19:59:17+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-kind-of-specific-actionable-information-is-contained-on-a-foundationone-cgp-report 2019-05-22T00:17:35+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-does-the-foundationone-cgp-improve-the-power-of-its-test-to-detect-an-alteration-that-is-present-in-only-some-but-not-all-of-the-tumor-cells 2019-05-21T23:52:09+0000 weekly 0.8 https://www.iqanda-cme.com/videos/for-what-solid-tumors-and-hematologic-malignancies-has-ngs-genomic-profiling-shown-to-be-most-valuable-for-identifying-mutations-that-can-reliably-guide-the-use-of-targeted-therapy 2019-05-22T00:07:26+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-genomic-alterations-i-e-driver-events-does-the-nccn-identify-for-non-small-cell-lung-cancer-nsclc-and-what-targeted-agents-does-the-nccn-recommend-for-these-specific-driver-events 2019-05-21T23:58:30+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-findings-of-exploratory-studies-in-which-foundationone-ngs-genomic-profiling-targeting-145-cancer-relevant-genes-is-applied-to-colorectal-cancer-and-gastric-cancer 2019-05-21T23:26:30+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-the-interventional-cardiology-setting-what-percentage-of-your-patients-do-not-achieve-the-esc-lipid-guideline-goal-of-70-mg/dl-and-therefore-are-suitable-candidates-for-pcsk9-inhibition-can-you-discuss-your-patient-selection-process 2019-03-19T23:42:03+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-you-select-patients-with-solid-tumors-that-are-appropriate-for-ngs-is-it-just-for-patients-who-present-with-cancer-for-patients-under-treatment-for-assessment-of-tumors-in-relapsed-patients 2019-05-21T23:52:27+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-current-status-of-molecular-profiling-in-the-context-of-nscl 2019-05-17T18:14:34+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-has-our-knowledge-of-the-safety-and-efficacy-of-pcsck9-inhibitors-evolved-and-how-has-the-odyssey-outcomes-treat-to-target-trial-helped-us-translate-these-advances-into-the-front-lines-of-interventional-cardiology-practice 2019-03-20T15:56:37+0000 weekly 0.8 https://www.iqanda-cme.com/videos/the-current-foundationone-assay-examines-about-315-genes-known-to-be-somatically-altered-in-human-solid-tumors-as-well-as-28-translocations-how-were-these-genes-determined-what-makes-them-significant 2019-05-21T23:53:35+0000 weekly 0.8 https://www.iqanda-cme.com/videos/have-advantages-been-documented-for-il-6-inhibitors-that-are-fully-human-such-as-sarilumab 2019-05-22T21:58:11+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-have-the-2016-canadian-cardiovascular-society-guidelines-for-ldl-c-reduction-positioned-their-recommendations-for-ldl-c-target-goals-and-how-do-you-anticipate-these-might-change-in-the-future-based-on-the-odyssey-outcomes-and-fourier 2019-03-12T18:16:35+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-provide-a-roadmap-for-how-insulin-plus-glp-1-ra-combination-formulations-should-be-titrated 2019-05-22T22:30:06+0000 weekly 0.8 https://www.iqanda-cme.com/videos/since-esc-and-acc/aha-are-examining-hard-ldl-c-targets-for-patients-at-risk-for-ascvd-how-does-odyssey-outcomes-help-inform-cardiologists-about-the-rationale-for-pcsk9-mediated-lowering-to-achieve-ultra-low-levels-i-e-50-mg/dl-of-ldl-c 2019-03-20T15:44:55+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-does-it-mean-that-a-tumor-sample-has-a-mutation-or-rearrangement-is-the-presence-of-a-mutation-an-all-or-none-phenomenon-or-are-there-additional-levels-once-an-alteration-is-identified 2019-05-22T00:06:31+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-mechanisms-of-action-by-which-iv-acetaminophen-exerts-pain-relieving-properties-and-how-is-it-different-from-other-agents-why-is-this-moa-suited-for-multimodal-therapy 2019-05-23T00:59:46+0000 weekly 0.8 https://www.iqanda-cme.com/videos/based-on-the-odyssey-outcomes-and-fourier-trials-which-patient-populations-including-individuals-with-t2d-do-you-believe-should-be-targeted-for-pcsk9-inhibitors 2019-03-20T00:12:55+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-did-odyssey-outcomes-and-fourier-teach-us-about-high-risk-patients-with-diabetes-and-the-relative-favorability-of-their-responses-to-ldl-c-lowering-with-pcsk9-inhibitors 2019-03-12T18:18:51+0000 weekly 0.8 https://www.iqanda-cme.com/videos/although-70-mg/dl-is-the-target-threshold-identified-by-both-esc-and-aha-should-the-interventionalist-in-a-patient-who-has-just-undergone-a-pci-and-has-an-ldl-c-of-69-mg/dl-be-considered-adequately-cv-risk-mitigated 2019-03-19T20:38:59+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-does-massively-parallel-dna-sequencing-overcome-considerations-regarding-pathological-tumor-specimens 2019-05-21T23:55:00+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-information-can-snp-based-nipt-in-twin-pregnancy-provide-in-the-setting-of-egg-donor-or-surrogate-pregnancies 2019-05-24T18:41:54+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-evidence-that-personalized-gene-directed-cancer-therapy-in-which-specific-molecular-drivers-of-a-patient-s-disease-are-aligned-with-specific-therapy-will-improve-outcomes1 2019-05-22T00:10:58+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-have-molecular-drivers-for-cancer-therapy-been-embraced-by-the-oncology-community-in-china-and-what-role-does-ngs-testing-and-genomic-profiling-currently-play-in-decision-making 2019-05-17T18:14:28+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-regulatory-approval-and-evaluation-processes-for-biosimilars-differ-from-those-used-for-small-molecule-generic-medications 2019-05-23T19:13:04+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-importance-of-opioid-avoidance-as-a-strategy-for-multimodal-pain-management-in-the-perioperative-setting-where-does-iv-acetaminophen-fit-into-that-best-pain-management-equation 2019-05-23T00:59:45+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-the-fixed-ratio-combinations-consisting-of-basal-insulin-and-glp-1-ras-help-mitigate-side-effects-of-both-the-insulin-and-glp-1-ra 2019-05-22T22:30:01+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-kind-of-clinical-samples-are-required-to-implement-next-generation-sequencing-ngs-can-ngs-be-applied-to-samples-other-than-ffpe1 2019-05-22T00:11:39+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-what-patient-subsets-ra-biomarker-subsets-obese-undifferentiated-ra-high-risk-ra-poor-responders-etc-do-il-6-inhibitors-appear-to-be-most-effective-why 2019-05-22T21:58:12+0000 weekly 0.8 https://www.iqanda-cme.com/videos/for-what-solid-tumors-and-hematologic-malignancies-has-ngs-genomic-profiling-shown-to-be-most-valuable-for-identifying-disease-alleles-which-can-reliably-guide-the-use-of-molecularly-targeted-therapy 2019-05-21T23:46:20+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-is-snp-based-prenatal-testing-supplanting-us-as-the-definitive-test-to-distinguish-chorionicity-and-zygosity-and-how-early-can-this-test-be-performed1 2019-05-24T18:41:51+0000 weekly 0.8 https://www.iqanda-cme.com/videos/which-critical-and-actionable-tumor-specific-molecular-targets-are-likely-to-be-missed-by-hot-spot-profiling-as-opposed-to-cgp-and-why-is-cgp-advantageous-in-most-cancer-patients 2019-05-21T23:30:21+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-unique-aspects-with-respect-to-all-cause-mortality-outcomes-and-baseline-ldl-c-levels-were-observed-in-the-odyssey-outcomes-trial-and-how-would-you-translate-these-results-into-patient-care 2019-03-20T00:59:49+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-kind-of-clinical-samples-are-required-to-implement-next-generation-sequencing-ngs-can-ngs-be-applied-to-samples-other-than-ffpe2 2019-05-22T00:18:53+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-an-interventional-cardiology-perspective-what-did-odyssey-outcomes-teach-us-about-the-large-subgroup-of-diabetic-patients-who-had-acs-plus-stent-insertions 2019-03-19T23:56:44+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-physiologic-rationale-of-combining-glp-1-ras-and-basal-insulin-into-fixed-ratio-combination-agents-such-as-iglarlixi-and-ideglira 2019-05-22T21:36:12+0000 weekly 0.8 https://www.iqanda-cme.com/videos/ic-and-lipid-specialists-are-challenged-to-maximize-cv-risk-reduction-in-high-risk-populations-how-should-they-approach-the-70-mg/dl-ldl-c-target-identified-in-the-aha-guidelines-and-when-is-the-30-mg/dl-70-mg/dl-even-more-desirable 2019-03-12T18:07:25+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-ldl-c-target-goals-should-a-consulting-or-treating-medical-cardiologist-recommend-for-patients-with-type-2-diabetes-with-a-known-acs-event-vs-diabetes-alone-as-a-risk-factor 2019-03-12T18:17:58+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-drill-down-into-the-specific-results-of-the-odyssey-outcomes-trial-that-demonstrate-unique-significant-reductions-in-associated-all-cause-mortality-and-how-these-findings-might-be-relevant-to-the-interventional-cardiologist 2019-03-20T15:49:33+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-what-types-of-solid-tumors-has-mutation-directed-therapy-been-shown-to-improve-patient-outcomes-including-progression-free-survival-and-overall-os 2019-05-22T00:14:02+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-what-types-of-solid-tumors-has-mutation-directed-therapy-been-shown-to-improve-patient-outcomes-including-progression-free-survival-pfs-and-overall-os 2019-05-22T00:19:33+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-review-for-us-the-implications-of-your-study-on-pten-genomic-rearrangements-and-loss-in-prostate-cancer-and-the-implications-for-ngs-based-profiling-in-this-disease 2019-05-28T19:15:32+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-evidence-that-more-personalized-gene-directed-cancer-therapy-in-which-specific-molecular-drivers-of-a-patient-s-disease-are-aligned-with-specific-therapy-will-improve-patient-outcomes 2019-05-22T00:16:44+0000 weekly 0.8 https://www.iqanda-cme.com/videos/professor-bhatt-you-presented-the-pharmacoeconomic-in-trial-analysis-for-alirocumab-based-on-the-odyssey-outcomes-trial-can-you-discuss-the-clinical-implications-of-your-analysis-and-how-reduced-costs-for-alirocumab-will-affect-ic-practi 2019-04-16T18:15:26+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-other-markers-besides-ldl-c-levels-do-you-believe-we-should-consider-to-refine-cv-risk-stratification 2019-03-19T20:16:59+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-ideal-clinical-profiles-for-and-distinctions-among-the-fixed-ratio-combination-formulations-what-are-their-potential-advantages-and-unique-therapeutic-windows-of-opportunities1 2019-05-22T21:36:10+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-discuss-the-importance-of-the-two-principal-psck9-cv-outcome-trials-odyssey-outcomes-and-fourier-and-how-they-are-similar-and-in-what-ways-they-are-different-what-are-the-implications-for-the-patient-with-t2d-and-ascvd 2019-03-20T00:03:19+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-give-us-a-roadmap-and-detailed-rationale-for-how-and-when-to-deploy-ngs-in-the-setting-of-prostate-cancer-how-do-improve-the-content-yields-of-prostate-biopsies-how-do-we-ferret-out-tumor-heterogeneity-issues 2019-05-28T19:03:06+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-importance-of-ngs-for-finding-egfr-sensitizing-mutations-such-as-exon-19-or-exon-21-in-nsclc-what-is-their-relationship-to-sensitivity-to-tkis-such-as-erlotinib-gefitinib-and-afatinib 2019-05-22T02:31:04+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-has-been-your-experience-with-respect-to-patient-satisfaction-discontinuation-rates-and-toleration-of-this-injection-based-approach-to-ldl-c-management 2019-03-12T18:23:20+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-kind-of-clinical-samples-are-required-to-implement-next-generation-sequencing-ngs-can-ngs-be-applied-to-samples-other-than-ffpe3 2019-05-22T00:14:47+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-the-current-environment-of-precision-treatments-for-cancer-what-kind-of-genetic-alterations-can-be-categorized-as-actionable-what-other-criteria-would-make-a-genetic-alteration-actionable 2019-05-21T23:53:53+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-guidance-can-you-give-when-the-f1m-cgp-profile-reveals-multiple-actionable-mutations-why-select-targeted-therapies-when-multiple-genomic-alterations-or-rearrangements-co-exist 2019-05-21T23:47:11+0000 weekly 0.8 https://www.iqanda-cme.com/videos/does-hybrid-capture-based-next-generation-sequencing-ngs-have-special-application-for-detecting-actionable-genomic-alterations-in-lung-adenocarcinoma 2019-05-22T00:06:52+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-regulatory-approval-and-evaluation-processes-for-biosimilars-differ-from-those-used-for-small-molecule-generic-medications1 2019-05-23T19:13:14+0000 weekly 0.8 https://www.iqanda-cme.com/videos/within-the-context-of-the-esc-and-u-s-guidelines-for-ldl-c-reduction-which-recommend-70-mg/dl-as-a-threshold-target-how-should-we-view-the-cholesterol-landscape-between-20-mg/dl-and-70-mg/dl-in-light-of-the-odyssey-outcomes-trial 2019-03-12T18:26:47+0000 weekly 0.8 https://www.iqanda-cme.com/videos/based-on-clinical-data-and-fda-approvals-why-do-nccn-guidelines-for-nsclc-recommend-erlotinib-and-gefitinib-as-first-line-systemic-therapy-in-patients-with-sensitizing-egfr-mutations 2019-05-21T23:58:02+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-light-of-the-recent-results-showing-a-reduction-in-associated-all-cause-mortality-in-the-odyssey-outcomes-trial-which-patients-deserve-our-greatest-attention-to-optimize-the-translational-impact-of-this-study 2019-03-12T18:21:37+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-a-high-risk-patient-who-has-undergone-multiple-stent-procedures-what-criteria-do-you-prioritize-for-initiating-a-pcsk9-inhibitor-in-the-setting-of-pci-and-what-absolute-ldl-c-targets-are-in-your-cross-hairs-based-on-the-odyssey-outcom 2019-03-20T15:58:56+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-help-us-de-convolute-what-is-more-important-a-the-absolute-level-of-ldl-c-level-attained-among-patients-in-the-odyssey-outcomes-trial-or-b-the-delta-i-e-the-relative-change-from-baseline-ldl-c-level-at-time-of-entry-into-the-tria 2019-03-20T15:52:15+0000 weekly 0.8 https://www.iqanda-cme.com/videos/although-the-aha-guidelines-emphasize-cv-risk-and-mortality-reductions-with-statins-odyssey-outcomes-provides-comparable-evidence-for-alirocumab-how-compelling-is-the-evidence-for-pcsk9-inhibition-as-a-mediator-of-cv-risk-and-mortality-r 2019-03-12T18:23:46+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-are-current-genomic-testing-models-based-on-targeted-sequencing-hot-spot-unsustainable-and-less-effective-than-comprehensive-genomic-profiling-cgp-developed-by-foundationone 2019-05-21T23:53:18+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-china-how-does-foundationone-ngs-sequencing-compare-to-common-hotspot-panels-with-respect-to-detecting-clinically-actionable-alterations 2019-05-22T02:30:28+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-should-the-ideal-target-ldl-c-be-in-the-type-2-diabetes-population-and-what-is-the-advantage-of-the-treat-to-target-strategy-employed-in-odyssey-outcomes-and-what-did-we-learn-about-associated-all-cause-mortality-with-alirocumab-in- 2019-03-19T23:46:11+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-should-we-expect-as-far-as-weight-gain-risk-of-hypoglycemia-and-degree-of-ha1c-lowering-with-fixed-ratio-combinations-such-a-iglarlixi-and-ideglira 2019-05-22T21:36:09+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-foundationone-heme-how-accurate-are-its-detection-rates-and-how-is-it-used-to-detect-genomic-alterations-that-can-impact-diagnosis-therapy-and-prognosis-in-hematologic-cancers 2019-05-22T00:10:03+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-do-clinical-trials-tell-us-about-what-strategies-are-optimal-for-ra-patients-who-are-inadequate-responders-to-dmards-and/or-biologic-therapy 2019-05-23T01:32:49+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-does-ngs-address-the-changes-that-cancer-treatment-is-undergoing-toward-the-use-of-molecularly-targeted-drugs-prescribed-to-selected-subsets-of-patients-across-multiple-tumor-types 2019-05-22T00:01:07+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-is-ngs-identification-of-microsatellite-instability-and-mismatch-repair-defects-and-molecular-target-stratification-that-comprehensive-genomic-profiling-improving-management-of-prostate-cancer 2019-05-28T19:11:53+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-specific-molecular-targets-are-detected-by-the-ngs-hybrid-capture-platform-how-is-actionability-determined-and-what-are-the-translational-implications-of-molecular-drivers 2019-05-21T20:59:47+0000 weekly 0.8 https://www.iqanda-cme.com/videos/as-an-ic-you-are-seeing-post-acs/post-pci-patients-whose-atherosclerotic-disease-burden-is-exceptional-and-potentially-amenable-to-pcsk9-mediated-cv-risk-reduction-where-is-your-specific-focus-for-using-these-agents-in-this-population 2019-03-14T23:23:10+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-the-specific-vantage-point-of-the-interventional-cardiologist-based-on-the-results-of-the-odyssey-outcomes-trial-which-patients-who-have-undergone-pci-do-you-believe-are-the-best-candidates-for-pcsk9-therapy 2019-03-20T15:54:24+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-have-we-learned-from-the-odyssey-outcomes-pharmacoeconomic-analysis-that-you-and-professor-deepak-bhatt-reported-at-the-aha-2018-meeting-and-what-are-the-implications-for-the-clinician-cardiologist-who-is-making-the-case-to-payors 2019-03-15T17:35:02+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-you-identify-progressing-patients-with-high-cv-risk-in-whom-pcsk9-therapy-represents-a-game-changing-strategy1 2019-03-19T22:29:08+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-do-we-know-from-the-sub-analyses-of-the-odyssey-outcomes-trial-that-looked-at-patients-with-ldl-c-levels-below-50-mg/dl-which-of-these-based-on-baseline-ldl-c-levels-derived-disproportionate-mortality-reduction-benefit-from-alirocum 2019-03-19T23:31:26+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-you-identify-progressing-patients-with-high-cv-risk-in-whom-pcsk9-therapy-represents-a-game-changing-strategy 2019-03-12T19:41:24+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-discuss-the-information-reported-in-the-genomics-alteration-section-of-the-foundationone-report-the-targeted-therapies-that-may-be-relevant-and-the-interpretive-statement-for-each-genomic-alteration 2019-05-22T00:17:06+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-exactly-did-you-and-your-colleagues-model-the-pharmacoeconomic-effectiveness-of-alirocumab-based-on-the-actual-results-of-the-odyssey-outcomes-trial 2019-03-20T16:25:11+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-role-of-hybrid-capture-based-ngs-diagnostic-testing-for-guiding-precision-based-treatments-for-colorectal-and-other-gi-cancers-italian 2020-08-11T00:04:45+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-the-view-of-an-interventional-cardiologist-and-a-lipid-medicine/atherosclerosis-specialist-can-you-discuss-what-ldl-c-thresholds-vs-clinical-burden/clinical-history-thresholds-are-important-for-patient-selection-for-pcsk9-based-risk 2019-03-19T22:27:12+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-tell-us-what-the-properties-are-of-the-two-fixed-ratio-insulin-glp-1-ra-combinations-and-how-to-titrate-them-and-what-metabolic-effects-in-patients-with-t2d-are-we-likely-to-see-in-clinical-practice 2019-05-22T22:30:00+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-what-kinds-of-non-melanoma-cancers-does-braf-v600-appear-to-be-a-targetable-oncogene-what-do-initial-studies-using-braf-v600-to-guide-vemurafenib-and-cetuximab-in-patients-with-colorectal-cancer-show 2019-05-22T00:16:01+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-unique-status-of-hybrid-capture-ngs-within-the-context-of-molecular-target-driven-therapy-for-solid-tumors1 2019-05-17T18:14:33+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-evidence-and-guidelines-have-supported-the-move-by-oncologists-toward-molecular-ngs-generated-mutational-drivers-as-the-optimal-approach-to-precision-cancer-medicine 2019-05-22T00:19:13+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-you-approach-the-diabetic-patient-who-also-has-a-constellation-of-multiple-high-risk-features-above-and-beyond-the-underlay-of-diabetes-what-is-the-relative-and-absolute-benefit-of-employing-pcsk9-inhibitors-in-this-patient-popula 2019-03-20T16:20:16+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-a-medical-cardiologist-and-acs-expert-perspective-can-you-identify-which-patients-should-undergo-consideration-for-pcsk9-mediated-ldl-c-reduction-and-what-risk-factors-should-encourage-cv-specialists-to-pursue-pcsk9-based-therapies 2019-03-20T16:13:22+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-are-current-genomic-testing-models-based-on-targeted-sequencing-hot-spot-unsustainable-and-more-limited-than-comprehensive-genomic-profiling-cgp-developed-by-foundationone 2019-05-21T23:27:00+0000 weekly 0.8 https://www.iqanda-cme.com/videos/pfs-is-improved-with-use-of-a-tki-in-patients-with-sensitizing-egfr-mutations-when-compared-with-standard-chemotherapy-please-summarize-clinical-results-and-implications-for-ngs-testing 2019-05-22T00:18:30+0000 weekly 0.8 https://www.iqanda-cme.com/videos/based-on-odyssey-outcomes-which-patients-in-an-interventional-cardiology-practice-do-you-believe-will-benefit-most-from-pcsk9-inhibition 2019-03-12T18:25:47+0000 weekly 0.8 https://www.iqanda-cme.com/videos/given-the-heterogeneity-of-genomic-aberrations-for-prostate-cancer-what-are-the-limitations-of-pcr-based-hot-spot-panels-for-identifying-actionable-molecular-profiles-homozygous-deletions-and-other-aberrations 2019-05-28T19:16:03+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-discuss-the-reductions-in-mace-events-reported-in-the-pcsk9-outcome-trials-and-how-they-shape-the-benefit/safety-equation-for-the-use-of-alirocumab-and-evolocumab-in-high-risk-patients-including-diabetics-for-secondary-prevention 2019-03-19T23:54:38+0000 weekly 0.8 https://www.iqanda-cme.com/videos/since-the-overwhelming-majority-of-post-acs-patients-in-odyssey-outcomes-had-pci-as-part-of-their-acs-management-what-have-we-learned-about-the-safety-and-efficacy-of-alirocumab-in-this-stent-rich-population-of-high-risk-patients 2019-03-19T23:37:31+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-overall-accuracy-and-reproducibility-rate-for-cancer-genomic-profiling-based-on-massively-parallel-dna-sequencing-at-what-point-in-the-disease-process-should-cgp-be-employed 2019-05-21T23:52:45+0000 weekly 0.8 https://www.iqanda-cme.com/videos/among-such-solid-tumors-as-nslc-melanoma-colorectal-and-breast-cancers-what-percentage-of-patients-will-have-actionable-genomic-alterations-detected-by-ngs-based-technologies-french 2020-08-11T00:02:56+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-should-the-approach-be-in-patients-who-have-had-a-coronary-event-with-an-ldl-c-level-of-70-mg/dl-do-the-outcome-studies-with-pcsk9-inhibitors-provide-an-evidentiary-roadmap-for-this-common-situation 2019-03-12T18:18:25+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-categories-of-genomic-alterations-are-identified-by-the-method-of-genomic-profiling-you-are-familiar-with-are-any-critical-genomic-alterations-not-identified-by-ngs 2019-05-22T00:11:20+0000 weekly 0.8 https://www.iqanda-cme.com/videos/based-on-odyssey-outcomes-and-fourier-what-are-the-findings-and/or-biologic-risk-features-lp-a-for-example-in-patients-managed-in-an-interventional-cardiology-setting-that-would-make-you-advocate-for-the-use-of-pcsk9-inhibitors 2019-03-20T01:05:35+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-was-the-rationale-for-developing-fixed-ratio-combinations-consisting-of-basal-insulin-and-glp-1-ras-and-what-advantages-do-they-offer 2019-05-22T22:30:03+0000 weekly 0.8 https://www.iqanda-cme.com/videos/with-respect-to-patients-with-hefh-and-homozygous-fh-who-are-challenged-with-lifelong-cv-disease-risk-burden-due-to-genetic-risk-what-role-do-you-believe-pcsk9-inhibitors-should-play-especially-in-younger-patient-populations 2019-03-12T18:27:05+0000 weekly 0.8 https://www.iqanda-cme.com/videos/if-someone-is-more-than-12-months-out-after-an-acs-event-and-currently-has-a-stent-would-you-still-consider-them-to-be-eligible-for-pcsk9-therapy-to-lower-ldl-c-and-residual-cv-risk 2019-03-19T23:49:27+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-you-select-patients-with-solid-tumors-that-are-appropriate-for-ngs-is-it-useful-just-for-patients-with-cancer-at-time-of-presentation-can-it-be-used-for-patients-under-treatment 2019-05-22T00:13:03+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-discuss-and-explain-the-study-design-rationale-results-and-clinical-implications-of-the-most-recent-clinical-evidence-i-e-clinical-trials-focused-on-the-safety-and-efficacy-of-approved-biosimilar-therapies-such-as-infliximab-dyyb 2019-05-23T19:13:11+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-does-systematic-profiling-with-ngs-optimize-genomic-and-molecular-stratification-for-prostate-cancer-and-what-actionable-subgroups-and-aberrations-have-you-identified 2019-05-28T19:13:25+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-evidence-that-a-systematic-and-comprehensive-ngs-generated-profiling-of-actionable-alterations-in-genes-associated-with-solid-tumors-should-or-can-inform-therapeutic-decision-making 2019-05-21T23:29:35+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-make-sense-of-the-results-and-designs-of-the-various-cardiovascular-outcome-trials-including-the-leader-trial-in-patients-with-t2d-and-what-do-you-believe-is-the-take-home-message1 2019-05-22T22:30:08+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-does-it-mean-that-a-tumor-sample-has-a-mutation-or-rearrangement-exactly-what-is-being-measured-is-the-presence-of-a-mutation-on-an-ngs-panel-an-all-or-none-phenomenon 2019-05-22T00:12:00+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-your-interventional-cardiology-practice-which-markers-of-risk-in-the-patient-who-has-undergone-a-pci-do-you-focus-on-to-promote-consideration-for-using-a-pcsk9-inhibitor 2019-03-12T18:25:24+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-importance-of-the-gene-encoding-the-ros1-proto-oncogene-receptor-tyrosine-kinase-as-a-distinct-molecular-subgroup-of-nsclc-in-what-percentage-of-patients-is-ros1-detected1 2019-05-22T01:37:13+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-discuss-and-explain-the-study-design-rationale-results-and-practical-clinical-implications-of-the-most-recent-clinical-evidence-focused-on-anti-tnf-inhibitor-biosimilars-for-infliximab-in-the-setting-of-ra-and-by-extrapolation-as 2019-05-23T19:14:34+0000 weekly 0.8 https://www.iqanda-cme.com/videos/does-foundationone-s-comprehensive-ngs-have-validation-studies-confirming-accuracy-across-multiple-alterations-in-a-peer-reviewed-journal 2019-05-22T00:01:32+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-well-do-other-non-f1m-methods-for-ngs-assessment-work-are-they-as-effective-highly-aggressive-or-resistant-tumors-cancers-of-unknown-primary-cancers-with-limited-tissue-samples 2019-05-21T23:51:46+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-you-interpret-the-reduction-in-associated-overall-mortality-seen-with-alirocumab-in-the-odyssey-outcome-trial-as-compared-to-the-lack-of-such-findings-at-least-prior-to-results-for-the-extension-phase-in-fourier-for-the-evolocumab 2019-03-20T16:29:06+0000 weekly 0.8 https://www.iqanda-cme.com/videos/odyssey-outcomes-reports-that-post-acs-patients-with-starting-ldl-c-levels-greater-than-100-mg/dl-benefited-most-but-you-have-noted-the-importance-of-assessing-aggregate-risk-when-identifying-triggers-for-pcsk9-based-therapy-can-you-disc 2019-03-20T16:06:19+0000 weekly 0.8 https://www.iqanda-cme.com/videos/given-what-we-know-about-the-safety-of-pcsk9-inhibitors-and-the-risk-of-recurrent-events-in-patients-who-have-experienced-an-acs 2019-03-19T19:04:54+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-the-setting-of-secondary-post-acs-prevention-what-is-your-trigger-for-moving-beyond-a-statin/ezetimibe-combination-to-a-pcsk9-inhibitor 2019-03-19T17:30:38+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-are-your-2019-esc/eas-guidelines-going-to-be-influenced-by-recent-rcts-including-odyssey-outcomes-and-fourier 2019-03-19T19:09:37+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-be-specific-about-how-ngs-based-signatures-in-metastatic-lung-cancer-can-provide-actionable-roadmaps-for-targeted-therapy 2019-05-28T19:06:00+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-what-ways-has-a-recent-recommendation-from-the-acmg-forced-us-to-rethink-and-expand-upon-prenatal-patient-populations-who-are-ideal-candidates-for-cell-free-fetal-dna-testing 2019-05-24T18:38:38+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-underlying-physiology-that-explains-the-role-of-incretins-in-the-disease-processes-leading-to-t2d 2019-05-22T21:38:05+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-role-of-ngs-for-identifying-her-2-enrichment-therapy-what-is-the-situation-in-asia-as-far-deploying-ngs-in-patients-with-breast-cancer 2019-05-28T19:09:33+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-translational-implications-of-the-leader-trial-based-on-the-results-reported-at-ada-2016 2019-05-22T21:36:57+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-do-we-know-about-patient-satisfaction-as-it-relates-to-perioperative-pain-management-including-in-patients-on-iv-acetaminophen-and-what-role-does-opioid-reduction-play 2019-05-23T00:59:49+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-currently-the-most-important-actionable-drivers-from-a-mutational-perspective-for-lung-cancer-and-what-is-the-emerging-importance-of-ret-kinase-inhibitors 2019-05-17T18:16:02+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-we-learning-about-the-efficacy-and-safety-of-ultra-long-acting-insulins-such-as-degludec-and-u300-glargine 2019-05-22T23:06:08+0000 weekly 0.8 https://www.iqanda-cme.com/videos/since-the-efficacy-of-biosimilars-is-typically-studied-for-a-single-indication-why-are-approvals-of-such-biosimilars-as-infliximab-dyyb-extended-to-other-diseases-in-which-the-biosimilar-was-not-tested-directly-against-the-reference 2019-05-23T19:15:46+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-specific-and-actionable-molecular-derangements-are-identified-by-ngs-to-guide-targeted-therapy 2019-05-28T19:03:37+0000 weekly 0.8 https://www.iqanda-cme.com/videos/based-on-the-results-of-the-leader-trial-where-would-you-position-liraglutide-in-the-ada/easd-sequencing-algorithm-for-antidiabetic-agents 2019-05-22T23:00:01+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-do-you-believe-the-results-of-leader-showing-cv-outcome-reduction-with-liraglutide-are-different-from-previous-trials-using-glp-1-ras-that-failed-to-demonstrate-cv-risk-reduction 2019-05-22T23:06:50+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-unique-advantages-in-the-immediate-and-extended-post-operative-period-of-iv-acetaminophen-in-the-bariatric-surgery-population-how-does-this-agent-offer-particular-advantages-in-light-of-the-gi-and-respiratory-disturbances-en 2019-05-23T01:08:03+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-has-the-eras-movement-affected-multimodal-pain-management-protocols-for-cabg-and-where-does-iv-acetaminophen-fit-into-these-perioperative-critical-pathways 2019-05-23T01:02:47+0000 weekly 0.8 https://www.iqanda-cme.com/videos/are-il-6-inhibitors-synergistic-with-methotrexate-and-how-do-they-compare-to-tnfis-as-far-as-their-efficacy-as-monotherapy-in-patients-with-ra 2019-05-22T22:02:59+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-does-non-invasive-prenatal-screening-nipt-using-cell-free-fetal-dna-integrate-into-the-current-paradigms-for-screening-and-diagnostic-testing-for-aneuploidy 2019-05-24T18:38:37+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-metabolic-and-hemodynamic-parameters-were-affected-most-significantly-in-leader-and-what-new-information-did-we-learn-about-the-safety-profile-of-liraglutide 2019-05-22T23:00:56+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-discuss-each-phase-manufacturing-efficacy-and-safety-testing-pk/pd-evaluation-clinical-outcomes-evaluation-in-the-approach-to-regulatory-approval-of-biosimilars 2019-05-23T19:13:18+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-take-us-through-the-flow-of-an-actual-patient-and-explain-how-you-use-snp-based-ngs-carrier-screening-to-provide-genetic-counseling 2019-05-24T18:37:24+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-physiologic-and-mechanistic-rationale-for-using-a-fixed-ratio-combination-insulin-plus-glp-1-receptor-agonist-such-as-ideglira-and-iglarlixi-as-part-of-the-treatment-landscape 2019-05-22T23:06:48+0000 weekly 0.8 https://www.iqanda-cme.com/videos/based-on-clinical-profiles-and-metabolic-parameters-which-patients-with-t2d-are-ideally-suited-for-treatment-with-a-fixed-ratio-combination-of-insulin-and-a-glp-1-ra 2019-05-22T23:12:24+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-compare-the-translational-implications-of-inhibiting-the-tnf-vs-il-6-cytokine-signaling-systems-how-are-these-differences-manifested-clinically 2019-05-22T22:03:13+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-sensitive-is-the-panorama-snp-based-nipt-test-in-twins-apparently-it-can-report-zygosity-even-for-fetal-fractions-as-low-as-2-8-please-explain-the-importance-of-this 2019-05-24T18:42:01+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-do-studies-show-about-the-use-of-iv-acetaminophen-as-part-of-multimodal-perioperative-pain-management-and-hospital-length-of-stay-for-various-surgical-procedures 2019-05-23T00:58:58+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-markers-and-strategies-do-you-recommend-for-titrating-fixed-dose-combination-regimens-what-dosing-considerations-apply-to-ensure-optimal-ha1c-control 2019-05-22T21:44:42+0000 weekly 0.8 https://www.iqanda-cme.com/videos/are-there-markers-in-ra-that-suggest-a-more-progressive-or-aggressive-disease-course-or-that-will-predict-non-responsiveness 2019-05-22T21:59:44+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-some-of-the-pitfalls-of-instituting-iv-acetaminophen-after-cardiac-surgery-as-opposed-to-starting-it-pre-or-intra-operatively-and-what-are-the-problems-associated-with-either-a-oral-acetaminophen-or-b-failing-to-administer-a-suf 2019-05-23T01:02:21+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-most-important-complexities-and/or-complications-i-e-cord-entanglement-singleton-demise-or-twin-to-twin-transfusion-syndrome-encountered-in-twin-pregnancies 2019-05-24T18:41:50+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-why-and-where-should-il-6-cytokine-inhibitors-fit-into-evidence-and/or-expert-based-roadmaps-for-sequential-approaches-to-ra-management 2019-05-22T21:58:15+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-validations-that-larger-molecular-profiling-panels-using-ngs-to-interrogate-several-hundred-genes-and-provide-comprehensive-genomic-profiles-are-superior-to-targeted-or-hot-spot-panels 2019-05-28T19:05:44+0000 weekly 0.8 https://www.iqanda-cme.com/videos/since-assessing-tumor-mutational-burden-requires-whole-exome-ngs-profiling-how-do-you-decide-which-tumor-subtypes-and-patients-are-appropriate-for-comprehensive-genomic-profiling 2019-05-28T19:07:46+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-foundational-importance-of-the-leader-trial-and-what-makes-it-different-and-perhaps-more-significant-than-previous-trials-evaluating-strategies-for-cv-risk-reduction-in-t2d 2019-05-22T22:29:54+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-contraindications-to-the-use-of-iv-acetaminophen 2019-05-23T01:01:26+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-is-snp-based-prenatal-testing-supplanting-us-as-the-definitive-test-to-distinguish-chorionicity-and-zygosity-and-how-early-can-this-test-be-performed 2019-05-24T18:41:59+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-is-ngs-altering-our-understanding-of-the-importance-of-combining-aggregating-and-analyzing-a-full-range-of-genomic-data-to-guide-therapeutic-decisions-especially-in-rare-tumor-types 2019-05-28T19:08:35+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-current-status-of-b-cell-targeting-agents 2019-05-22T22:03:03+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-provide-some-background-including-dosing-and-units-of-each-component-for-the-two-fixed-ratio-combination-insulin-plus-glp-1-receptor-agonist-formulations-that-have-been-investigated-and-are-likely-to-be-approved 2019-05-22T22:29:21+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-level-of-ha1c-reduction-is-achieved-with-the-fixed-ratio-combination-and-how-is-the-side-effect-profile-of-the-glp-1-ra-affected-by-the-combination-formulation-and-the-titration-strategy-it-utilizes 2019-05-22T22:59:55+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-your-discussions-with-many-other-cardiac-surgery-centers-focused-on-reducing-opioid-use-and-pushing-forward-eras-based-protocols-what-consensus-if-any-have-you-seen-regarding-iv-acetaminophen-use 2019-05-23T01:01:55+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-is-the-exclusive-use-of-iv-opioids-in-bariatric-surgery-patients-problematic-and-why-is-iv-acetaminophen-uniquely-qualified-to-be-part-of-multimodal-post-operative-pain-management 2019-05-23T00:59:05+0000 weekly 0.8 https://www.iqanda-cme.com/videos/does-foundationone-s-comprehensive-ngs-genomic-profiling-have-validation-studies-confirming-accuracy-across-multiple-alterations-in-a-peer-reviewed-journal 2019-05-17T18:16:34+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-did-we-learn-about-hypoglycemic-risk-from-the-leader-trial-as-it-relates-to-the-glp-1-ra-evaluated 2019-05-22T23:06:41+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-compare-the-results-time-lines-and-insights-gleaned-from-the-leader-trial-with-liraglutide-a-glp-1-ra-to-those-reported-for-empa-reg-which-evaluated-an-sglt2-inhibitor-on-cv-risk 2019-05-22T23:06:09+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-discuss-study-design-rationale-results-and-implications-of-recent-trials-focused-on-anti-tnf-biosimilars-in-the-setting-of-ra-as-and-related-conditions 2019-05-23T19:15:49+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-can-we-expect-in-terms-of-price-reductions-for-biosimilar-vs-the-reference-product-what-factors-determine-these-pricing-patterns-for-biosimilars 2019-05-23T19:13:19+0000 weekly 0.8 https://www.iqanda-cme.com/videos/based-on-leader-is-there-an-ideal-age-group-for-liraglutide-should-it-be-used-in-younger-and-older-patients-what-dose-should-we-be-trying-to-achieve-what-is-the-toleration-profile 2019-05-22T22:59:59+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-current-price-differences-between-the-originator-product-such-as-brand/originator-versions-for-infliximab-versus-the-biosimilar-does-it-vary-from-country-to-country 2019-05-23T19:15:44+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-often-do-you-see-incorrect-fetal-sex-results-with-nipt 2019-05-24T18:35:34+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-provide-a-specific-patient-example-in-a-patient-with-egfr-positive-nsclc-where-ctdna-may-redirect-treatment 2019-05-28T19:05:56+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-the-pk/pd-dimensions-of-glp-1-ras-determine-their-proper-alignment-with-specific-glycemic-regulation-needs-fpg-vs-ppg-and-with-specific-clinical-profiles-of-patients-with-t2d 2019-05-22T21:36:20+0000 weekly 0.8 https://www.iqanda-cme.com/videos/when-for-reasons-of-toleration-combination-therapy-with-methotrexate-is-not-possible-what-is-the-role-of-biologic-agents-including-il-6-inhibitors-as-part-of-monotherapeutic-regimen 2019-05-22T22:16:05+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-real-world-data-supporting-the-use-of-infliximab-biosimilars-such-as-infliximab-dyyb 2019-05-23T19:15:10+0000 weekly 0.8 https://www.iqanda-cme.com/videos/since-genomic-alterations-change-as-a-cancer-evolves-how-do-we-employ-whole-exome-genomic-profiling-as-part-of-a-longitudinal-patient-management-strategy-korean 2019-05-28T19:03:24+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-advances-in-therapeutic-targeting-with-ngs-comprehensive-genomic-profiling-and-multiplex-testing-have-we-witnessed-in-patients-with-nsclc 2019-05-17T18:14:37+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-role-do-the-following-play-in-identifying-high-risk-ra-patients-and-what-are-the-implications-of-stratifying-patients-using-these-markers-disease-duration-high-titer-of-rf-elevated-ccp-sustained-elevations-of-crp-or-esr-high-number- 2019-05-22T22:08:20+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-patient-types-or-clinical-scenarios-sex-of-patient-aggressiveness-of-disease-poor-treatment-response-host-risk-factors-history-of-response-etc-are-ideally-aligned-with-agents-targeting-il-6 2019-05-22T22:02:06+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-is-there-is-a-discrepancy-between-cell-free-dna-testing-and-ultrasound-regarding-the-sex-of-the-baby 2019-05-24T18:37:28+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-do-bariatric-surgery-patients-represent-an-ideal-patient-population-for-use-of-iv-acetaminophen-as-a-part-of-multimodal-post-operative-pain-management 2019-05-23T00:59:06+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-you-identify-high-risk-patients-who-are-likely-to-benefit-from-biological-therapy 2019-05-22T22:03:09+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-will-we-make-drug-selection-and-sequencing-choices-now-that-biosimilars-including-ant-tnf-agents-are-available 2019-05-23T19:13:05+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-does-snp-based-nipt-compare-to-maternal-serum-screening-mss-with-respect-to-sensitivity-specificity-false-negative-rates-false-positive-rates-and-positive-predictive-value-ppv 2019-05-24T18:35:47+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-main-side-effects-of-the-tnfis 2019-05-22T22:09:02+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-a-practical-titration-perspective-what-important-clinical-guidance-can-you-provide-to-optimize-effectiveness-of-the-fixed-ratio-insulin-glp-1-ra-combination 2019-05-22T21:41:33+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-regulatory-approval-and-evaluation-processes-for-biosimilars-differ-from-those-used-for-small-molecule-generic-medications3 2019-05-23T19:15:57+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-rationale-therefore-of-combining-glp-1-ras-and-basal-insulin-into-fixed-ratio-combination-agents 2019-05-22T21:44:33+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-is-the-snp-based-approach-preferred-for-screening-for-microdeletions 2019-05-24T18:39:32+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-do-the-clinician-and-pharmacist-need-to-know-as-it-relates-to-what-drug-will-actually-be-dispensed-to-the-patient-when-a-prescription-is-issued-for-the-biosimilar-or-reference-drug 2019-05-23T19:13:09+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-value-of-molecular-profiling-in-the-first-line-setting-korean 2019-05-28T19:03:18+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-likelihood-that-a-patient-with-a-low-fetal-fraction-result-is-able-to-obtain-a-result-on-repeat-draw 2019-05-24T18:36:36+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-rationale-of-combining-glp-1-ras-and-long-acting-insulin-into-fixed-ratio-combination-agents 2019-05-22T21:42:23+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-clinical-implications-of-the-fact-that-liraglutide-s-benefits-were-seen-in-a-high-risk-population-that-was-already-on-maximal-therapy-for-cv-risk-reduction 2019-05-22T23:06:05+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-your-practice-how-early-do-you-recommend-performing-whole-exome-sequencing-and-in-what-tumors-and-is-it-critical-to-detect-mutations-translocations-allelic-fractions-and-amplifications 2019-05-28T19:04:21+0000 weekly 0.8 https://www.iqanda-cme.com/videos/based-on-physiologic-properties-which-patients-are-eligible-for-short-vs-long-acting-glp-1-ras-and-why-is-the-combination-of-basal-insulin-and-glp-1-ra-a-reasonable-strategy 2019-05-22T21:44:39+0000 weekly 0.8 https://www.iqanda-cme.com/videos/given-the-modest-reductions-in-such-cv-risk-factors-as-bp-and-weight-what-might-be-the-mechanistic-effects-that-explain-the-significant-reduction-in-cv-outcomes-observed-in-leader 2019-05-22T23:06:47+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-will-fixed-ratio-basal-insulin-glp-1-ra-combinations-likely-fit-into-the-sequencing-algorithm-for-diabetes-care-how-do-we-select-among-the-available-options-and-in-whom-should-we-use-these-formulations 2019-05-22T22:29:14+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-some-of-the-practical-real-world-aspects-of-using-snp-based-cell-free-dna-fractions-for-nipt-can-you-take-us-through-this-at-the-patient-care-interface 2019-05-24T18:39:24+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-meta-analysis-evidence-that-earlier-therapy-for-ra-is-preferable-to-improve-outcomes-what-is-the-conclusion-from-looking-at-the-medical-literature 2019-05-22T22:09:53+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-tnfis-and-il-6-inhibitors-compare-as-far-as-their-effectiveness-when-used-as-monotherapy 2019-05-22T22:02:18+0000 weekly 0.8 https://www.iqanda-cme.com/videos/if-met-amplification-is-documented-in-nsclc-why-is-crizotinib-considered-to-have-targeted-activity-against-this-tumor-profile-what-support-suggests-high-activity-in-patients-with-tumors-manifesting-this-genetic-alteration 2019-05-17T18:15:20+0000 weekly 0.8 https://www.iqanda-cme.com/videos/based-on-currently-available-snp-based-testing-platforms-for-nipt-including-the-panorama-test-and-results-of-clinical-studies-can-you-provide-a-clinical-practice-roadmap-for-the-foundational-role-and-actionable-information-chorionicity-z 2019-05-24T18:41:52+0000 weekly 0.8 https://www.iqanda-cme.com/videos/should-biologically-naive-patients-be-approached-differently-from-patients-on-previous-b-dmard-therapy-but-have-suboptimal-clinical-results-what-is-the-role-of-il-6-inhibitors-in-this-population 2019-05-22T21:59:57+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-has-nipt-progressed-from-first-to-second-generation-testing-and-what-specific-delineation-does-the-evolution-to-snp-based-testing-make-possible 2019-05-24T18:35:43+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-we-educate-clinicians-to-ensure-appropriate-safe-outcome-and-cost-effective-deployment-of-anti-tnf-biosimilars-in-the-setting-of-ra-as-and-related-conditions 2019-05-23T19:15:07+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-follow-up-should-be-done-when-nipt-is-discrepant-with-ultrasound-for-fetal-sex 2019-05-24T18:38:36+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-did-we-learn-from-the-leader-trial-about-regimen-adherence-with-once-daily-liraglutide 2019-05-22T23:01:03+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-will-hybrid-capture-based-ngs-improve-identification-of-patients-with-breast-cancer-who-will-benefit-from-trastuzumab-therapy 2019-05-28T19:07:54+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-clinical-trials-have-been-conducted-or-are-in-progress-evaluating-il-6-inhibitors-for-the-management-of-ra-can-you-discuss-tocilizumab-and-sarilumab-and-the-specific-trial-designs 2019-05-22T21:59:53+0000 weekly 0.8 https://www.iqanda-cme.com/videos/with-respect-to-clinical-response-what-is-the-trigger-for-using-a-different-moa-including-il-6-inhibition-in-a-patient-who-has-failed-a-tnfi 2019-05-22T22:08:24+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-identify-the-specific-composition-of-fixed-ratio-combination-long-acting-insulin/glpa-1-ra-formulations-and-how-clinicians-should-titrate-and-deploy-these-agents 2019-05-22T22:59:51+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-provide-some-discrete-clinical-and-patient-profiles-where-fixed-ratio-combination-regimens-consisting-of-a-long-acting-insulin-and-glp-1-ra-should-be-strongly-considered 2019-05-22T21:41:37+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-did-you-address-the-issue-of-a-poor-pain-control-and/or-b-recurrent-emergency-department-visits-and/or-hospital-readmissions-in-your-patients-who-underwent-bariatric-surgery 2019-05-23T00:59:41+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-a-no-call-result-and-what-are-the-implications-of-getting-this-result-what-is-the-approach-if-this-is-reported-what-is-the-role-of-fetal-fraction-in-producing-a-no-call-result 2019-05-24T18:38:29+0000 weekly 0.8 https://www.iqanda-cme.com/videos/trials-evaluating-il-6-inhibitors-such-as-sarilumab-in-ra-patients-have-used-global-function-and-disability-as-outcome-benchmarks-for-assessing-patient-outcomes-why-is-this-important 2019-05-22T22:08:59+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-has-the-landscape-of-actionable-alterations-changed-over-time-with-respect-to-new-fusion-configurations-in-the-setting-of-lung-cancer-for-example-and-how-do-we-approach-the-more-rare-cancers 2019-05-28T19:04:31+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-implications-of-fda-approval-of-pd-1-inhibitors-across-a-broad-spectrum-of-mismatch-repair-deficient-tumors-what-are-the-implications-for-ngs-based-molecular-diagnostics 2019-05-28T19:06:45+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-kind-of-clinical-samples-are-required-to-implement-next-generation-sequencing-ngs-can-ngs-be-applied-to-samples-other-than-ffpe 2019-05-17T18:19:26+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-biomarkers-clinical-findings-or-previous-treatment-history-do-you-rely-on-to-identify-patients-who-might-be-uniquely-responsive-to-il-6-inhibition 2019-05-22T21:58:26+0000 weekly 0.8 https://www.iqanda-cme.com/videos/nsclc-is-one-solid-tumor-where-comprehensive-genomic-profiling-can-dramatically-alter-precision-based-strategy-can-you-give-an-example-where-the-detection-of-a-rare-insertion-altered-treatment 2019-05-28T19:04:46+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-long-does-it-typically-take-to-receive-carrier-screening-results 2019-05-24T18:36:45+0000 weekly 0.8 https://www.iqanda-cme.com/videos/given-the-established-use-of-metformin-and-sglt2-inhibitors-as-oral-foundation-agents-where-do-you-believe-the-glp-1-ra/insulin-combination-regimens-which-are-injectable-are-likely-to-play-the-most-important-role-in-guideline-directed-ca 2019-05-22T22:29:59+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-does-ngs-vs-hot-spot-testing-address-the-changes-in-cancer-treatment-toward-the-use-of-molecularly-targeted-drugs-prescribed-to-selected-subsets-of-patients-across-multiple-tumor-types 2019-05-17T18:16:29+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-kinds-of-comparable-outcomes-and-end-points-are-investigators-documenting-when-comparing-the-reference-molecule-to-a-biosimilar-agent 2019-05-23T19:15:43+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-strengths-and-weaknesses-of-conventional-measures-of-ra-disease-activity-i-e-acr-scores-as-compared-to-patient-reported-outcomes-pros-and-what-is-the-role-of-treat-to-target 2019-05-22T22:16:07+0000 weekly 0.8 https://www.iqanda-cme.com/videos/when-a-suboptimal-clinical-response-has-been-encountered-with-a-traditional-dmard-what-therapeutic-approaches-for-escalating-therapy-are-appropriate 2019-05-22T22:08:18+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-does-snp-based-technology-compare-with-the-counting-method-when-you-are-utilizing-cffdna-to-identify-women-at-risk-for-carrying-microdeletion-syndromes 2019-05-24T18:35:37+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-characterize-the-different-laboratory-techniques-used-to-amplify-cell-free-dna-to-determine-the-likelihood-that-the-fetus-has-one-of-the-common-chromosome-abnormalities 2019-05-24T18:40:00+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-would-you-approach-a-65-year-old-patient-with-t2d-who-has-reasonable-control-of-fbg-but-clear-documentation-of-ppg 2019-05-22T21:41:32+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-mechanism-by-which-glp-1-ras-induce-weight-loss 2019-05-22T21:36:50+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-advances-in-long-acting-insulin-and-glp-1-ra-and-combination-approaches-are-having-a-positive-impact-on-management-of-t2d-how-should-pk/pd-properties-affect-our-choice-of-specific-glp-1-ra 2019-05-22T22:29:53+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-should-one-sequence-therapy-in-patients-who-require-biologics-is-there-a-one-sequence-fits-all-strategy-can-one-start-with-any-biologic-agent-as-initial-therapy-in-conjunction-with-methotrexate 2019-05-22T22:16:13+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-the-results-and-study-design-of-leader-differ-from-the-cv-outcomes-study-that-evaluated-lixisenatide-in-patients-with-t2d-was-the-cv-protection-seen-in-leader-observed-in-diabetic-patients-on-statins-how-does-leader-differ-from-th 2019-05-22T23:06:06+0000 weekly 0.8 https://www.iqanda-cme.com/videos/are-all-ngs-platforms-created-equally-how-are-they-different 2019-05-28T19:03:35+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-the-setting-of-lung-cancer-what-is-the-advantage-of-using-whole-exome-ngs-versus-targeted-gene-testing-why-do-you-advocate-comprehensive-molecular-profiling 2019-05-28T19:06:35+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-implications-of-using-anti-tnf-biosimilars-for-clinical-practice-in-ra-for-cost-savings-what-have-we-learned-about-biosimilars-for-infliximab-in-the-setting-of-ra 2019-05-23T19:13:15+0000 weekly 0.8 https://www.iqanda-cme.com/videos/which-patient-subgroups-with-t2d-do-you-feel-are-the-best-candidates-for-fixed-ratio-combination-therapy 2019-05-22T23:06:43+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-current-and-emerging-role-of-liquid-biopsies 2019-05-17T18:18:51+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-importance-of-finding-egfr-sensitizing-mutations-such-as-exon-19-or-exon-21-in-nsclc-what-is-their-relationship-to-sensitivity-to-tkis-such-as-erlotinib-gefitinib-and-afatinib 2019-05-17T18:20:58+0000 weekly 0.8 https://www.iqanda-cme.com/videos/with-respect-to-acr-treatment-guidelines-for-ra-do-you-differentiate-between-conventional-synthetic-and-biologic-dmards 2019-05-22T21:59:48+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-make-sense-of-the-results-and-designs-of-the-various-cardiovascular-outcome-trials-including-the-leader-trial-in-patients-with-t2d-and-what-do-you-believe-is-the-take-home-message 2019-05-22T21:36:55+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-aspects-of-glp-1-ra-do-you-think-are-most-important-for-the-practicing-physician-caring-for-patients-with-t2d 2019-05-22T21:36:13+0000 weekly 0.8 https://www.iqanda-cme.com/videos/other-non-opioid-iv-agents-that-have-been-explored-as-co-therapies-to-achieve-eras-does-iv-acetaminophen-have-properties-that-are-superior-to-other-agents-in-the-multimodal-perioperative-context 2019-05-23T01:08:08+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-summarize-the-key-dimensions-of-the-leader-trial-evaluating-the-effect-of-liraglutide-on-cv-outcomes-including-its-design-physiologic-rationale-data-collection-and-clinical-objectives 2019-05-22T23:12:32+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-additional-clinical-value-of-using-a-hybrid-capture-based-ngs-platform-can-you-discuss-in-terms-of-false-negativity-and-sensitivity-analyses1 2019-05-17T18:20:37+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-were-trials-designed-that-evaluated-the-effectiveness-and-safety-of-the-fixed-ratio-combination-of-insulin-glargine-and-lixisenatide-and-what-did-we-learn-about-titration-and-mitigating-side-effects 2019-05-22T21:41:34+0000 weekly 0.8 https://www.iqanda-cme.com/videos/is-there-a-patient-preference-component-that-is-a-significant-driver-to-helping-select-agents-for-multimodal-therapy-and-what-about-expectations-as-part-of-the-eras-pathway 2019-05-23T00:59:52+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-would-you-approach-a-middle-aged-female-non-smoker-diagnosed-with-stage-1-b-lung-adenocarcinoma-in-which-the-foundationone-cgp-identified-a-trim33-ret-fusion 2019-05-17T18:15:13+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-pharmacoeconomic-and-pain-management-policy-implications-of-your-study-evaluating-costs-and-clinical-metrics-in-bariatric-surgery-patients-managed-with-iv-acetaminophen 2019-05-23T00:59:08+0000 weekly 0.8 https://www.iqanda-cme.com/videos/given-its-efficacy-and-safety-profile-across-what-range-of-surgical-procedures-is-iv-acetaminophen-ideally-employed-as-part-of-an-eras-strategy-in-the-context-of-multimodal-pain-mitigation 2019-05-23T01:08:01+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-clinical-and-trial-data-including-false-positive-rates-and-ppv-supporting-the-expanded-routine-use-of-cell-free-dna-based-nipt-in-lower-and-average-risk-patients 2019-05-24T18:37:30+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-give-an-example-of-a-patient-in-which-the-failure-to-initially-deploy-but-subsequent-use-of-ngs-based-comprehensive-molecular-profiling-led-to-improvements-in-their-clinical-course 2019-05-28T19:06:51+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-provide-an-overview-of-the-actionable-targets-such-as-egfr-alk-and-met-that-are-relevant-for-patients-with-nsclc-and-how-to-deploy-ngs-technologies-to-identify-molecular-drivers 2019-05-17T18:15:15+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-compare-platforms-for-genomic-profiling-hot-spot-panels-mammoprint-cgp-with-hybrid-capture-and-explain-why-cgp-platforms-with-hybrid-capture-have-emerged-as-the-gold-standard 2019-05-17T18:21:04+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-importance-of-finding-egfr-sensitizing-mutations-such-as-exon-19-or-exon-21-in-nsclc-what-is-their-relationship-to-sensitivity-to-tkis-such-as-erlotinib-gefitinib-and-afatinib1 2019-05-17T18:14:40+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-discuss-study-design-rationale-results-and-clinical-implications-of-the-most-recent-clinical-evidence-focused-on-the-safety-immunogenicity-and-efficacy-of-approved-biosimilar-therapies-for-ra 2019-05-23T19:15:21+0000 weekly 0.8 https://www.iqanda-cme.com/videos/if-you-have-a-surgical-patient-who-is-on-both-iv-acetaminophen-and-an-iv-opioid-and-the-patient-becomes-intolerant-to-the-opioid-can-you-continue-the-iv-acetaminophen-alone-as-monotherapy 2019-05-23T01:03:04+0000 weekly 0.8 https://www.iqanda-cme.com/videos/based-on-the-results-of-the-leader-trial-where-would-you-likely-position-liraglutide-in-the-framework-of-individualized-ada/easd-guidelines 2019-05-22T23:00:50+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-explain-current-policy-as-it-relates-to-biosimilars-including-considerations-that-apply-to-interchangeability-for-anti-tnf-biosimilars-and-product-naming-guidelines 2019-05-23T19:15:17+0000 weekly 0.8 https://www.iqanda-cme.com/videos/using-foundationone-ngs-based-whole-exome-profiling-what-foundational-and-clinically-actionable-information-is-provided-and-how-should-clinicians-apply-findings-to-the-front-lines-of-practice 2019-05-28T19:04:28+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-withdrawal-and-regimen-adherence-rates-with-the-glp-1-ra/insulin-regimens-and-how-do-the-fixed-ratio-combination-formulations-affect-gi-side-effects-sometimes-encountered-with-glp-1-ras-is-the-incidence-of-side-effects-lower 2019-05-22T22:29:55+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-general-can-we-extrapolate-efficacy-of-biosimilars-across-all-the-disease-states-for-which-the-originator-has-indication 2019-05-23T19:15:14+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-role-of-incretin-axis-for-lowering-ppg 2019-05-22T21:36:18+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-multiple-benefits-of-carrier-screening-why-should-carrier-testing-be-a-routine-part-of-the-prenatal-evaluation-process-and-what-ethnic-groups-or-families-will-benefit-most 2019-05-24T18:37:22+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-rationale-for-using-genome-wide-ngs-in-the-setting-of-precision-cancer-medicine 2019-05-28T19:07:00+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-is-whole-genome-sequencing-with-ngs-uniquely-applicable-to-patients-with-nsclc 2019-05-28T19:03:31+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-you-approach-drug-selection-decisions-when-you-encounter-multiple-actionable-targets 2019-05-17T18:20:35+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-side-effects-should-we-be-on-the-lookout-for-in-patients-treated-with-il-6-inhibitors-and-how-should-we-manage-them 2019-05-22T22:09:15+0000 weekly 0.8 https://www.iqanda-cme.com/videos/for-which-solid-tumors-do-you-find-ngs-genomic-profiling-to-be-most-valuable-for-identifying-molecular-drivers-that-can-reliably-guide-the-use-of-targeted-therapy 2019-05-17T18:19:24+0000 weekly 0.8 https://www.iqanda-cme.com/videos/which-results-from-leader-are-the-most-transformative-as-far-as-cv-risk-reduction-in-t2d-and-what-might-the-implications-be-about-the-mechanism-by-which-liraglutide-reduces-cv-events 2019-05-22T22:59:57+0000 weekly 0.8 https://www.iqanda-cme.com/videos/is-there-a-one-sequence-fits-all-strategy-or-can-one-start-with-any-of-the-biologic-agents-as-an-initial-therapy-in-conjunction-with-methotrexate 2019-05-22T22:10:03+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-give-us-an-example-of-a-real-world-patient-with-a-rare-or-refractory-cancer-whose-treatment-course-was-altered-by-an-ngs-based-foundationone-report 2019-05-28T19:04:44+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-important-is-the-mechanistic-complementarity-between-basal-insulin-and-glp-1-ras-and-what-implication-does-this-have-for-fixed-ratio-combinations-such-as-iglarlixi-and-ideglira 2019-05-22T21:36:22+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-still-unanswered-questions-about-combination-basal-insulin-glp-1-ra-formulations 2019-05-22T21:44:37+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-would-you-deploy-the-fixed-ratio-combination-agents-in-a-58-year-old-obese-male-patient-who-was-not-meeting-ha1c-target-goals-on-metformin-alone-or-a-second-oral-agent 2019-05-22T21:37:58+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-microdeletions-and-what-is-the-rationale-for-offering-screening-for-these-conditions-using-nipt-especially-to-detect-for-with-a-microdeletion-syndrome-such-as-22q11-1 2019-05-24T18:39:30+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-metabolic-or-hematologic-markers-should-we-monitor-in-patients-on-il-6-therapy 2019-05-22T22:02:19+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-patients-be-expected-to-absorb-po-acetaminophen-as-soon-as-they-are-tolerating-a-liquid-diet-following-cardiac-surgery 2019-05-23T01:01:33+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-has-been-your-experience-with-the-cmmi-cabg-bundle-and-how-has-this-affected-your-approach-to-eras-protocols 2019-05-23T01:02:15+0000 weekly 0.8 https://www.iqanda-cme.com/videos/when-in-the-course-of-diagnosis-and-history-does-whole-exome-hybrid-capture-ngs-sequencing-fit-into-the-diagnostic-roadmap-for-identifying-targeted-therapies-how-does-ngs-compare-to-hot-spot-testing 2019-05-28T19:06:47+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-attributes-mechanistically-metabolically-and-physiologically-of-glp-1-ras-in-your-mind-support-their-position-as-foundational-agents-across-a-broad-spectrum-of-patients-with-t2d 2019-05-22T21:42:22+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-degree-of-ha1c-lowering-do-the-studies-report-with-the-use-of-glp-1-ras 2019-05-22T21:36:51+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-does-nipt-differ-from-aneuploidy-screening-using-maternal-serum-hormone-levels-combining-maternal-serum-hormone-levels/biochemistry-and-ultrasound-markers 2019-05-24T18:38:39+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-we-assess-to-what-degree-ppg-is-playing-a-role-in-failing-to-achieve-goal-directed-ha1c-levels-how-do-we-use-fpg-and-ppg-to-determine-the-need-for-agents-for-ppg-control 2019-05-22T21:38:00+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-long-of-a-trial-using-traditional-dmard-therapy-with-methotrexate-do-you-recommend-prior-to-intensifying-treatment-with-a-biologic-agent 2019-05-22T22:08:13+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-types-of-diseases-are-typically-considered-for-carrier-screening 2019-05-24T18:37:25+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-adverse-effects-should-clinicians-be-aware-of-when-treating-ra-patients-with-il-6-inhibitors 2019-05-22T22:02:13+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-addition-to-iv-acetaminophen-pre-op-and-post-op-how-do-you-combine-it-with-opioids-do-you-use-the-iv-narcotic-as-a-primary-pain-reliever-in-bariatric-surgery-or-as-a-rescue-medication 2019-05-23T00:58:57+0000 weekly 0.8 https://www.iqanda-cme.com/videos/when-evaluating-receptivity-of-a-patient-and-tumor-to-immune-checkpoint-blockade-why-are-total-mutational-burden-and-genomic-stability-as-important-as-expression-of-the-ic-receptor 2019-05-28T19:05:40+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-recommended-guidelines-for-carrier-screening-what-are-the-similarities-and-differences-among-different-professional-societies-and-associations 2019-05-24T18:36:39+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-trial-based-evidence-do-you-think-is-most-compelling-to-support-the-use-of-iv-acetaminophen-in-tkr-and-thr-a-high-pain-model-in-orthopedic-surgery-context 2019-05-23T01:01:22+0000 weekly 0.8 https://www.iqanda-cme.com/videos/are-there-any-contraindications-to-the-use-of-iv-acetaminophen-in-the-setting-of-bariatric-or-other-surgical-procedures-what-are-the-implications-for-dosing-and/or-dose-reduction 2019-05-23T01:07:51+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-you-differentiate-among-the-available-biologics-with-respect-to-their-propensity-to-produce-side-effects-or-other-treatment-complications 2019-05-22T21:58:25+0000 weekly 0.8 https://www.iqanda-cme.com/videos/which-of-the-nipt-reports-snp-tests-by-specific-laboratories-are-known-to-have-the-advantage-of-having-high-positive-predictive-values-ppv 2019-05-24T18:40:07+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-general-how-rapid-is-the-onset-of-action-of-il-6-inhibitors-and-can-these-agents-be-used-as-monotherapy 2019-05-22T22:16:16+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-the-simplified-disease-activity-index-sdai-or-cdai-provide-information-that-guides-aggressiveness-of-ra-therapy-do-you-consider-abnormal-results-sufficient-to-trigger-biologic-therapy 2019-05-22T22:16:09+0000 weekly 0.8 https://www.iqanda-cme.com/videos/by-what-mechanisms-do-you-think-the-glp-1-ra-liraglutide-might-have-affected-cardiovascular-events-based-on-the-finding-of-the-leader-trial 2019-05-22T23:06:14+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-can-a-provider-expect-with-respect-to-timing-of-results-reporting-methods-and-technical-support-for-nipt-results 2019-05-24T18:38:32+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-share-a-case-history-of-a-patient-who-was-failing-multiple-standard-therapies-and-then-responded-to-treatment-based-on-ngs-profiling 2019-05-28T19:06:40+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-optimal-dosing-for-iv-acetaminophen-and-how-should-it-be-combined-with-other-modalities-what-is-the-safety-profile-of-iv-acetaminophen-and-what-is-its-opioid-sparing-profile-for-cardiac-surgical-patients 2019-05-23T01:02:49+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-treatment-triggers-for-employing-disease-modifying-anti-rheumatic-drugs-dmards-what-classes-of-biologic-agents-including-il-6-inhibitors-have-demonstrated-efficacy-as-monotherapy 2019-05-22T22:02:11+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-is-iv-acetaminophen-your-foundational-multimodal-agent-and-as-a-surgical-patient-transitions-from-iv-to-po-acetaminophen-after-cardiac-surgery-what-are-some-of-the-pitfalls-and-tips-for-making-this-transition 2019-05-23T01:02:50+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-most-important-activating-egfr-mutations-and-what-are-the-specific-implications-of-their-detection-and-what-if-these-patients-relapse-on-a-tki 2019-05-28T19:06:04+0000 weekly 0.8 https://www.iqanda-cme.com/videos/since-the-reduction-in-non-fatal-mi-in-the-leader-trial-was-not-significant-enough-to-explain-the-impressive-22-in-cv-mortality-what-factors-do-you-think-might-have-played-a-role 2019-05-22T23:06:03+0000 weekly 0.8 https://www.iqanda-cme.com/videos/once-analytics-pharmacokinetics-pharmacodynamics-and-clinical-trials-confirm-the-clinical-value-and-safety-of-the-biosimilar-how-does-this-translate-into-cost-savings 2019-05-23T19:15:54+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-rationale-for-incorporating-genomic-target-driven-therapies-into-the-front-lines-of-oncology-practice-can-we-expect-ngs-to-uncover-more-molecular-drivers-and-actionable-mutations 2019-05-17T18:20:24+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-implications-of-fda-approval-of-pd-1-inhibitors-for-msi-high-tumors-and-what-other-molecular-alterations-might-trigger-immunotherapy-based-on-ngs-generated-markers-and-drivers-agnostic-to-tumor-type 2019-05-28T19:04:15+0000 weekly 0.8 https://www.iqanda-cme.com/videos/do-the-trials-with-the-il-6-inhibitor-sarilumab-suggest-any-differences-between-this-agent-and-the-establish-il-6-inhibitor-indicated-for-ra 2019-05-22T22:08:26+0000 weekly 0.8 https://www.iqanda-cme.com/videos/with-respect-to-reduction-in-overall-costs-associated-with-deployment-of-pre-and-post-operative-iv-acetaminophen-in-bariatric-surgery-where-did-you-observe-the-greatest-cost-savings 2019-05-23T00:59:37+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-do-clinicians-managing-patients-with-t2d-need-to-be-aware-of-the-trials-physiologic-basis-side-effects-and-other-dimensions-of-deploying-fixed-ratio-long-acting-insulin-glp-1-ra-combination-regimens 2019-05-22T22:29:15+0000 weekly 0.8 https://www.iqanda-cme.com/videos/as-an-investigator-for-leader-what-features-of-this-study-with-respect-to-cv-and-mortality-outcomes-deserve-special-emphasis-how-do-they-differ-from-other-cv-outcome-trials-in-diabetes 2019-05-22T23:06:45+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-clinical-trials-have-been-conducted-and/or-are-currently-in-progress-evaluating-il-6-inhibitors-for-ra-how-are-the-trials-designed-to-identify-patients-most-suitable-for-il-6-inhibition 2019-05-22T22:02:09+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-walk-us-through-the-practical-and-best-practice-aspects-and-roadmap-for-how-to-dose-and-infuse-iv-acetaminophen-including-timing-and-duration-of-administration-as-part-of-an-eras-protocol 2019-05-23T01:01:17+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-discuss-study-design-rationale-results-and-clinical-implications-of-the-most-recent-clinical-evidence-focused-on-the-safety-immunogenicity-and-efficacy-of-approved-biosimilar-therapies-for-ra1 2019-05-23T19:15:47+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-mechanism-s-of-action-by-which-iv-acetaminophen-exerts-its-pain-relieving-properties-and-how-is-this-differentiated-from-other-agents 2019-05-23T01:02:05+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-did-the-tkr-orthopedic-study-by-sinatra-and-colleagues-show-about-the-pain-relieving-properties-of-iv-acetaminophen-four-doses-and-its-effect-on-rescue-opioid-use-and-reduction-of-total-morphine-usage 2019-05-23T01:02:10+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-are-you-using-ngs-and-comprehensive-genomic-profiling-in-south-korea-and-in-which-cancer-subtypes-are-you-using-ngs-to-identify-actionable-molecular-targets-and-targeted-treatment-strategies-korean 2019-05-28T19:08:52+0000 weekly 0.8 https://www.iqanda-cme.com/videos/do-you-use-iv-acetaminophen-as-part-of-a-standardized-protocol-or-do-you-select-patients-you-think-are-appropriate-for-this-approach-based-on-specific-criteria 2019-05-23T00:59:03+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-benefits-of-agg-interruption-testing-as-part-of-carrier-screening-for-fragile-x-syndrome 2019-05-24T18:37:21+0000 weekly 0.8 https://www.iqanda-cme.com/videos/given-some-of-the-conflicting-results-reported-by-precision-medicine-trials-how-do-you-reconcile-some-of-the-divergent-results-and-their-implications-for-ngs-based-molecular-stratification 2019-05-28T19:04:12+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-the-sensitivities-and-false-positive-rates-for-aneuploidy-and-gender-the-improved-ppv-for-snp-in-sex-chromosome-abnormalities-in-particular-compare-for-the-various-methodologies 2019-05-24T18:40:04+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-specific-information-variances-actionable-guidance-and-clinical/biological-interpretations-are-provided-on-a-ngs-pathology-report-how-do-you-apply-an-ngs-report-clinically-korean 2019-05-28T19:07:40+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-rationale-for-early-dmard-therapy-once-the-diagnosis-of-ra-is-established 2019-05-22T22:09:12+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-would-deploy-the-fixed-ratio-combination-agents-in-an-obese-patient-who-was-not-meeting-ha1c-target-goals-on-metformin-alone-or-a-second-oral-agent 2019-05-22T21:42:34+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-clinical-importance-of-avoiding-the-hepatic-first-pass-effect-when-using-the-iv-versus-oral-formulation-of-acetaminophen-and-what-pk-auc-and-c-max-advantages-and-tissue-penetration/compartment-effects-are-observed-that-are-re 2019-05-23T01:01:20+0000 weekly 0.8 https://www.iqanda-cme.com/videos/do-you-monitor-leukocyte-counts-in-ra-patients-taking-il-6-inhibitors 2019-05-22T22:09:52+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-evidence-for-early-aggressive-therapy-with-biologics-in-ra 2019-05-22T22:03:04+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-we-extrapolate-from-what-we-learned-about-liraglutide-in-the-leader-trial-to-combination-therapy-that-would-employ-a-basal-insulin-in-combination-with-this-glp-1-ra 2019-05-22T21:36:48+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-role-of-ngs-and-role-of-fusion-detection-in-particular-in-wild-type-egfr-nsclc-non-squamous-head-and-neck-cancer-and-glioblastoma 2019-05-28T19:08:37+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-dosing-schedule-do-you-recommend-for-acetaminophen-why-do-you-feel-that-iv-acetaminophen-is-preferable-to-oral-and-what-is-the-effect-of-iv-opioids-on-absorption-and-blood-levels 2019-05-23T01:02:59+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-would-you-integrate-all-the-currently-available-tests-ngs-based-mutational-profiles-and-burden-and-ihc-biomarkers-to-stratify-patients-into-cohorts-likely-to-be-responsive-to-pd-1-checkpoint-inhibitors 2019-05-28T19:07:51+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-do-we-know-about-the-cost-effectiveness-and-superiority-of-nipt-why-is-the-snp-based-nipt-more-cost-effective-than-serum-screening 2019-05-24T18:38:35+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-summarize-your-study-results-evaluating-cost-savings-and-clinical-metric-improvements-using-iv-acetaminophen-within-multimodal-pain-management-for-bariatric-surgery 2019-05-23T00:59:39+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-predictors-of-risk-progression-and/or-poor-therapeutic-response-in-ra-that-would-make-a-patient-appropriate-for-early-aggressive-therapy-with-biologic-therapy 2019-05-22T21:58:16+0000 weekly 0.8 https://www.iqanda-cme.com/videos/is-it-appropriate-to-offer-nipt-to-a-patient-with-a-known-vanished-twin 2019-05-24T18:35:35+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-slow-dose-titration-strategies-for-the-fixed-ratio-combination-formulations-i-e-glargine-insulin-plus-lixisenatide-vs-degludec-insulin-plus-liraglutide-potentially-affect-the-side-effects-seen 2019-05-22T21:42:29+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-significant-differences-in-time-points-and-types-of-vascular-benefits-seen-in-leader-using-a-glp-1-ra-vs-the-empa-reg-trial-which-evaluated-an-sglt2-inhibitor 2019-05-22T23:01:00+0000 weekly 0.8 https://www.iqanda-cme.com/videos/are-there-head-to-head-comparisons-looking-at-the-effects-of-different-glp-1-ras-on-ppg-control-what-are-the-results-and-implications-of-those-studies 2019-05-22T21:38:03+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-a-front-lines-translational-perspective-where-are-combination-insulin-plus-glp-1-ra-regimens-likely-to-fit-into-the-sequencing-algorithm-for-care-of-patients-with-t2d 2019-05-22T22:29:22+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-optimal-dosing-schedule-for-iv-acetaminophen-and-how-should-it-be-combined-with-opioid-therapy 2019-05-23T01:02:01+0000 weekly 0.8 https://www.iqanda-cme.com/videos/length-of-stay-is-a-critical-cost-and-best-practice-metric-what-have-studies-shown-as-far-as-the-effect-of-iv-acetaminophen-on-los-and-eras-across-surgical-procedures 2019-05-23T01:08:05+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-rationale-for-deploying-snp-based-nipt-in-larger-swaths-of-the-population-especially-in-lower-risk-populations-do-recent-acmg-guidelines-suggest-a-value-in-low-risk-patients 2019-05-24T18:39:27+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-dose-of-iv-acetaminophen-do-you-recommend-for-your-cabg-patients-and-have-any-of-the-patients-who-received-iv-acetaminophen-after-cardiac-surgery-required-no-other-iv-narcotics 2019-05-23T01:02:44+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-identify-the-specific-composition-of-fixed-ratio-combination-long-acting-insulin/glpa-1-ra-formulations-and-how-clinicians-should-titrate-and-deploy-these-agents1 2019-05-22T21:41:30+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-do-t-max-focused-studies-show-about-the-advantages-of-the-iv-route-of-administration-of-acetaminophen-over-oral-and-other-formulations 2019-05-23T01:03:50+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-do-you-recommend-regarding-the-timing-for-ngs-based-genomic-profiling-do-you-believe-it-should-be-used-early-in-the-neoadjuvant-setting-or-only-in-advanced-resistant-or-metastatic-disease-korean 2019-05-28T19:09:30+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-clinical-scenarios-and-patient-types-with-ra-and-related-diseases-can-you-imagine-where-the-use-of-a-biosimilar-infliximab-dyyb-or-others-makes-good-pharmacoeconomic-and-clinical-sense 2019-05-23T19:15:55+0000 weekly 0.8 https://www.iqanda-cme.com/videos/are-there-any-specific-patient-profiles-in-ra-or-biomarker-signatures-that-would-suggest-that-a-patient-might-respond-better-to-one-biologic-dmard-and-moa-including-il-6-inhibition-versus-another 2019-05-22T21:58:24+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-can-a-snp-based-test-performed-as-early-as-9-weeks-help-reduce-the-risk-of-potential-complications-of-twin-to-twin-transfusion-syndrome-in-what-way-is-ultrasound-less-accurate-than-nipt-in-diagnosing-monochorionicity-in-a-twin-pregna 2019-05-24T18:41:57+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-review-for-us-the-design-and-rationale-of-the-leader-trial 2019-05-22T22:59:46+0000 weekly 0.8 https://www.iqanda-cme.com/videos/where-might-the-fixed-ratio-combination-regimens-consisting-of-a-long-acting-insulin-and-glp-1-ra-fit-into-the-ada-and-aace-guidelines-and-how-do-your-see-their-use-in-the-sequencing-algorithm-for-t2d 2019-05-22T21:37:57+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-a-clinical-perspective-who-are-the-ideal-patient-candidates-for-the-fixed-ratio-combination-formulations-i-e-glargine-insulin-plus-lixisenatide-vs-degludec-insulin-plus-liraglutide 2019-05-22T21:36:52+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-we-use-biomarkers-in-any-way-to-help-align-therapy-in-ra-with-a-specific-therapeutic-agent 2019-05-22T21:59:45+0000 weekly 0.8 https://www.iqanda-cme.com/videos/are-there-next-generation-glp-1-ras-in-development-how-are-they-similar-and-how-might-they-differ-from-currently-available-agents-dosing-wise-efficacy-side-effects-weight-loss 2019-05-22T23:06:52+0000 weekly 0.8 https://www.iqanda-cme.com/videos/at-what-stage-of-a-cancer-s-presentation-is-the-oncologist-advised-to-deploy-genomic-profiling-to-inform-clinical-decision-making-and-therapeutic-choices-aligned-with-specific-alterations-and-mutations 2019-05-17T18:20:32+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-you-initiate-dmard-therapy-and-what-agents-or-combinations-do-you-employ 2019-05-22T22:03:10+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-unique-value-of-cell-free-dna-snp-based-testing-in-the-setting-of-vanishing-twins-why-and-how-is-the-test-employed-what-is-the-limitation-of-the-counting-method-in-this-case 2019-05-24T18:39:25+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-ethics-on-a-societal-and-individual-level-of-nipt-screening-and-why-is-it-critical-that-we-screen-for-these-fetal-abnormalities 2019-05-24T18:39:33+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-have-your-studies-shown-as-far-as-the-optimal-way-to-advance-basal-insulin-therapy-and-combining-basal-insulin-with-either-prandial-insulin-or-a-glp-1-ra 2019-05-22T21:36:21+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-physiologic-and-clinical-rationale-for-combining-basal-insulin-and-a-glp-1-ra-as-a-treatment-strategy-for-t2d 2019-05-22T21:37:54+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-should-clinicians-managing-patients-with-ra-select-among-available-agents-including-biosimilars-for-infliximab 2019-05-23T19:15:12+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-was-liraglutide-titrated-and-what-dose-end-point-were-you-trying-to-achieve-what-was-the-adherence-rate-to-the-study-medication-in-the-liraglutide-arm 2019-05-22T23:12:17+0000 weekly 0.8 https://www.iqanda-cme.com/videos/although-you-work-in-a-tertiary-cancer-referral-and-research-center-where-many-patients-have-advanced-disease-at-what-point-in-the-natural-history-of-cancer-do-you-think-is-the-ideal-time-to-perform-ngs 2019-05-28T19:06:42+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-strengths-and-weaknesses-of-conventional-measures-of-ra-disease-activity-i-e-acr-scores-as-compared-to-the-increasingly-important-patient-reported-outcomes-pros 2019-05-22T22:10:08+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-is-hybrid-capture-based-sequencing-the-optimal-molecular-profiling-platform-in-precision-cancer-medicine-can-you-use-lung-cancer-as-an-example-of-how-ngs-can-generate-drug-alignments-korean 2019-05-28T19:03:21+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-a-practical-perspective-how-should-we-deploy-the-new-ultra-long-basal-insulins-and-for-which-patient-populations-t1d-and/or-t2d-are-they-best-suited-how-are-these-agents-titrated 2019-05-22T23:12:27+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-translational-implications-for-ngs-as-you-understand-it-from-the-results-of-the-aacr/msk-genie-consortium-project-recently-reported-in-cancer-discovery 2019-05-28T19:08:41+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-other-agents-or-perioperative-physiological-factors-can-affect-absorption-of-oral-acetaminophen-thereby-making-this-route-potentially-problematic-and-less-reliable-than-iv-acetaminophen 2019-05-23T01:01:28+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-actionable-interfaces-between-ngs-based-whole-exome-profiling-and-immunotherapy-focusing-on-new-data-on-tumor-mutational-burden-microsatellite-instability-msi-and-related-signatures 2019-05-28T19:07:44+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-are-current-genomic-testing-models-based-on-targeted-sequencing-hot-spot-less-sustainable-and-less-effective-than-comprehensive-ngs-based-genomic-profiling-cgp 2019-05-28T19:04:39+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-benefits-of-screening-for-sex-chromosome-aneuploidies-scas 2019-05-24T18:39:22+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-your-guidance-about-when-to-integrate-tests-for-circulating-tumor-dna-ctdna-into-protocols-for-precision-cancer-medicine-how-does-this-test-compare-to-tissue-based-ngs 2019-05-28T19:07:48+0000 weekly 0.8 https://www.iqanda-cme.com/videos/does-ngs-report-molecular-rearrangements-as-an-all-or-none-phenomenon-what-is-the-importance-of-subclones-as-far-as-interpretation-of-genomic-profiles-of-tumors-spanish 2020-08-11T00:03:26+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-disease-activity-measures-for-ra-do-you-consider-to-be-most-important 2019-05-22T22:03:12+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-evidence-that-personalized-gene-directed-cancer-therapy-in-which-specific-molecular-drivers-of-a-patient-s-disease-are-aligned-with-specific-therapy-will-improve-outcomes2 2019-05-21T23:46:51+0000 weekly 0.8 https://www.iqanda-cme.com/videos/interventional-cardiologists-have-a-strong-incentive-to-use-pcsk9-inhibitors-in-many-high-risk-patients-but-real-world-factors-such-as-cost-can-present-barriers-to-optimizing-cv-risk-prevention-can-you-discuss-this-and-its-relevance-to-t 2019-03-20T16:01:32+0000 weekly 0.8 https://www.iqanda-cme.com/videos/does-foundationone-s-comprehensive-genomic-profiling-have-validation-studies-confirming-accuracy-across-multiple-alterations-in-a-peer-reviewed-journal1 2019-05-21T23:25:59+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-is-genomic-profiling-helpful-in-identifying-actionable-molecular-targets 2019-05-22T00:05:45+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-what-ways-does-ngs-and-cgp-address-the-fundamental-changes-that-cancer-treatment-is-undergoing-toward-the-use-of-molecularly-targeted-drugs-prescribed-to-patients-across-tumor-types 2019-05-17T18:19:25+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-evidence-that-personalized-gene-directed-cancer-therapy-in-which-specific-molecular-drivers-of-a-patient-s-disease-are-aligned-with-specific-therapy-will-improve-outcomes 2019-05-17T18:16:28+0000 weekly 0.8 https://www.iqanda-cme.com/videos/eular-guidelines-as-well-as-acr-recommendations-for-ra-management-are-relatively-agnostic-as-far-as-which-biologic-dmard-should-be-used-to-intensify-ra-therapy-after-a-methotrexate-or-other-synthetic-dmard-failure-what-factors-do-you-con 2019-05-22T21:58:22+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-dosing-considerations-should-we-keep-in-mind-for-liraglutide-based-on-the-results-of-the-leader-trial-and-what-are-the-implications-for-insulin-glp-1-ra-combination-therapy 2019-05-22T23:06:13+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-asa/aps-guideline-recommendations-for-multimodal-perioperative-pain-management-and-how-important-are-opioids-as-drivers-to-prolongation-of-los 2019-05-23T01:01:57+0000 weekly 0.8 https://www.iqanda-cme.com/videos/at-what-point-in-the-natural-history-of-a-cancer-do-you-recommend-that-ngs-cgp-with-a-hybrid-capture-based-platform-like-foundationone-be-performed 2019-05-17T18:20:22+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-similar-are-biosimilars-to-the-originator-product-what-confidence-intervals-are-acceptable-and-what-level-of-analytical-rigor-and-drift-are-acceptable 2019-05-23T19:15:08+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-in-both-ada-and-aace-guidelines-statements-do-glp-1-receptor-agonists-represent-a-foundational-approach-for-management-of-t2d 2019-05-22T21:44:31+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-key-clinical-parameters-biomarkers-symptoms-and-patient-reported-outcomes-do-you-prioritize-when-determining-the-need-for-escalating-therapy-in-ra 2019-05-22T21:59:55+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-degree-of-ha1c-reductions-can-we-expect-to-see-with-fixed-ratio-basal-insulin-glp-1-ra-combinations 2019-05-22T21:36:16+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-relationship-between-between-glp-1-ra-and-body-weight-what-did-we-learn-about-liraglutide-dosing-regimens-and-body-weight-specifically-weight-loss-from-leader-and-other-trials 2019-05-22T23:06:50+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-role-of-b-cell-depletion-therapy-in-ra 2019-05-22T22:09:01+0000 weekly 0.8 https://www.iqanda-cme.com/videos/do-we-currently-have-biomarkers-in-the-setting-of-ra-that-will-predict-patient-response-to-the-range-of-agents-including-inhibitors-of-il-6-tnf-and-other-signaling-cytokines-currently-used-for-ra 2019-05-22T22:02:02+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-is-the-combination-of-basal-insulin-and-a-glp-1-ra-logical-from-the-standpoint-of-mechanistic-complementarity 2019-05-22T21:41:27+0000 weekly 0.8 https://www.iqanda-cme.com/videos/which-of-the-four-classes-of-genomic-alterations-base-substitutions-insertions-and-deletions-copy-number-alterations-and-rearrangements-can-a-typical-multi-gene-hot-spot-test-detect 2019-05-17T18:18:49+0000 weekly 0.8 https://www.iqanda-cme.com/videos/are-all-expanded-carrier-screenings-the-same-how-do-these-technologies-differ-what-screening-technology-do-you-use-and-why 2019-05-24T18:37:17+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-your-impressions-of-the-profiler-study-and-its-implications-for-employing-ngs-and-channeling-people-into-trials-driven-by-early-molecular-profiling 2019-05-28T19:04:34+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-do-we-know-about-dosing-as-it-might-impact-cv-outcomes-for-liraglutide-in-the-leader-trial-and-how-does-this-compare-to-what-we-learned-from-sglt2-inhibitor-based-cv-outcomes-trials 2019-05-22T21:36:57+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-an-ha1c-control-perspective-what-is-the-advantage-of-using-glp-1-ras-in-combination-with-long-acting-insulin-rather-than-as-stand-alone-therapy-or-as-add-on-to-metformin 2019-05-22T21:42:33+0000 weekly 0.8 https://www.iqanda-cme.com/videos/do-you-have-any-explanation-for-why-liraglutide-was-associated-a-lower-risk-of-hypoglycemia-than-in-the-control-arm-of-the-leader-trial 2019-05-22T23:00:02+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-physiological-safety-efficacy-and-compliance-focused-rationale-for-combining-basal-insulin-plus-glp-1-ra-into-a-fixed-ratio-formulation-how-does-this-impact-fpg-and-ppg-control1 2019-05-22T21:41:29+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-should-one-optimally-sequence-therapy-in-patients-who-require-biologic-therapy-is-there-a-one-sequence-fits-all-strategy 2019-05-22T22:16:08+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-discuss-the-unique-mechanistic-effects-of-il-6-inhibition-including-the-role-of-gp-130-that-differentiate-it-from-other-cytokines-that-are-targeted-in-ra 2019-05-22T22:03:15+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-go-into-detail-with-the-snp-single-nucleotide-polymorphism-based-testing-method-and-describe-its-methodology 2019-05-24T18:40:02+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-precise-immunopathobiologic-mechanism-of-action-for-agents-targeting-il-6-in-the-setting-of-ra-what-are-the-implications-for-using-il-6-inhibitors-as-monotherapy 2019-05-22T22:08:22+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-would-deploy-the-fixed-ratio-combination-agents-in-an-obese-patient-who-was-not-meeting-ha1c-target-goals-on-metformin-alone-or-a-second-oral-agent1 2019-05-22T22:29:58+0000 weekly 0.8 https://www.iqanda-cme.com/videos/when-are-combination-approaches-with-a-dmard-and-biologic-used-to-treat-ra-and-when-might-monotherapeutic-approaches-be-preferable 2019-05-22T22:02:10+0000 weekly 0.8 https://www.iqanda-cme.com/videos/is-the-efficacy-of-iv-acetaminophen-universal-across-many-types-of-surgical-procedures 2019-05-23T00:59:50+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-your-strategy-in-a-patient-who-has-become-intolerant-of-an-opioid 2019-05-23T00:59:43+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-bring-genomic-profiling-down-to-the-oncologist-patient-level-and-explain-what-a-foundationone-report-is-how-long-it-takes-to-generate-and-what-the-translational-value-is 2019-05-17T18:14:38+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-role-of-hybrid-capture-based-ngs-for-identifying-targeted-therapies-in-the-setting-of-orphan-cancers-such-as-sarcoma-where-can-ngs-offer-actionable-insights-and-specific-treatment-roadmaps 2019-05-28T19:07:56+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-importance-of-the-gene-encoding-the-ros1-proto-oncogene-receptor-tyrosine-kinase-as-a-distinct-molecular-subgroup-of-nsclc-in-what-percentage-of-patients-is-ros1-detected 2019-05-17T18:15:22+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-your-mind-what-are-the-implications-of-the-leader-trial-evaluating-liraglutide-in-reducing-cv-outcomes 2019-05-22T23:12:30+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-your-current-guidance-about-whether-and/or-how-and-when-to-integrate-tests-for-circulating-tumor-dna-ctdna-into-protocols-for-precision-cancer-medicine 2019-05-28T19:04:49+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-a-patient-outcomes-perspective-how-well-defined-are-the-predictive-effects-of-the-drug-sensitive-egfr-mutations-exon19-and-21-deletions-and-l858r-in-patients-with-nsclc 2019-05-17T18:20:59+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-regulatory-approval-and-evaluation-processes-for-biosimilars-differ-from-those-used-for-small-molecule-generic-medications2 2019-05-23T19:15:51+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-benefits-of-enhanced-sma-spinal-muscular-atrophy-testing 2019-05-24T18:36:41+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-evidence-that-personalized-gene-directed-therapy-in-which-molecular-drivers-identified-by-ngs-produce-treatments-that-are-better-aligned-with-actionable-targets-will-improve-outcomes 2019-05-28T19:07:39+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-have-we-learned-about-resistance-to-molecular-targets-and-how-have-serial-ngs-assessments-with-progressive-biopsies-helped-us-understand-drug-resistance-and-sequential-therapies 2019-05-17T18:16:31+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-does-the-il-6-pathway-and-family-of-cytokines-affect-inflammation-and-non-joint-clinical-manifestations 2019-05-22T22:08:08+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-biosimilars-differ-from-biomimics 2019-05-23T19:15:42+0000 weekly 0.8 https://www.iqanda-cme.com/videos/based-on-leader-what-do-you-believe-the-implications-are-for-the-use-of-liraglutide-to-mitigate-or-stabilize-diabetic-nephropathy-what-degree-of-cv-event-reduction-was-observed-in-patients-with-ckd 2019-05-22T23:00:46+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-kind-of-tissue-samples-and-cellularity-are-required-for-accurate-and-actionable-ngs 2019-05-28T19:07:32+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-your-current-guidance-about-whether-and/or-how-and-when-to-integrate-tests-for-circulating-tumor-dna-ctdna-into-protocols-for-precision-cancer-medicine1 2019-05-28T19:06:52+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-physiologic-and-clinical-properties-of-incretin-system-targeting-agents 2019-05-22T21:36:59+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-advantages-of-snp-based-technology-compared-with-the-counting-method-when-utilizing-cell-free-dna-to-identify-women-at-increased-risk-to-be-carrying-a-fetus-with-a-microdeletion-syndrome-such-as-22q11-1-which-test-has-the-mo 2019-05-24T18:39:30+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-your-assessment-of-the-cardiovascular-risk-profile-associated-with-il-6-therapy-and-the-possible-role-of-il-6-inhibition-as-a-mitigator-of-any-effects-related-to-ldl-elevation 2019-05-22T22:08:19+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-has-il-6-emerged-as-an-important-target-for-treating-ra-and-through-what-mechanisms-does-inhibition-of-il-6-affect-the-pathogenesis-of-ra 2019-05-22T22:02:16+0000 weekly 0.8 https://www.iqanda-cme.com/videos/if-braf-v600e-mutations-are-documented-in-nsclc-why-are-such-agents-as-vemurafenib-and-dabrafenib-considered-by-the-nccn-to-have-targeted-activity-against-this-tumor-profile 2019-05-17T18:21:02+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-differences-in-quality-of-life-and/or-patient-reported-pain-measures-or-scores-did-you-observe-in-the-group-treated-with-iv-acetaminophen 2019-05-23T00:59:36+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-share-specific-patient-examples-where-molecular-profiling-has-affected-a-clinical-treatment-decision-and-produced-a-favorable-outcome 2019-05-17T18:20:26+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-effective-is-the-snp-based-platform-for-determining-gender-of-the-fetus 2019-05-24T18:42:02+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-you-interpret-the-leader-results-showing-reduction-in-microvascular-events-as-well-as-macrovascular-events-what-drove-these-reductions 2019-05-22T23:00:00+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-does-one-optimize-the-safety-profile-of-il-6-inhibitors 2019-05-22T21:59:41+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-drill-down-into-the-results-of-leader-including-primary-end-points-and-breakdown-of-mace-events-what-did-we-learn-about-the-dose-of-liraglutide-required-for-cv-outcome-improvement 2019-05-22T23:06:01+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-was-the-rationale-and-design-framework-for-leader-what-were-the-inclusionary-and-exclusionary-criteria-and-what-was-the-objective-as-it-relates-to-the-glp-1-ra-liraglutide 2019-05-22T23:12:38+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-have-we-learned-about-the-relationship-between-the-use-of-iv-acetaminophen-as-part-of-multimodal-pain-management-in-various-surgical-settings-and-reduction-of-length-of-stay-outcomes 2019-05-23T01:07:55+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-do-we-know-about-the-relationship-between-ppg-and-cardiovascular-risk 2019-05-22T21:38:01+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-be-specific-about-which-families-based-on-historical-features-ethnicity-and-other-factors-should-be-offered-carrier-testing-should-it-be-offered-to-all-families-prior-to-conception 2019-05-24T18:37:22+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-should-we-integrate-and-incorporate-ctdna-profiling-with-tissue-based-whole-exome-ngs-including-longitudinal-biopsies-when-are-these-two-tests-potentially-complementary 2019-05-28T19:07:50+0000 weekly 0.8 https://www.iqanda-cme.com/videos/who-exactly-should-be-offered-screening-can-you-distinguish-between-high-risk-and-low-risk-patients-what-does-the-american-college-of-medical-genetics-acmg-recommend-as-far-as-nipt 2019-05-24T18:37:31+0000 weekly 0.8 https://www.iqanda-cme.com/videos/we-hear-a-lot-about-depth-of-read-from-various-laboratories-is-depth-of-read-more-important-that-fetal-fraction-please-explain 2019-05-24T18:36:37+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-tools-are-available-to-help-providers-explain-nipt-to-patients 2019-05-24T18:38:32+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-should-the-nt-nuchal-translucency-scan-and-first-trimester-ultrasound-be-integrated-with-nipt-for-aneuploidy-screening-why-should-screening-be-part-of-every-prenatal-screening-program 2019-05-24T18:39:22+0000 weekly 0.8 https://www.iqanda-cme.com/videos/are-there-differences-pharmacokinetic-safety-weight-loss-control-of-ppg-between-the-two-combination-formulations-i-e-glargine-insulin-plus-lixisenatide-iglarlixi-vs-degludec-insulin-plus-liraglutide-ideglira 2019-05-22T21:36:14+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-does-each-of-the-nipt-testing-products-meet-the-laboratory-guidelines-for-nipt-set-forth-by-acmg-and-acog/smfm-especially-reporting-guidelines-such-as-ppv-and-npv-are-reports-from-any-particular-company-consistent-with-the-recently-i 2019-05-24T18:40:08+0000 weekly 0.8 https://www.iqanda-cme.com/videos/among-the-platforms-available-for-ngs-comprehensive-genomic-profiling-what-features-do-you-look-for-when-selecting-an-ngs-platform-what-do-you-use-in-your-precision-cancer-clinic 2019-05-28T19:05:52+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-potential-inflammatory-interfaces-that-are-affected-by-inhibition-of-the-il-6-cytokine-pathway-how-does-each-pathway-potentially-affect-clinical-manifestations-of-ra 2019-05-22T22:03:00+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-mechanisms-of-action-by-which-iv-acetaminophen-exerts-pain-relieving-properties-and-how-is-this-different-from-other-agents-what-is-the-approved-dosing-schedule-for-this-agent 2019-05-23T01:07:58+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-other-gene-rearrangements-ie-gene-fusions-have-recently-been-identified-such-as-ros1-braf-ret-that-are-susceptible-to-targeted-therapies-what-are-the-current-clinical-implications-for-testing 2019-05-17T18:14:36+0000 weekly 0.8 https://www.iqanda-cme.com/videos/even-though-biopharmaceuticals-and-biosimilars-are-made-in-different-manufacturing-contexts-do-we-have-data-to-confirm-that-such-differences-are-clinically-insignificant-in-the-case-of-biosimilars-for-infliximab-used-in-ra 2019-05-23T19:13:16+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-give-us-patient-specific-examples-that-demonstrate-the-potential-clinical-benefits-improvements-in-pfs-os-and-other-metrics-of-whole-exome-hybrid-capture-based-ngs 2019-05-28T19:06:38+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-will-the-evaluation-of-cffdna-change-the-approach-to-prenatal-screening-for-genetic-disorders-beyond-the-common-aneuploidies-in-the-future-does-this-approach-deserve-widespread-application-across-multiple-risk-groups-and-if-so-why 2019-05-24T18:35:44+0000 weekly 0.8 https://www.iqanda-cme.com/videos/using-the-foundationone-report-as-an-example-can-you-explain-what-should-appear-on-an-ngs-report-and-what-interpretative-dimensions-are-necessary-to-optimize-its-clinical-value-as-treatment-roadmap 2019-05-28T19:05:42+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-evidence-that-early-aggressive-treatment-with-biologics-produces-the-best-outcomes-in-patients-with-ra-are-the-guidelines-supportive-of-this 2019-05-22T22:16:14+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-do-clinicians-managing-t2d-patients-need-to-be-aware-of-the-trials-physiologic-basis-side-effects-and-other-dimensions-of-fixed-ratio-long-acting-insulin-glp-1-ra-combination-regimens 2019-05-22T21:42:25+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-triggers-do-you-use-in-your-ra-patients-to-begin-a-dmard-or-biologic-agent 2019-05-22T22:02:04+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-was-the-physiological-safety-and-compliance-focused-rationale-for-combining-basal-insulin-plus-glp-1-ra-into-a-fixed-ratio-formulation-how-would-this-approach-achieve-pan-glycemic-fbg-and-ppg-control 2019-05-22T22:29:54+0000 weekly 0.8 https://www.iqanda-cme.com/videos/are-there-are-surgical-procedures-outside-the-context-of-bariatric-surgery-where-you-think-this-approach-to-pain-control-may-provide-similar-advantages 2019-05-23T01:07:54+0000 weekly 0.8 https://www.iqanda-cme.com/videos/given-that-iv-opioids-inhibit-peristalsis-and-gi-absorption-and-potentially-affect-pk/pd-and-c-max/t-max-profiles-of-oral-acetaminophen-what-is-the-rationale-for-using-iv-acetaminophen 2019-05-23T01:02:56+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-important-developments-at-ada-2016-as-far-as-glp-1-ras 2019-05-22T21:36:54+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-a-translational-perspective-who-are-the-ideal-candidates-for-fixed-ratio-combinations-i-e-glargine-insulin-plus-lixisenatide-iglarlixi-vs-degludec-insulin-plus-liraglutide-ideglira 2019-05-22T21:42:26+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-gestational-age-and-maternal-weight-bmi-affect-fetal-fraction-and-what-is-the-importance-of-separating-out-maternal-fraction-from-fetal-fraction-by-nipt 2019-05-24T18:38:29+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-rationale-for-combining-a-basal-insulin-and-glp-1-ra-in-a-fixed-ratio-formulation 2019-05-22T22:29:25+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-precise-is-our-understanding-of-the-comparative-effectiveness-of-targeting-different-cytokine-or-immune-mediating-signaling-systems-how-long-do-the-effects-of-a-biologic-last 2019-05-22T22:09:16+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-do-you-speculate-might-be-the-most-important-mechanistic-explanations-for-the-reduction-in-cv-events-reported-with-liraglutide-in-the-leader-trial 2019-05-22T23:00:52+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-a-safety-and-efficacy-standpoint-what-is-the-rationale-for-using-such-agents-as-iv-acetaminophen-as-part-of-multimodal-analgesia-to-reduce-overall-opioid-consumption 2019-05-23T00:59:55+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-principal-take-away-from-the-leader-trial-about-the-role-of-liraglutide-in-patients-with-t2d-and-cv-risk-factors 2019-05-22T23:01:05+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-implications-of-iv-acetaminophen-having-100-bioavailability-versus-the-oral-formulation-which-undergoes-first-pass-hepatic-metabolism 2019-05-23T01:03:48+0000 weekly 0.8 https://www.iqanda-cme.com/videos/although-triploidy-is-one-of-the-most-common-chromosome-abnormalities-identified-in-human-conceptions-why-does-the-counting-methodology-fail-to-detect-triploidy 2019-05-24T18:36:33+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-discuss-the-translational-implications-of-the-leader-trial-as-it-relates-to-the-deployment-of-the-glp-1-receptor-agonist-liraglutide-at-the-front-lines-of-diabetes-care 2019-05-22T23:12:35+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-practical-translational-implications-of-leader-and-how-might-we-explain-mechanistically-or-physiologically-the-reduction-in-mace-events-observed-in-the-liraglutide-group 2019-05-22T23:12:20+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-cardiac-surgery-patients-the-elderly-and-others-are-the-ideal-candidates-for-iv-acetaminophen-therapy-what-clinical-factors-suggest-this-approach-is-especially-appropriate-as-part-of-multimodal-analgesia 2019-05-23T01:01:29+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-physiological-safety-efficacy-and-compliance-focused-rationale-for-combining-basal-insulin-plus-glp-1-ra-into-a-fixed-ratio-formulation-how-does-this-impact-fpg-and-ppg-control 2019-05-22T22:59:50+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-south-korea-how-is-ngs-playing-an-increasingly-important-role-in-the-yonsei-cancer-center-in-the-genomic-profiling-of-cancer-and-to-guide-selection-of-oncology-treatment-korean 2019-05-28T19:07:35+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-in-the-setting-of-lung-cancer-specifically-should-oncologists-optimally-deploy-specific-ngs-technologies-especially-those-that-use-hybrid-capture-to-identify-molecular-drivers-of-nsclc-in-the-clinic 2019-05-17T18:15:16+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-role-of-ngs-for-the-assessment-of-gastric-and-colorectal-cancer-korean 2019-05-28T19:09:27+0000 weekly 0.8 https://www.iqanda-cme.com/videos/based-on-the-evidence-available-how-should-we-be-integrating-and-incorporating-ctdna-profiling-liquid-biopsies-with-tissue-based-whole-exome-ngs-including-longitudinal-biopsies 2019-05-28T19:03:26+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-has-the-clinical-trial-landscape-for-precision-oncology-changed-under-the-influence-of-ngs 2019-05-28T19:03:33+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-important-developments-at-ada-2016-as-far-as-glp-1-ras1 2019-05-22T22:29:28+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-describe-the-kinds-of-patients-evaluated-in-the-leader-trial-and-based-on-the-results-what-cv-risk-groups-and-clinical-profiles-with-t2d-would-be-most-amenable-to-treatment-with-liraglutide 2019-05-22T23:00:47+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-has-nipt-changed-the-landscape-of-prenatal-testing-and-what-are-the-specific-advantages-that-accrue-to-patients-who-undergo-nipt 2019-05-24T18:35:43+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-your-view-what-impact-should-and-will-the-leader-trial-have-on-clinical-management-of-patients-with-t2d-especially-those-at-risk-for-cardiovascular-disease 2019-05-22T23:00:57+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-advantages-and-disadvantages-of-using-iv-opioids-as-monotherapy-outside-the-context-of-multimodal-therapy-where-other-agents-are-used-in-conjunction-as-part-of-eras 2019-05-23T01:02:53+0000 weekly 0.8 https://www.iqanda-cme.com/videos/where-does-the-evidentiary-grounding-come-from-to-achieve-fda-approval-for-a-biosimilar-how-many-clinical-trials-are-required-to-support-the-analytics-what-end-points-are-evaluated 2019-05-23T19:13:21+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-role-of-nursing-focused-education-to-facilitate-introduction-of-iv-acetaminophen-into-a-multimodal-pain-management-protocol-and-what-degree-of-reduction-of-iv-opioid-use-did-you-observe-after-this-protocol-change 2019-05-23T01:01:35+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-what-types-of-solid-tumors-has-mutation-directed-therapy-been-shown-to-improve-patient-outcomes-including-progression-free-survival-and-overall-os1 2019-05-17T18:16:01+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-is-carrier-screening-for-duchenne-muscular-dystrophy-now-being-offered 2019-05-24T18:36:42+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-have-we-learned-about-the-equivalency-and-outcome-based-efficacy-of-biosimilars-within-the-context-of-a-single-switch-between-the-originator-and-biosimilar-including-the-nor-switch-study-and-what-are-the-implications-for-clinical-pr 2019-05-23T19:14:50+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-are-the-risks-of-hypoglycemia-very-low-when-using-the-fixed-ratio-combination-regimens-does-this-have-to-do-with-slow-titration-or-mechanistic-complementarity 2019-05-22T21:41:38+0000 weekly 0.8 https://www.iqanda-cme.com/videos/while-improvements-in-los-are-documented-with-iv-acetaminophen-what-other-improvements-and-outcomes-have-been-observed-in-orthopedic-colorectal-and-general-surgery-studies 2019-05-23T01:02:51+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-has-attention-to-optimizing-multimodal-analgesia-to-achieve-eras-affected-patient-care-of-cardiac-surgical-patients-and-why-have-you-chosen-pre-emptive-iv-acetaminophen-as-a-foundational-approach-to-eras-and-outcome-optimization-in-t 2019-05-23T01:02:16+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-precise-immunopathobiologic-mechanism-of-action-moa-for-agents-targeting-il-6-in-the-setting-of-ra-how-does-il-6-affect-bone-loss-in-ra 2019-05-22T22:02:57+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-provide-clinical-profiles-where-there-is-a-strong-rationale-to-move-from-a-regimen-of-metformin-and-sglt2-inhibitor-to-a-fixed-ratio-combination-of-a-basal-insulin-plus-glp-1-ra 2019-05-22T21:44:34+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-does-the-moa-of-iv-acetaminophen-suggest-how-to-combine-it-with-other-agents-as-part-of-multimodal-management-for-eras 2019-05-23T01:02:07+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-do-we-know-about-the-comparative-immunogenicity-profiles-of-originator-anti-tnf-vs-biosimilars-for-infliximab-do-we-have-evidence-confirming-the-safety-of-biosimilars-for-patients-with-ra 2019-05-23T19:15:22+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-insights-have-we-gained-about-drug-based-management-of-the-diabetic-heart 2019-05-22T21:42:27+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-rationale-for-deploying-snp-based-nipt-in-larger-swaths-of-the-population-especially-in-lower-risk-populations-do-studies-economic-and-clinical-studies-suggest-there-is-value-using-these-tests-in-low-risk-patients 2019-05-24T18:39:59+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-good-are-the-disease-outcome-metrics-recommended-by-acr-and-what-are-their-limitations 2019-05-22T22:10:00+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-might-the-results-of-leader-impact-the-prioritization-of-glp-1-ras-as-foundational-agents-for-t2d-either-alone-or-in-combination-with-sglt2-inhibitors-or-long-acting-basal-insulin 2019-05-22T23:06:11+0000 weekly 0.8 https://www.iqanda-cme.com/videos/and-how-do-you-approach-the-biologically-naive-patient 2019-05-22T22:10:05+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-discuss-the-immunogencity-issues-i-e-anti-drug-antibodies-adas-for-biosimilars-vs-reference-biologics 2019-05-23T19:13:06+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-rationale-for-using-the-iv-form-of-acetaminophen-for-eras-and-other-dimensions-of-pain-control-in-the-operative-and-post-operative-setting 2019-05-23T01:08:09+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-do-we-know-about-dosing-as-it-might-impact-cv-outcomes-for-liraglutide-in-the-leader-trial-and-how-does-this-compare-to-what-we-learned-from-sglt2-inhibitor-based-cv-outcomes-trials1 2019-05-22T22:59:48+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-appropriate-way-to-add-fixed-ratio-combination-glp-1-ra/insulin-regimens-to-oral-foundational-therapy-are-these-drugs-added-sequentially-should-the-oral-agents-be-discontinued 2019-05-22T21:44:26+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-important-are-quality-of-life-measures-in-ra-and-how-effective-are-il-6-inhibitors-in-this-regard-compared-to-tnfis-according-to-the-latest-clinical-studies 2019-05-22T22:08:27+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-markers-and-strategies-do-you-recommend-for-titrating-fixed-dose-combination-regimens-what-dosing-considerations-apply-to-ensure-optimal-ha1c-control1 2019-05-22T22:29:23+0000 weekly 0.8 https://www.iqanda-cme.com/videos/among-the-biologic-agents-are-there-any-significant-efficacy-or-safety-differentiators-that-prompt-you-to-deploy-one-agent-in-preference-to-another-in-any-particular-sequence 2019-05-22T22:08:15+0000 weekly 0.8 https://www.iqanda-cme.com/videos/when-is-the-ideal-timing-for-obtaining-whole-exome-sequencing-is-the-timing-strategy-tumor-dependent 2019-05-28T19:03:39+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-would-you-approach-a-65-year-old-patient-with-t2d-who-has-reasonable-control-of-fbg-but-clear-documentation-of-ppg1 2019-05-22T22:59:54+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-discuss-the-design-and-results-of-the-target-trial 2019-05-22T21:59:58+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-implications-of-the-leader-trial-for-practitioners-at-the-front-lines-of-diabetes-care-and-how-will-it-fit-into-the-treatment-algorithm 2019-05-22T23:06:07+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-your-interpretation-of-the-results-from-the-studies-evaluating-the-effectiveness-and-safety-of-fixed-ratio-insulin-glp-1-ra-combinations 2019-05-22T21:44:38+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-recommended-next-steps-for-couples-who-screen-positive 2019-05-24T18:36:40+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-your-detailed-analysis-of-the-results-from-profiler-study-evaluating-ngs-based-whole-exome-molecular-profiling-in-patients-with-advanced-or-refractory-cancer 2019-05-28T19:05:36+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-often-do-we-encounter-false-positive-and-false-negative-results-and-how-do-we-determine-positive-predictive-value 2019-05-24T18:37:19+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-will-the-aca-and-other-regulations-affect-strategies-for-taking-care-of-post-operative-pain-what-parameters-of-success-will-be-evaluated 2019-05-23T01:02:11+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-your-assessment-of-the-secondary-end-points-especially-renal-markers-such-as-albuminuria-reported-in-leader-that-may-be-drivers-of-atheroinflammatory-cv-disease 2019-05-22T23:06:42+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-comprehensive-spectrum-of-molecular-alterations-that-whole-exome-ngs-provides-that-are-integral-to-precision-based-treatment-for-lung-adenocarcinoma 2019-05-28T19:05:58+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-role-do-anti-cpp-antibodies-play-in-assessing-undifferentiated-arthritis-are-they-predictive-of-responses-with-biologic-agents-what-are-implications-of-acpa-positivity-for-il-6-inhibitors 2019-05-22T22:16:10+0000 weekly 0.8 https://www.iqanda-cme.com/videos/based-on-the-evidence-for-efficacy-of-iv-versus-po-acetaminophen-which-route-do-you-prefer-in-bariatric-surgery-and-why-how-long-do-you-give-iv-acetaminophen-prior-to-switching-to-po 2019-05-23T00:58:55+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-critical-elements-of-the-current-american-college-of-rheumatology-acr-guidelines-algorithm-for-ra-where-does-il-6-inhibition-fit-into-these-guidelines 2019-05-22T22:02:07+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-pathophysiological-and-mechanistic-factors-associated-with-the-glp-1-agonist-liraglutide-might-explain-the-reduction-in-overall-mortality-mace-and-cv-mortality-reported-in-the-leader-trial 2019-05-22T23:06:08+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-a-practical-titration-perspective-what-important-clinical-guidance-can-you-provide-to-optimize-effectiveness-of-the-fixed-ratio-insulin-glp-1-ra-combination1 2019-05-22T22:59:57+0000 weekly 0.8 https://www.iqanda-cme.com/videos/are-there-significant-clinical-differences-pharmacokinetic-safety-degree-of-weight-loss-control-of-ppg-between-the-two-combination-formulations-i-e-glargine-insulin-plus-lixisenatide-iglarlixi-vs-degludec-insulin-plus-liraglutide-ideglir 2019-05-22T22:29:16+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-level-of-ha1c-reduction-is-achieved-with-the-fixed-ratio-combination-and-how-is-the-side-effect-profile-of-the-glp-1-ra-affected-by-the-combination-formulation-and-the-titration-strategy-it-utilizes1 2019-05-22T21:41:33+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-does-carrier-screening-differ-from-diagnostic-testing 2019-05-24T18:37:26+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-does-the-use-of-iv-acetaminophen-differ-from-the-use-of-oral-acetaminophen-do-gi-symptoms-nausea-vomiting-and-intolerance-to-po-intake-affect-your-decision 2019-05-23T00:59:42+0000 weekly 0.8 https://www.iqanda-cme.com/videos/are-there-situations-where-you-might-consider-the-use-of-iv-acetaminophen-as-monotherapy-for-certain-surgical-procedures-as-opposed-to-its-use-as-part-of-a-multimodal-approach 2019-05-23T01:02:04+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-addition-to-the-molecular-alterations-identified-by-the-ngs-what-additional-information-is-provided-by-these-reports-that-is-critical-to-drug-selection 2019-05-17T18:20:30+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-is-hybrid-based-ngs-leading-to-improved-stratification-of-patients-with-breast-cancer 2019-05-28T19:09:31+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-role-of-ngs-based-molecular-profiling-for-providing-roadmaps-suggesting-how-combination-targeted-therapy-can-produce-improved-clinical-outcomes 2019-05-28T19:04:24+0000 weekly 0.8 https://www.iqanda-cme.com/videos/at-what-point-in-the-ada-and-aace-sequencing-algorithm-for-glycemic-control-in-patients-with-t2d-is-the-use-of-glp-1-ra-recommended-what-are-the-treatment-triggers-for-glp-1-ra 2019-05-22T21:36:50+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-does-the-side-effect-profile-of-acetaminophen-compare-with-placebo-or-other-non-opioid-agents 2019-05-23T00:59:01+0000 weekly 0.8 https://www.iqanda-cme.com/videos/is-nipt-appropriate-for-pregnant-women-who-are-at-average-risk-for-chromosomal-abnormalities-please-explain-the-pros-and-cons 2019-05-24T18:35:39+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-the-capabilities-of-ngs-compare-to-hot-spot-testing-and-why-is-whole-exome-sequencing-based-on-hot-spot-panels-preferred-in-the-setting-of-precision-oncology-practice-korean 2019-05-28T19:03:13+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-have-we-learned-from-the-recent-trials-looking-at-the-ability-of-ngs-to-drive-precision-based-treatments-across-a-broad-spectrum-of-tumor-subtypes-korean 2019-05-28T19:07:42+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-makes-the-side-effect-profile-of-iv-acetaminophen-uniquely-suited-for-perioperative-pain-management-as-compared-to-iv-opioids 2019-05-23T01:01:25+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-patients-at-risk-for-or-a-previous-history-of-serious-infection-are-there-some-biologic-agents-that-seem-to-lower-the-risk-of-such-a-complication 2019-05-22T22:02:00+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-discuss-and-explain-recent-clinical-evidence-focused-on-anti-tnf-inhibitor-biosimilars-for-infliximab-in-the-setting-of-ra-and-by-extrapolation-as-ibd-and-related-conditions 2019-05-23T19:15:59+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-slow-dose-titration-strategies-for-the-fixed-ratio-combination-formulations-i-e-glargine-insulin-plus-lixisenatide-iglarlixi-vs-degludec-insulin-plus-liraglutide-ideglira-potentially-affect-the-side-effects-seen 2019-05-22T22:29:20+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-summarize-the-key-features-of-the-new-guidelines-for-ra-issued-by-the-acr 2019-05-22T22:09:03+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-summarize-the-key-features-of-the-leader-trial-including-the-primary-mace-end-points-and-the-patient-populations-studied 2019-05-22T23:00:55+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-you-prioritize-the-genomic-information-provided-by-ngs-and-how-do-you-curate-the-importance-of-alterations-rearrangements-and-fusion-events-reported-by-ngs-korean 2019-05-28T19:07:36+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-incretin-targeted-therapies-are-available-to-modulate-the-incretin-hormones-and-what-are-the-clinical-differences-among-the-available-options 2019-05-22T21:38:05+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-actionable-insights-can-we-draw-upon-from-the-european-experience-with-iv-acetaminophen-in-the-setting-of-multimodal-pain-management-for-surgical-procedures 2019-05-23T01:02:45+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-provide-background-including-dosing-and-units-of-each-component-for-the-two-fixed-ratio-combination-insulin-plus-glp-1-receptor-agonist-formulations-likely-to-be-approved 2019-05-22T21:44:41+0000 weekly 0.8 https://www.iqanda-cme.com/videos/when-a-suboptimal-clinical-response-is-encountered-with-tnfis-or-interleukins-antagonists-what-other-strategies-may-be-effective-how-are-these-decisions-made-and-where-might-an-il-6-inhibitor-fit 2019-05-22T22:09:55+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-percentage-of-patients-started-on-a-tnfi-will-respond-and-to-what-degree-will-they-respond 2019-05-22T22:09:06+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-some-of-the-causes-of-false-positive-results-and-how-does-the-snp-method-aid-the-clinician-to-rule-out-maternal-sex-chromosome-mosaicism/abnormalities 2019-05-24T18:37:28+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-immunopathobiologic-mechanism-of-action-for-agents-targeting-il-6-in-ra-are-these-moas-synergistic-with-other-moas-with-which-other-agents-should-il-6-targeting-agents-be-used 2019-05-22T22:08:11+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-would-specific-basal-insulin-glp-1-ra-combination-agents-be-used-in-specific-patient-populations-with-t2d-are-there-trials-that-shed-light-on-this 2019-05-22T21:36:53+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-factors-fueled-the-introduction-of-biosimilars 2019-05-23T19:15:13+0000 weekly 0.8 https://www.iqanda-cme.com/videos/which-t2d-patients-will-be-the-best-candidates-for-the-fixed-ratio-combination-regimens-i-e-iglarlixi-or-ideglira-and-how-effective-and-safe-are-these-formulations-at-lowering-ha1c-levels 2019-05-22T21:41:36+0000 weekly 0.8 https://www.iqanda-cme.com/videos/are-there-situations-where-you-might-consider-iv-acetaminophen-as-monotherapy-as-opposed-to-its-use-as-a-non-opioid-agent-that-is-part-of-a-multimodal-approach-requiring-rescue-with-opioids 2019-05-23T00:59:02+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-explain-reporting-and-other-differences-between-the-various-commercially-available-nipt-products 2019-05-24T18:40:05+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-would-specialists-use-biosimilars-can-you-discuss-how-rheumatologists-and-pharmacists-make-cost-reduction-based-clinical-decisions-when-selecting-anti-tnf-biologics-in-the-setting-of-ra-as-psoriatic-arthritis-and-related-conditions 2019-05-23T19:15:56+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-the-simplified-disease-activity-index-sdai-provide-predictive-information-that-guides-aggressiveness-of-therapy-for-ra 2019-05-22T21:58:17+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-a-front-lines-translational-perspective-where-are-combination-insulin-plus-glp-1-ra-regimens-likely-to-fit-into-the-sequencing-algorithm-for-care-of-patients-with-t2d1 2019-05-22T21:44:41+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-have-we-learned-from-the-genie-consortium-project-about-discrepancies-between-mutational-profiles-identified-in-the-tcga-database-versus-those-identified-by-ngs-in-the-genie-project 2019-05-28T19:08:39+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-give-us-a-sense-for-who-the-patients-were-that-were-studied-in-the-leader-trial-what-were-some-of-their-baseline-characteristics 2019-05-22T23:12:33+0000 weekly 0.8 https://www.iqanda-cme.com/videos/based-on-the-genie-consortium-project-what-percentage-of-patients-is-estimated-to-be-eligible-for-targeted-therapy-within-the-framework-of-precision-cancer-medicine-when-evaluated-with-ngs 2019-05-28T19:08:42+0000 weekly 0.8 https://www.iqanda-cme.com/videos/does-foundationone-s-comprehensive-genomic-profiling-have-validation-studies-confirming-accuracy-across-multiple-alterations-in-a-peer-reviewed-journal 2019-05-17T18:16:02+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-does-the-availability-of-insulin-glp-1-ra-combinations-advance-our-ability-to-customize-therapy-in-patients-with-t2d 2019-05-22T23:06:44+0000 weekly 0.8 https://www.iqanda-cme.com/videos/do-you-modify-your-dose-of-il-6-inhibitor-if-you-encounter-elevations-in-ldl-level 2019-05-22T21:59:47+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-pk/pd-properties-for-glp-1-ras-and-how-do-these-differences-affect-their-clinical-roles-and-specifically-how-do-long-vs-short-acting-glp-1-ras-affect-ppg-vs-fpg 2019-05-22T21:36:58+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-would-approach-a-mildly-obese-patient-with-t2d-on-a-maximum-dose-of-metformin-who-is-not-yet-achieving-fpg-or-ppg-target-goals 2019-05-22T21:41:31+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-you-work-with-genetic-counselors-to-optimize-the-value-of-cell-free-da-test-results-for-nipt-in-your-patients 2019-05-24T18:39:25+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-trials-and-meta-analyses-evaluating-ra-patients-have-used-health-related-quality-of-life-hrqol-for-assessing-patient-outcomes-which-agents-have-been-evaluated-against-this-metric 2019-05-22T22:09:50+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-were-the-specific-clinical-and-cv-risk-profiles-of-the-patients-studied-in-leader-and-how-will-this-help-us-identify-patients-who-might-benefit-from-liraglutide 2019-05-22T23:06:46+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-should-rheumatologists-and-pharmacists-make-clinical-decisions-when-choosing-between-biosimilars-and-their-reference-biologic-agents-in-the-setting-of-ra-as-psoriatic-arthritis-and-related-conditions 2019-05-23T19:15:18+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-biomarkers-or-clinical-or-symptomatic-metrics-have-you-used-to-identify-those-patients-who-will-clearly-require-biologic-therapy-as-foundational-approach 2019-05-22T22:09:13+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-have-we-learned-about-the-equivalency-and-outcome-based-efficacy-of-biosimilars-within-the-context-of-a-single-switch-between-the-originator-and-biosimilar-including-the-nor-switch-study 2019-05-23T19:16:17+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-is-comprehensive-characterization-of-genomic-alterations-that-defines-an-individual-patient-s-tumor-useful-for-oncologists-and-pathologists-to-guide-optimal-therapeutic-strategies-german 2020-08-10T23:49:23+0000 weekly 0.8 https://www.iqanda-cme.com/videos/which-patient-subgroups-based-on-the-leader-trial-are-most-likely-to-benefit-from-liraglutide-therapy-high-risk-low-risk-both-at-what-point-in-the-natural-history-of-t2d-early-late-both 2019-05-22T22:59:58+0000 weekly 0.8 https://www.iqanda-cme.com/videos/is-it-your-view-that-the-effectiveness-and-side-effect-profiles-of-different-il-6-inhibitors-established-and-soon-to-market-will-reflect-a-class-effect-or-do-you-feel-they-will-be-clinically-differentiated 2019-05-22T22:16:17+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-do-you-think-are-some-of-the-most-important-unmet-needs-in-ra 2019-05-22T22:10:10+0000 weekly 0.8 https://www.iqanda-cme.com/videos/is-it-appropriate-to-offer-concurrent-patient/partner-carrier-screening 2019-05-24T18:37:18+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-we-define-ppg-how-do-we-confirm-its-presence-as-an-actionable-metabolic-derangement-in-need-of-intervention-and-where-does-iglarlixi-fit-into-this-treatment-algorithm-for-ppg 2019-05-22T21:38:04+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-the-fixed-ratio-insulin-formulations-mitigate-the-side-effects-associated-with-either-insulin-alone-or-a-glp-1-ra-given-alone 2019-05-22T23:06:49+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-what-specific-surgical-procedures-is-iv-acetaminophen-indicated-as-a-core-agent-in-the-context-of-multimodal-management-and-eras-and-what-are-the-indications-for-this-agent 2019-05-23T01:03:00+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-patients-with-t2d-are-most-likely-to-benefit-from-fixed-ratio-combinations-such-a-ideglira-and-iglarlixi 2019-05-22T22:29:26+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-evidence-is-available-to-guide-us-in-adding-antiglycemic-agents-to-intensify-basal-insulin-therapy-what-is-the-rationale-for-using-a-fixed-ratio-insulin-glp-1-ra-combination-formulation 2019-05-22T23:12:22+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-degree-of-ha1c-lowering-are-studies-reporting-with-fixed-ratio-combinations-using-a-basal-insulin-plus-glp-1-ra 2019-05-22T21:36:13+0000 weekly 0.8 https://www.iqanda-cme.com/videos/given-the-therapies-statins-sglt2-inhibitors-antihypertensive-agents-etc-we-can-use-to-reduce-cv-risk-in-t2d-patients-where-do-you-see-liraglutide-fitting-in-based-on-leader 2019-05-22T23:06:04+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-time-parameters-did-you-use-for-tracking-reduction-in-ed-visits-and-hospital-readmissions-associated-with-iv-acetaminophen-use-and-what-about-the-need-to-use-rescue-narcotics 2019-05-23T00:59:38+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-triggers-for-using-a-biologic-agent-how-early-in-the-course-of-the-disease-is-initiation-with-a-tnfi-or-il-6-inhibitor-warranted 2019-05-22T22:09:09+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-microdeletions-and-what-is-the-rationale-for-offering-screening-for-microdeletions-using-nipt-which-microdeletions-are-of-special-importance 2019-05-24T18:35:36+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-cardiovascular-effects-of-glp-1-ras 2019-05-22T21:41:29+0000 weekly 0.8 https://www.iqanda-cme.com/videos/based-on-leader-what-does-the-typical-t2d-patient-look-like-who-could-possibly-benefit-from-cv-risk-reduction-associated-with-glp-1-ra-therapy-what-doses-of-liraglutide-appear-to-be-optimal 2019-05-22T23:06:40+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-problematic-aspect-for-the-patient-of-employing-a-platform-that-fails-to-detect-an-actionable-molecular-alteration 2019-05-28T19:04:41+0000 weekly 0.8 https://www.iqanda-cme.com/videos/do-mutational-targets-in-solid-tumors-change-over-time-and-does-this-justify-multiple-biopsies-and-repeat-ngs-based-profiling-in-the-case-of-progressive-disease-to-identify-new-drivers 2019-05-17T18:20:34+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-does-the-incidence-of-22q11-2-deletion-compare-with-down-syndrome-in-terms-of-incidence-at-various-maternal-ages-what-is-the-rationale-for-screening-for-this-deletion 2019-05-24T18:39:31+0000 weekly 0.8 https://www.iqanda-cme.com/videos/does-the-leader-trial-data-provide-any-guidance-for-how-we-might-use-fixed-ratio-combinations-of-basal-insulin-plus-glp-1-ra-or-should-we-avoid-such-cross-trial-comparisons 2019-05-22T21:36:49+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-was-the-physiological-safety-and-compliance-focused-rationale-for-combining-basal-insulin-plus-glp-1-ra-into-a-fixed-ratio-formulation 2019-05-22T21:38:01+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-importance-of-ppg-and-glucose-excursions-as-a-management-metric-and-what-are-the-implications-for-selecting-a-specific-glp-1-ra-with-a-specific-pk/pd-profile 2019-05-22T21:37:59+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-you-identify-patients-with-targetable-alterations-that-would-suggest-their-triage-into-clinical-trials 2019-05-28T19:06:37+0000 weekly 0.8 https://www.iqanda-cme.com/videos/considering-the-relationship-between-total-mutational-burden-and-responsiveness-to-immune-checkpoint-inhibition-how-will-hybrid-capture-based-whole-exome-ngs-guide-precision-based-treatment 2019-05-28T19:08:33+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-rationale-for-more-concentrated-basal-insulins-u200-degludec-and-u300-insulin-glargine-and-what-advantages-do-they-offer-in-glycemic-control-and-hypoglycemia-risk 2019-05-22T23:12:25+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-some-of-the-reasons-for-rare-false-positive-nipt-results 2019-05-24T18:38:33+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-review-the-mechanism-of-action-of-il-6-inhibitors-in-ra-and-what-we-have-learned-from-trials-evaluating-the-safety-and-efficacy-of-sarilumab-tocilizumab-and-other-drugs-in-this-class 2019-05-22T21:59:38+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-translational-implications-of-the-leader-trial-based-on-the-results-reported-at-ada-20161 2019-05-22T22:59:47+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-possible-advantages-of-the-fixed-ratio-combination-insulin-formulations-such-as-ideglira-and-iglarlixi 2019-05-22T23:06:42+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-insights-have-we-gained-about-drug-based-management-of-the-diabetic-heart1 2019-05-22T22:29:19+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-risk-of-not-performing-comprehensive-ngs-molecular-profiling-and-relying-exclusively-on-more-targeted-panels-what-might-we-miss 2019-05-28T19:06:44+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-role-of-ngs-in-triple-negative-breast-cancer-are-there-actionable-insights-than-emerge-from-full-exome-sequencing-in-patients-with-tnbc-who-have-progressed-on-standard-therapies 2019-05-28T19:08:27+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-was-the-physiological-safety-and-compliance-focused-rationale-for-combining-basal-insulin-plus-glp-1-ra-into-a-fixed-ratio-formulation-how-would-this-approach-achieve-pan-glycemic-fbg-and-ppg-control1 2019-05-22T21:42:32+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-did-we-learn-from-the-reduction-in-microvascular-end-points-including-those-reflecting-renal-function-reported-in-the-leader-trial 2019-05-22T23:01:02+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-would-you-deploy-the-fixed-ratio-combination-regimens-in-patients-who-had-documented-postprandial-hyperglycemia-would-one-combination-offer-an-advantage-over-the-other 2019-05-22T21:42:35+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-biomarkers-and-clinical-findings-are-most-useful-for-guiding-therapy-in-ra 2019-05-22T22:03:05+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-benefit-of-molecular-carrier-screening-for-hemoglobinopathies-when-the-gold-standard-for-screening-has-been-cbc-with-hemoglobin-electrophoresis 2019-05-24T18:36:43+0000 weekly 0.8 https://www.iqanda-cme.com/videos/case-study-a-42-year-old-woman-presented-with-a-painful-left-thigh-mass-a-biopsy-of-which-showed-undifferentiated-sarcoma-lung-nodule-submitted-for-genomic-profiling-showed-lmna-ntrk-gene-fusion 2019-05-28T19:04:52+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-should-one-sequence-therapy-in-patients-who-require-biologic-therapy-is-there-a-one-sequence-fits-all-strategy-can-one-start-with-any-biologic-agent-in-conjunction-with-methotrexate 2019-05-22T21:59:56+0000 weekly 0.8 https://www.iqanda-cme.com/videos/at-what-stage-in-the-presentation-of-nsclc-should-one-consider-doing-comprehensive-ngs-with-hybrid-capture 2019-05-17T18:15:23+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-would-you-deploy-the-fixed-ratio-combination-regimens-in-patients-who-had-documented-postprandial-hyperglycemia-would-one-combination-offer-an-advantage-over-the-other-based-on-pharmacokinetic-properties-of-the-glp-1-ra 2019-05-22T22:29:57+0000 weekly 0.8 https://www.iqanda-cme.com/videos/when-should-dmards-be-used-as-monotherapy-in-ra-patients-what-is-the-optimal-patient-profile-for-combination-therapy-and-which-biologics-have-been-shown-to-be-successful-as-monotherapy 2019-05-22T21:59:50+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-sources-are-used-and-should-be-used-in-china-to-determine-what-targeted-anti-cancer-therapies-should-be-deployed-in-genomic-alterations-detected-by-ngs-sequencing 2019-05-17T18:19:28+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-information-variances-actionable-guidance-and-clinical-interpretations-are-provided-on-a-ngs-pathology-report-how-do-you-deal-with-uncertainties-and-variations-of-unknown-significance 2019-05-28T19:07:33+0000 weekly 0.8 https://www.iqanda-cme.com/videos/since-a-significant-effect-of-acetaminophen-is-on-central-cns-receptors-what-do-studies-measuring-csf-levels-show-regarding-iv-administration-of-acetaminophen 2019-05-23T01:03:51+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-a-clinical-nipt-perspective-what-unique-advantages-and-what-precision-focused-capabilities-can-be-ascribed-to-snp-technology-and-its-targeted-approach-to-fetal-abnormalities 2019-05-24T18:40:03+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-are-current-genomic-testing-models-based-on-targeted-sequencing-hot-spot-unsustainable-given-what-we-know-about-genomically-targeted-therapy 2019-05-17T18:18:50+0000 weekly 0.8 https://www.iqanda-cme.com/videos/pfs-is-improved-with-use-of-a-tki-in-patients-with-sensitizing-egfr-mutations-when-compared-with-standard-chemotherapy-although-os-is-not-statistically-different-please-summarize-clinical-results 2019-05-17T18:21:00+0000 weekly 0.8 https://www.iqanda-cme.com/videos/there-is-a-lot-of-uncertainty-about-the-use-of-liquid-biopsies-ctdna-can-you-identify-situations-where-analysis-of-ctdna-may-be-complementary-to-ngs-based-assessment-of-tissue-samples 2019-05-28T19:06:56+0000 weekly 0.8 https://www.iqanda-cme.com/videos/with-respect-to-fetal-fraction-why-is-cell-free-dna-snp-based-technology-superior 2019-05-24T18:38:30+0000 weekly 0.8 https://www.iqanda-cme.com/videos/if-a-clinician-is-contemplating-ideglira-or-iglarlixi-in-a-t2d-patient-on-an-oral-antidiabetic-agent-who-is-not-meeting-ha1c-goals-should-the-oral-medication-be-adjusted-in-any-way-or-discontinued 2019-05-22T23:12:28+0000 weekly 0.8 https://www.iqanda-cme.com/videos/will-non-invasive-snp-based-prenatal-screening-nipt-be-used-by-lower-risk-patient-subgroups-what-is-the-perspective-of-professional-agencies-on-the-use-of-cell-free-fetal-dna-testing 2019-05-24T18:38:37+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-such-nonsteroidal-agents-as-iv-toradol-be-safely-used-after-cardiac-surgery-what-are-the-problematic-aspects-of-this-approach-and-why-might-iv-acetaminophen-be-preferable-in-certain-patient-populations 2019-05-23T01:01:30+0000 weekly 0.8 https://www.iqanda-cme.com/videos/did-your-study-show-that-the-group-that-received-iv-acetaminophen-incurred-fewer-emergency-department-visits-hospital-readmissions-pain-related-complaints-and-lower-indirect-costs 2019-05-23T00:59:09+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-what-setting-and-in-what-patient-profiles-do-glp-1-ras-make-most-sense-what-degrees-of-ha1c-reduction-are-seen 2019-05-22T21:44:31+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-review-for-us-the-design-and-rationale-of-the-leader-trial1 2019-05-22T21:36:56+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-would-approach-a-mildly-obese-patient-with-t2d-on-a-maximum-dose-of-metformin-who-is-not-yet-achieving-fpg-or-ppg-target-goals1 2019-05-22T22:59:52+0000 weekly 0.8 https://www.iqanda-cme.com/videos/considering-results-from-saril-ra-target-saril-ra-mobility-extend-and-monarch-how-do-you-differentiate-among-agents-and-patients-to-identify-ideal-candidates-for-this-il-6-inhibitor-vs-others 2019-05-22T21:59:39+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-current-lab-technologies-including-high-throughput-ngs-have-made-expanded-carrier-screening-possible-what-do-the-panels-report-how-many-disorders-can-be-screened 2019-05-24T18:37:23+0000 weekly 0.8 https://www.iqanda-cme.com/videos/are-patients-with-a-low-fetal-fraction-at-increased-risk-for-aneuploidy-if-so-why 2019-05-24T18:36:35+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-rapid-is-the-onset-of-action-for-iv-acetaminophen-and-when-is-the-c-max-achieved-after-a-15-minute-infusion-how-does-the-iv-formulation-c-max-metrics-compare-to-the-oral-formulation 2019-05-23T00:59:47+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-advantages-are-offered-by-the-two-fixed-ratio-combination-formulations-i-e-glargine-insulin-plus-lixisenatide-vs-degludec-insulin-plus-liraglutide 2019-05-22T21:36:19+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-evidence-and-clinical-guidance-is-offered-by-trials-evaluating-the-role-safety-and-efficacy-of-il-6-targeting-agents-in-the-setting-of-ra 2019-05-22T22:02:01+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-we-motivate-physicians-and-patients-to-deploy-biosimilars-as-their-go-to-therapies 2019-06-06T17:41:07+0000 weekly 0.8 https://www.iqanda-cme.com/videos/if-met-amplification-is-documented-in-nsclc-why-is-crizotinib-considered-by-the-nccn-to-have-targeted-activity-against-this-tumor-profile-what-high-activity-in-patients-with-this-genetic-alteration 2019-05-17T18:14:40+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-is-snp-based-prenatal-testing-on-women-with-twins-clinically-important-and-why-is-there-an-urgency-to-make-the-diagnosis-and-initiate-evaluation-to-determine-chorionicity-and-zygosity-can-you-provide-an-overview-of-how-nipt-and-surve 2019-05-24T18:41:56+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-guidance-can-you-give-when-the-f1m-cgp-profile-reveals-multiple-relevant-actionable-mutations-why-select-targeted-therapies-when-multiple-genomic-alterations-or-rearrangements-co-exist 2019-05-17T18:16:33+0000 weekly 0.8 https://www.iqanda-cme.com/videos/physicians-frequently-encounter-false-positives-for-monosomy-x-with-nipt-what-is-the-reason-for-this-finding 2019-05-24T18:36:38+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-steps-in-the-development-of-an-anti-tnf-biosimilar-such-as-infliximab-ensure-the-likelihood-that-the-reference-product-and-biosimilar-produce-similar-clinical-effects 2019-05-23T19:15:48+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-unmet-biomarker-and/or-therapeutic-needs-in-patients-with-ra 2019-05-22T22:03:01+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-effects-of-iv-opioids-on-gastric-emptying-transit-and-gi-absorption-of-iv-acetaminophen-versus-oral-acetaminophen 2019-05-23T01:02:08+0000 weekly 0.8 https://www.iqanda-cme.com/videos/are-there-any-studies-available-utilizing-pre-operative-multimodal-analgesia-before-cardiac-surgery 2019-05-23T01:02:18+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-describe-a-patient-example-and-tumor-type-where-whole-exome-sequencing-wes-with-ngs-generated-an-effective-treatment-option-that-would-not-have-emerged-empirically-without-ngs 2019-05-28T19:03:28+0000 weekly 0.8 https://www.iqanda-cme.com/videos/upon-failure-of-a-tnfi-what-is-the-evidence-and-rationale-for-switching-to-an-agent-with-an-alternative-moa-including-an-il-6-inhibitor-or-t-cell-co-modulating-agent 2019-05-22T22:09:10+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-ideal-clinical-profiles-for-and-distinctions-among-the-fixed-ratio-combination-formulations-what-are-their-potential-advantages-and-unique-therapeutic-windows-of-opportunities 2019-05-22T22:29:51+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-percentage-of-patients-who-have-had-an-inadequate-response-to-an-initial-biologic-agent-such-as-tnf-seem-to-respond-to-biologics-with-a-different-moa-such-as-an-il-6-inhibitor 2019-05-22T21:59:42+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-were-the-results-of-the-leader-trial-how-were-critical-cv-risk-parameters-such-as-bp-weight-and-ha1c-levels-affected-what-was-the-take-away-implication-of-this-cv-outcomes-trial 2019-05-22T23:12:19+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-would-you-deploy-a-combination-of-tissue-based-ngs-and-ctdna-to-potentially-provide-a-more-detailed-roadmap-for-targeted-therapy-and-supplementary-prognostic-information 2019-05-28T19:05:54+0000 weekly 0.8 https://www.iqanda-cme.com/videos/within-glp-1-ras-are-there-comparative-distinctions-dosing-pk/pd-side-effects-weight-loss-lipid-profiles-and-bp-that-have-clinical-relevance-that-should-be-highlighted-how-do-they-differentially-affect-ppg 2019-05-22T21:42:23+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-what-way-have-recent-guidelines-issued-by-national-associations-including-smfm/acog-and-acmg-changed-for-cell-free-dna-nipt-especially-for-so-called-average-risk-patients 2019-05-24T18:39:28+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-unique-aspects-of-your-trial-design-do-you-think-are-worth-emphasizing-what-are-the-take-home-messages-about-the-mechanism-s-by-which-iv-acetaminophen-reduces-indirect-costs 2019-05-23T01:07:53+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-define-loss-of-response-to-a-dmard-based-therapy-in-ra-what-markers-do-you-use-is-remission-always-the-end-point 2019-05-22T22:09:18+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-and-when-was-nipt-first-implemented-in-prenatal-screening-and-why-is-this-test-essential-for-an-accurate-evaluation-of-the-pregnant-patient-at-multiple-levels-of-risk 2019-05-24T18:35:42+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-important-clinical-and-regulatory-distinction-between-bioequivalency-and-interchangeability-as-it-relates-to-biosimilar-drugs-and-their-reference-product 2019-05-23T19:15:23+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-new-data-related-to-the-use-of-tnfis-and-the-use-of-il-6-inhibitors-do-we-have-as-it-relates-to-drug-persistence-and-safety-profiles 2019-05-22T22:08:10+0000 weekly 0.8 https://www.iqanda-cme.com/videos/the-naming-of-the-biosimilars-is-creating-a-lot-of-confusion-can-you-give-us-a-roadmap-for-making-sense-of-the-naming-strategies-for-these-drugs 2019-05-23T19:15:09+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-risks-for-infection-when-treating-ra-patients-with-biologics 2019-05-22T22:02:21+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-role-of-liquid-biopsies-and-hybrid-capture-ngs-in-the-face-of-our-understanding-that-there-is-sub-clonal-evolution-in-many-solid-tumors1 2019-05-17T18:14:35+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-does-snp-based-nipt-technology-offer-distinct-advantages-for-nipt 2019-05-24T18:35:45+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-evolving-role-of-ngs-in-identifying-targeted-therapies-in-the-setting-of-metastatic-colorectal-cancer-with-a-focus-on-braf-mutations-her2-amplification-testing-and-detection-of-microsatellite-instability-msi 2019-05-28T19:08:31+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-a-precision-medicine-perspective-how-should-we-be-integrating-and-incorporating-ctdna-profiling-i-e-liquid-biopsies-with-tissue-based-whole-exome-ngs-including-longitudinal-biopsies 2019-05-28T19:04:18+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-the-two-methods-generally-described-as-the-traditional-first-generation-counting-method-and-the-second-generation-snp-single-nucleotide-polymorphism-based-testing-differ-from-one-another-let-s-start-with-the-counting-method-first 2019-05-24T18:40:01+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-technology-platforms-from-hot-spot-panels-to-foundationone-for-characterizing-molecular-drivers-differ-and-why-do-ngs-based-hybrid-capture-platforms-offer-the-most-reproducible-and-actionable-results 2019-05-17T18:20:28+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-does-the-landscape-for-biosimilars-look-like-for-ra-and-other-connective-tissue-disorders-look-like 2019-05-23T19:13:08+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-is-it-important-to-recognize-mono-or-dichorionicity-early-how-accurate-is-ultrasound-in-making-the-distinction-of-monozygous-monochorionic-twins-based-on-results-of-recent-studies 2019-05-24T18:41:58+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-results-from-leader-showing-cv-risk-reduction-with-liraglutide-do-you-think-are-most-important-and-how-are-they-likely-to-change-our-use-of-glp-1-ras-in-high-risk-patients-with-t2d 2019-05-22T23:12:16+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-importance-of-avoiding-the-hepatic-first-pass-effect-when-using-iv-versus-oral-acetaminophen-and-what-pk-advantages-and-tissue-penetration-effects-are-observed 2019-05-23T01:01:19+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-we-make-sense-of-an-ngs-based-molecular-profile-when-there-appear-to-be-a-number-of-potentially-actionable-genomic-alterations-how-might-a-molecular-tumor-board-be-helpful 2019-05-28T19:04:36+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-mission-statement-of-your-eras-group-focused-on-cardiac-surgery-and-what-is-the-foundational-role-of-iv-acetaminophen-to-push-your-eras-goals-including-reduced-opioid-consumption-and-reduced-los-forward 2019-05-23T01:01:36+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-what-subtypes-of-cancer-have-we-validated-the-efficacy-of-comprehensive-ngs-screening-for-improving-outcomes-by-aligning-molecular-targets-with-appropriate-therapies-and-predictive-biomarkers-of-efficacy-korean 2019-05-28T19:09:28+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-do-studies-and-guidelines-suggest-as-successful-therapeutic-strategies-for-ra-patients-who-have-been-inadequate-responders-to-tnf-therapy 2019-05-22T22:10:06+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-specific-strategies-are-currently-in-the-t2d-pharmacologic-toolkit-that-have-been-shown-effective-for-reducing-ppg-where-do-glp-1-ras-fit-into-this-scheme 2019-05-22T21:38:02+0000 weekly 0.8 https://www.iqanda-cme.com/videos/are-there-clinically-relevant-differences-between-the-fixed-ratio-combination-regimens-iglarlixi-or-ideglira-consisting-of-a-long-acting-insulin-and-glp-1-ra 2019-05-22T21:41:40+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-a-translational-perspective-who-are-the-ideal-patient-candidates-for-the-fixed-ratio-combination-formulations-i-e-glargine-insulin-plus-lixisenatide-iglarlixi-vs-degludec-insulin-plus-liraglutide-ideglira 2019-05-22T22:29:18+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-side-effects-are-you-most-concerned-about-when-using-tnfis-or-il-6-inhibitors 2019-05-22T22:09:59+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-south-korea-how-are-you-using-ngs-based-molecular-profiling-in-the-setting-of-nsclc-korean 2019-05-28T19:03:10+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-importance-of-ros-1-fusion-mutations-what-are-the-therapeutic-implications-of-their-detection 2019-05-28T19:06:08+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-provide-an-example-of-a-luminal-a-patient-with-metastatic-breast-cancer-in-whom-treatment-was-optimized-by-ngs-based-comprehensive-genomic-assessment 2019-05-28T19:07:53+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-best-outcomes-measures-for-ra 2019-05-22T22:08:23+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-clinical-implications-of-the-reporting-differences 2019-05-24T18:40:06+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-fetal-fraction-and-how-does-the-fetal-fraction-affect-the-sensitivity-of-nipt-using-the-counting-method-and-snp-based-technology 2019-05-24T18:38:28+0000 weekly 0.8 https://www.iqanda-cme.com/videos/given-the-side-effects-of-iv-opioids-what-role-does-iv-acetaminophen-play-in-reducing-opioid-doses-required-to-achieve-multimodal-pain-control-and-eras 2019-05-23T01:08:06+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-importance-of-postprandial-hyperglycemia-ppg-and-glucose-excursions-as-a-management-metric-and-what-are-the-implications-for-selecting-glp-1-ras 2019-05-22T21:44:35+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-role-of-ppg-in-comprehensive-ha1c-level-control-how-early-in-t2d-management-do-you-think-fixed-ratio-combination-basal-insulin-glp-1-ra-formulations-play-a-role 2019-05-22T21:44:36+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-pivotal-mechanisms-by-which-il-6-contributes-to-the-pathogenesis-of-ra 2019-05-22T22:03:08+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-is-it-important-to-look-for-and-treat-ppg 2019-05-22T21:36:17+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-what-spectrum-of-tumors-and-at-what-point-in-the-natural-history-of-the-disease-do-you-use-ngs-based-molecular-profiling-korean 2019-05-28T19:03:15+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-a-practical-perspective-how-should-clinicians-titrate-the-fixed-ratio-combinations-such-a-ideglira-and-iglarlixi 2019-05-22T22:29:26+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-optimal-time-for-initiating-iv-acetaminophen-at-the-beginning-of-surgery-before-the-surgical-insult-what-is-the-rationale-for-pre-emptive-use-of-this-pain-reliever 2019-05-23T01:08:04+0000 weekly 0.8 https://www.iqanda-cme.com/videos/who-do-you-believe-would-benefit-from-a-fixed-ratio-combination-of-a-glp-1-ra-with-long-acting-insulin 2019-05-22T21:41:28+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-explain-policy-as-it-relates-to-biosimilars-including-considerations-that-apply-to-extrapolation-substitutability-and/or-interchangeability-for-anti-tnf-biosimilars 2019-05-23T19:15:05+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-what-ways-do-you-believe-the-fixed-ratio-combinations-of-insulin-plus-a-glp-1-ra-will-help-overcome-the-barriers-we-have-seen-with-intensifying-insulin-or-glp-ra-therapy 2019-05-22T23:06:51+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-rationale-for-using-a-validated-genomic-profiling-platform-that-uses-high-sensitivity-hybrid-capture-based-ngs-methodology-to-assess-molecular-drivers-in-solid-tumors1 2019-05-17T18:20:36+0000 weekly 0.8 https://www.iqanda-cme.com/videos/do-studies-provide-information-about-the-comparative-efficacy-of-non-opioid-agents-used-as-part-of-multimodal-perioperative-pain-management-what-about-comparative-safety 2019-05-23T00:59:53+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-has-been-the-role-of-iv-acetaminophen-in-establishing-enhanced-recovery-after-surgery-eras-protocols-across-the-spectrum-of-surgical-procedures-and-what-are-the-objectives-of-eras 2019-05-23T01:08:00+0000 weekly 0.8 https://www.iqanda-cme.com/videos/since-the-technology-for-cell-free-dna/snp-based-testing-can-be-complex-how-do-you-work-with-the-companies-and-what-kind-of-technical-support-is-required-to-optimize-nipt-in-this-context 2019-05-24T18:39:26+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-will-fixed-ratio-basal-insulin-glp-1-ra-combinations-likely-fit-into-the-sequencing-algorithm-for-diabetes-care-how-do-we-select-among-the-available-options-and-in-whom-should-we-use-these-formulations1 2019-05-22T21:37:56+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-rationale-for-referring-this-patient-to-a-phase-ii-study-of-cabozantinib-or-other-multi-tki-if-she-had-had-surgery-and-chemotherapy-but-shows-progression-after-cytotoxic-chemotherapy 2019-05-17T18:15:14+0000 weekly 0.8 https://www.iqanda-cme.com/videos/when-a-suboptimal-clinical-response-is-encountered-with-tnf-or-interleukins-antagonists-what-other-strategies-may-be-effective-how-might-an-il-6-inhibitor-fit-into-the-treatment-plan 2019-05-22T22:10:01+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-impact-do-the-results-of-carrier-screening-have-on-non-health-related-issues-and-affordability 2019-05-24T18:37:20+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-discuss-the-recommendations-for-biologic-therapy-in-ra-issued-by-the-acr-guidelines-and-compare-these-to-the-eular-guidelines-for-ra-where-do-il-6-inhibitors-fall-into-the-treatment-pathways 2019-05-22T21:58:21+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-what-tumor-subtypes-based-on-what-molecular-targets-braf-egfr-mek-alk-1-etc-has-hybrid-capture-based-ngs-been-validated-as-a-foundational-diagnostic-test-that-leads-to-better-response-rates-and-improved-overall-survival 2019-05-28T19:05:46+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-evidence-that-opioid-related-side-effects-compromise-patient-related-outcomes-and-satisfaction-and-prolong-los 2019-05-23T01:01:59+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-optimal-dosing-for-deploying-iv-acetaminophen-and-how-should-it-be-combined-with-opioid-therapy 2019-05-23T00:58:59+0000 weekly 0.8 https://www.iqanda-cme.com/videos/would-you-describe-some-clinical-scenarios-that-illustrate-types-of-patients-for-whom-you-would-utilize-nipt-specifically-the-snp-based-technology-in-your-clinical-practice 2019-05-24T18:39:23+0000 weekly 0.8 https://www.iqanda-cme.com/videos/is-there-a-risk-of-acetaminophen-masking-a-surgical-infection-because-of-its-anti-pyretic-effect 2019-05-23T01:01:24+0000 weekly 0.8 https://www.iqanda-cme.com/videos/when-a-suboptimal-clinical-response-has-been-encountered-with-tnf-do-you-recommend-switching-to-a-biologic-with-a-different-moa-such-as-an-il-6-inhibitor-or-co-modulating-agent 2019-05-22T22:08:16+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-physiologic-properties-of-incretin-system-targeting-agents 2019-05-22T21:36:15+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-should-the-mfm-specialist-or-ob-gyn-follow-for-each-of-the-following-nipt-results-1-no-result-no-redraw-recommended-2-no-result-redraw-recommended-high-risk-low-risk-other 2019-05-24T18:36:34+0000 weekly 0.8 https://www.iqanda-cme.com/videos/are-there-significant-clinical-differences-pharmacokinetic-safety-weight-loss-control-of-ppg-between-the-two-combination-formulations-i-e-glargine-insulin-plus-lixisenatide-iglarlixi-vs-degludec-insulin-plus-liraglutide-ideglira 2019-05-22T22:29:24+0000 weekly 0.8 https://www.iqanda-cme.com/videos/with-respect-to-egfr-mutations-in-nsclc-what-validations-support-routine-target-profiling-using-hybrid-capture-based-ngs-platforms-and-what-target-drug-alignments-have-improved-pfs 2019-05-17T18:20:56+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-side-effects-of-tnf-inhibitors-and-how-do-you-manage-risk-for-infection-and-how-does-this-side-effect-profile-compare-to-that-of-il-6-inhibitors 2019-05-22T21:59:51+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-possible-limitations-of-ngs-and-what-is-the-importance-of-working-with-a-molecular-tumor-board 2019-05-28T19:03:41+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-kind-of-specific-actionable-information-is-contained-on-an-ngs-cgp-report-in-what-context-is-hybrid-capture-based-ngs-especially-valuable-at-the-front-lines-of-precision-cancer-care 2019-05-28T19:06:54+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-should-the-front-line-clinician-treating-t2d-patients-translate-the-results-of-the-leader-trial-into-clinical-practice-have-these-results-prioritized-glp-1-ras-in-the-t2d-treatment-pathway 2019-05-22T23:06:12+0000 weekly 0.8 https://www.iqanda-cme.com/videos/for-what-reasons-does-insulin-remain-a-foundational-therapy-for-managing-patients-with-t2d-and-why-does-the-addition-of-a-glp-1-ra-potentially-augment-the-utility-of-insulin-based-management 2019-05-22T21:42:21+0000 weekly 0.8 https://www.iqanda-cme.com/videos/when-are-you-inclined-to-use-combination-therapy-with-a-dmard-and-biologic-and-when-is-monotherapy-with-a-dmard-alone-a-reasonable-strategy 2019-05-22T22:02:14+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-major-unmet-needs-in-patients-with-ra 2019-05-22T21:58:20+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-significance-of-the-fda-approval-of-pd-1-inhibitors-for-tumors-with-msi-what-other-canonical-driver-mutations-braf-alk-and-others-of-similar-significance-are-coming 2019-05-28T19:05:38+0000 weekly 0.8 https://www.iqanda-cme.com/videos/from-a-practical-perspective-where-are-combination-insulin-plus-glp-1-ra-regimens-likely-to-fit-into-the-sequencing-algorithm-for-care-of-patients-with-t2d 2019-05-22T21:42:31+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-specific-pattern-of-treatment-response-failures-do-you-require-to-switch-a-patient-from-a-tnfi-to-an-il-6-inhibitor-of-co-stimulatory-blockade 2019-05-22T22:09:04+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-compare-clinical-efficacy/equivalency-and-adverse-side-effects-that-have-been-reported-with-administration-of-the-anti-tnf-biosimilar-versus-the-originator-product-infliximab 2019-05-23T19:16:00+0000 weekly 0.8 https://www.iqanda-cme.com/videos/based-on-your-current-assessment-of-anti-tnf-biosimilars-what-is-the-optimal-trajectory-of-these-agents-in-the-setting-of-ra-and-related-immune-related-conditions 2019-05-23T19:15:20+0000 weekly 0.8 https://www.iqanda-cme.com/videos/is-there-a-systematic-approach-for-aligning-specific-cohorts-of-patients-with-ra-with-specific-therapies-with-il-6-inhibitors-tnfis-or-co-modulating-activating-agents 2019-05-22T22:03:14+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-your-current-perspective-on-the-leader-trial-and-how-should-we-translate-its-findings-to-the-front-lines-of-diabetes-care-can-you-describe-the-trial-design 2019-05-22T21:42:28+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-will-mandated-cardiac-surgery-bundles-that-go-into-effect-in-january-2018-affect-strategies-for-perioperative-management-and-eras-of-patients-undergoing-cardiac-surgery 2019-05-23T01:02:12+0000 weekly 0.8 https://www.iqanda-cme.com/videos/are-there-any-biomarkers-for-ra-severity-that-are-uniquely-predictive-of-responsiveness-with-il-6-inhibitors 2019-05-22T22:16:12+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-advances-in-long-acting-insulin-and-glp-1-ra-and-combination-approaches-are-having-a-positive-impact-on-management-of-t2d-how-should-pk/pd-properties-affect-our-choice-of-specific-glp-1-ra1 2019-05-22T21:37:55+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-summarize-the-foundational-role-of-iv-acetaminophen-in-improving-functional-pain-and-los-related-outcomes-across-the-spectrum-of-surgical-procedures 2019-05-23T01:02:52+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-importance-of-alk-fusion-mutations-what-are-the-therapeutic-implications-of-detection-how-effective-are-second-generation-alk-inhibitors-what-does-the-data-show-as-far-as-pfs 2019-05-28T19:06:06+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-advantages-of-targeting-the-il-6-cytokine-system-please-discuss-as-it-relates-to-stabilization-of-chronic-disease-global-symptom-scores-and-ability-to-mitigate-rapidly-progressive-ra 2019-05-22T22:09:57+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-evidence-based-approach-to-non-responsiveness-to-a-tnfi 2019-05-22T22:09:48+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-multi-factorial-effects-of-glp-1-ras 2019-05-22T21:37:52+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-did-we-learn-from-the-shiva-trial-and-how-might-the-disappointing-results-of-this-trial-have-been-misinterpreted-thereby-underestimating-the-potential-benefits-of-targeted-therapy 2019-05-28T19:06:48+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-effective-was-the-glycemic-control-achieved-in-the-glp-1-ra-treatment-arm-of-the-leader-trial 2019-05-22T23:00:53+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-concept-of-eras-and-how-does-it-affect-your-selection-of-pain-relieving-agents-and-strategies-including-multimodal-approaches-in-the-perioperative-setting 2019-05-23T01:02:55+0000 weekly 0.8 https://www.iqanda-cme.com/videos/when-aessessing-the-rationale-for-switching-from-an-originator-anti-tnf-to-a-biosimilar-single-switch-data-is-convincing-for-efficacy-safety-and-comparable-immunogenicity-of-the-ant-tnf-biosimilar-in-what-situations-might-multiple-switch 2019-05-23T19:15:16+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-reasons-why-a-woman-and/or-family-would-want-to-know-the-gender-of-a-fetus-in-a-twin-pregnancy-when-during-gestation-can-the-snp-based-test-be-performed 2019-05-24T18:41:54+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-observations-argue-that-iv-acetaminophen-should-be-a-component-of-multimodal-pain-management-whereas-iv-opioids-should-be-rescue-or-pain-breakthrough-alleviating-agents 2019-05-23T01:07:57+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-discuss-the-safety-profile-of-liraglutide-based-on-the-results-of-the-leader-trial-with-a-specific-focus-on-pancreatitis-and-pancreatic-cancer 2019-05-22T23:12:36+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-your-mind-what-are-the-most-impressive-results-reported-for-both-primary-and-secondary-end-points-in-the-leader-trial 2019-05-22T23:06:13+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-role-of-ccp-antibodies-in-ra 2019-05-22T22:09:08+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-do-the-evolutionary-studies-of-tumor-progression-and-heterogeneity-teach-us-about-timing-longitudinal-sampling-serial-biopsies-and-sampling-sites-for-ngs-based-genomic-testing-in-metastatic-cancer 2019-05-17T18:18:48+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-safety-profile-of-iv-acetaminophen-and-what-makes-this-safety-and-side-effect-profile-uniquely-suited-to-multimodal-pain-relief-in-bariatric-patients-undergoing-bariatric-surgery 2019-05-23T00:58:54+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-optimal-timing-and-sequence-for-incorporating-ngs-cgp-in-cancer-patients-are-there-guidelines-or-established-protocols-for-a-genomically-informed-approach-you-can-provide 2019-05-17T18:16:36+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-does-utilization-of-nipt-in-place-of-mss-reduce-the-number-of-women-who-receive-a-false-positive-screening-result-and-the-associated-anxiety-please-explain-why-the-accuracy-of-these-tests-differ 2019-05-24T18:36:32+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-distinct-advantages-does-snp-based-technology-offer-in-resolving-the-cause-of-the-abnormal-result-including-the-presence-or-absence-of-maternal-findings-and-vanishing-twins 2019-05-24T18:38:34+0000 weekly 0.8 https://www.iqanda-cme.com/videos/given-the-positive-results-of-leader-can-you-speculate-on-the-likely-mechanisms-that-explain-the-cv-risk-reduction-that-was-observed 2019-05-22T23:00:59+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-compare-and-contrast-the-efficacy-and-safety-of-iv-acetaminophen-with-the-other-iv-non-opioid-agents-that-are-sometimes-used-in-conjunction-with-iv-opioids 2019-05-23T01:03:02+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-outcomes-was-the-leader-trial-powered-to-assess-can-you-specifically-discuss-the-secondary-microvascular-outcomes-in-the-kidney 2019-05-22T23:00:44+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-did-we-learn-about-glycemic-control-achieved-with-liraglutide-in-leader-might-the-differences-in-glycemic-exposure-and-other-metabolic-factors-explain-the-reduction-on-kidney-disease 2019-05-22T23:06:02+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-withdrawal-and-adherence-rates-with-glp-1-ra/insulin-regimens-and-how-do-fixed-ratio-combination-formulations-affect-gi-side-effects-sometimes-encountered-with-glp-1-ras 2019-05-22T21:44:27+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-summarize-how-when-and-whom-you-utilize-nipt-in-your-own-practice 2019-05-24T18:35:40+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-do-we-know-about-the-rationale-for-employing-ngs-based-whole-exome-profiling-in-nsclc-patients-who-have-progressed-to-metastatic-disease-on-chemotherapy-is-molecular-profiling-at-this-stage-of-the-disease-useful 2019-05-28T19:06:02+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-range-of-mutational-rearrangements-and-alterations-that-can-be-identified-by-hybrid-capture-based-ngs-and-that-have-clinical-applications 2019-05-28T19:08:45+0000 weekly 0.8 https://www.iqanda-cme.com/videos/after-physicochemical-criteria-are-met-what-kind-of-clinical-trials-with-what-end-points-and-safety-profiles-must-be-achieved-for-regulatory-agencies-to-approve-biosimilars 2019-05-23T19:15:52+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-efficacy-profile-of-il-6-inhibitors-how-does-it-compare-as-monotherapy-to-methotrexate-plus-and-tnfi-what-are-the-side-effects-we-should-monitor 2019-05-22T22:09:51+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-algorithm-s-can-obs-and-mfms-use-to-integrate-nipt-into-prenatal-care-and-how-do-you-utilize-nipt-in-your-practice-as-a-first-line-test 2019-05-24T18:38:31+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-strategies-for-individualizing-treatment-in-patients-with-ra 2019-05-22T22:08:12+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-role-of-ngs-based-mutational-testing-in-patients-with-triple-negative-breast-cancer 2019-05-17T18:20:23+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-appropriate-way-to-add-fixed-ratio-combination-glp-1-ra/insulin-regimens-to-oral-foundational-therapy-are-these-drugs-added-sequentially-should-the-oral-agents-be-discontinued1 2019-05-22T22:29:56+0000 weekly 0.8 https://www.iqanda-cme.com/videos/why-is-there-a-growing-reliance-among-precision-oncology-specialists-on-full-exome-sequencing-with-ngs-such-as-that-provided-by-foundationone-medicine-as-opposed-to-targeted-hotspot-panels 2019-05-28T19:08:29+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-distinguishes-the-natera-panorama-snp-based-test-in-the-setting-of-twin-pregnancy-from-other-nipt-tests-used-for-aneuploidies 2019-05-24T18:42:00+0000 weekly 0.8 https://www.iqanda-cme.com/videos/when-is-the-best-time-to-offer-carrier-screening 2019-05-24T18:36:44+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-your-current-perspective-on-the-leader-trial-and-how-should-we-translate-its-findings-to-the-front-lines-of-diabetes-care-can-you-describe-the-trial-design1 2019-05-22T22:29:19+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-summarize-the-literature-and-trial-based-support-for-the-use-of-iv-acetaminophen-as-part-of-multimodal-pain-management-in-the-surgical-setting 2019-05-23T01:01:21+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-has-carrier-screening-for-cystic-fibrosis-changed 2019-05-24T18:36:40+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-optimal-dosing-strategy-for-deploying-iv-acetaminophen-and-how-should-it-be-combined-with-iv-or-opioid-therapy-what-is-the-role-of-this-approach-in-the-ambulatory-surgery-unit 2019-05-23T01:02:58+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-provide-specific-patient-examples-where-longitudinal-assessment-with-a-combination-of-tissue-based-ngs-and-ctdna-can-provide-a-more-detailed-roadmap-of-targeted-therapy 2019-05-28T19:06:58+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-was-the-physiological-safety-and-compliance-rationale-for-combining-basal-insulin-plus-glp-1-ra-into-a-fixed-ratio-formulation-how-does-this-achieve-pan-glycemic-fbg-and-ppg-control 2019-05-22T21:44:29+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-meant-exactly-by-a-fixed-ratio-combination 2019-05-22T21:36:47+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-the-unique-advantages-of-snp-based-testing-for-twin-pregnancies-what-aneuploidies-are-detected-and-what-other-information-gender-determination-zygosity-chorionicity-is-available-to-optimize-management-of-these-pregnancies 2019-05-24T18:41:55+0000 weekly 0.8 https://www.iqanda-cme.com/videos/if-her2-rearrangements-are-documented-in-nsclc-why-are-such-agents-as-trastuzimab-and-afatninib-considered-by-the-nccn-to-have-targeted-activity-against-this-tumor-profile 2019-05-17T18:21:01+0000 weekly 0.8 https://www.iqanda-cme.com/videos/based-on-your-experience-how-many-doses-of-iv-acetaminophen-are-required-to-optimize-pain-control-after-cardiac-surgery-do-you-individualize-your-approach-and-if-so-based-on-what-factors 2019-05-23T01:01:32+0000 weekly 0.8 https://www.iqanda-cme.com/videos/are-there-differences-pharmacokinetic-safety-weight-loss-control-of-ppg-between-the-two-combination-formulations-i-e-glargine-insulin-plus-lixisenatide-iglarlixi-vs-degludec-insulin-plus-liraglutide-ideglira1 2019-05-22T21:42:26+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-is-the-rationale-for-combining-basal-insulin-plus-glp-1-ra-into-a-fixed-ratio-formulation-how-does-this-impact-pan-glycemic-fpg-and-ppg-control-and-other-target-goals-and-risk-factors 2019-05-22T21:41:25+0000 weekly 0.8 https://www.iqanda-cme.com/videos/do-companies-that-provide-nipt-tests-also-report-results-of-uncertain-significance-what-are-the-clinical-implications-of-this 2019-05-24T18:39:29+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-do-current-acr-guidelines-recommend-as-far-as-sequencing-therapy-in-patients-who-have-had-an-insufficient-response-to-methotrexate 2019-05-22T22:03:06+0000 weekly 0.8 https://www.iqanda-cme.com/videos/can-you-detail-the-characteristics-of-the-cohorts-studied-in-the-leader-trial-what-percentage-of-patients-was-evaluated-for-primary-prevention-vs-secondary-prevention-of-cv-events 2019-05-22T23:14:34+0000 weekly 0.8 https://www.iqanda-cme.com/videos/given-the-use-of-metformin-and-sglt2-inhibitors-as-oral-foundation-agents-what-role-are-the-injectable-glp-1-ra/insulin-combination-regimens-likely-to-play-in-guideline-directed-care 2019-05-22T21:45:13+0000 weekly 0.8 https://www.iqanda-cme.com/videos/how-do-we-identify-ra-patients-that-are-likely-to-respond-to-inhibition-of-tnf-vs-those-likely-to-respond-to-inhibition-of-il-6-cytokine 2019-05-22T22:09:14+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-are-some-of-the-possible-causes-of-false-positive-results-and-how-does-the-snp-method-aid-the-physician-in-ruling-out-maternal-sex-chromosome-mosaicism-abnormalities 2019-05-24T18:35:38+0000 weekly 0.8 https://www.iqanda-cme.com/videos/what-aspects-of-design-and-implementation-of-leader-deserve-the-greatest-emphasis-what-metabolic-target-goals-and-cv-outcomes-achieved-by-liraglutide-were-most-significant 2019-05-22T23:00:49+0000 weekly 0.8 https://www.iqanda-cme.com/videos/in-what-patient-subsets-ra-biomarkers-obese-undifferentiated-ra-high-risk-ra-poor-responders-etc-do-il-6-inhibitors-appear-to-be-most-effective 2019-05-22T22:16:18+0000 weekly 0.8 https://www.iqanda-cme.com/specialties/test/the-evolving-science-and-medicine-of-cardioprotection-in-type-2-diabetes 2019-03-12T00:33:49+0000 weekly 0.8 https://www.iqanda-cme.com/courses/genomic-profiling-english-7159 2018-12-05T21:27:55+0000 weekly 0.8 https://www.iqanda-cme.com/courses/genomic-profiling-italian-7509 2018-12-06T00:05:17+0000 weekly 0.8 https://www.iqanda-cme.com/courses/genomic-profiling-portuguese-7602 2018-12-06T00:07:12+0000 weekly 0.8 https://www.iqanda-cme.com/courses/genomic-profiling-spanish-7508 2018-12-05T21:48:20+0000 weekly 0.8 https://www.iqanda-cme.com/courses/genomic-profiling-german-7600 2018-12-06T00:05:58+0000 weekly 0.8 https://www.iqanda-cme.com/courses/genomics-in-cancer-7505 2018-12-05T21:47:26+0000 weekly 0.8 https://www.iqanda-cme.com/courses/glycemic-regulation-6729 2018-12-05T01:26:25+0000 weekly 0.8 https://www.iqanda-cme.com/courses/rheumatoid-arthritis-intelligence-6549 2023-04-14T03:42:05+0000 weekly 0.8 https://www.iqanda-cme.com/courses/diabetes-mangement-7158 2018-12-05T03:10:32+0000 weekly 0.8 https://www.iqanda-cme.com/courses/pain-management-7837 2019-01-17T19:47:29+0000 weekly 0.8 https://www.iqanda-cme.com/courses/ngs-and-genomic-profiling-7838 2018-12-18T02:47:13+0000 weekly 0.8 https://www.iqanda-cme.com/courses/prenatal-screening-7504 2018-12-06T00:36:39+0000 weekly 0.8 https://www.iqanda-cme.com/courses/nipt-in-twin-pregnancies-8558 2023-04-14T03:42:22+0000 weekly 0.8 https://www.iqanda-cme.com/courses/iqanda-pcsk9-cardiovascular-medicine-intelligence-zone 2023-04-14T03:35:41+0000 weekly 0.8 https://www.iqanda-cme.com/courses/ra-biosimilars-7844 2018-12-06T02:49:13+0000 weekly 0.8 https://www.iqanda-cme.com/courses/moving-beyond-hba1c-new-monitoring-standards-and-target-destinations-for-optimizing-glycemic-control-with-cgm 2023-10-27T22:59:47+0000 weekly 0.8 https://www.iqanda-cme.com/courses/new-trends-in-reimbursement-protocols-health-quality-metrics-and-device-accuracy-for-sensor-based-glycemic-monitoring-in-the-managed-care-pharmacy-setting 2023-10-27T23:02:31+0000 weekly 0.8 https://www.iqanda-cme.com/courses/test-cme 2025-11-25T00:44:34+0000 weekly 0.8 https://www.iqanda-cme.com/courses/pushing-the-limits-of-what-sensing-can-do-for-t1d-and-t2d 2026-03-07T01:25:50+0000 weekly 0.8 https://www.iqanda-cme.com/courses/best-practice-advances-in-front-line-management-to-optimize-clinical-outcomes-in-nontuberculous-mycobacterial-ntm-lung-disease 2026-03-07T01:21:54+0000 weekly 0.8 https://www.iqanda-cme.com/news/00 2024-12-18T21:19:43+0000 weekly 0.8 https://www.iqanda-cme.com/flexpaper/the-odyssey-outcomes-trial-topline-results-alirocumab-in-patients-after-acute-coronary-syndrome 2019-03-12T01:25:55+0000 weekly 0.8 https://www.iqanda-cme.com/flexpaper/applicability-and-cost-implications-for-pcsk9-inhibitors-based-on-the-odyssey-outcomes-trial 2019-03-12T01:32:36+0000 weekly 0.8 https://www.iqanda-cme.com/flexpaper/2018-aha/acc-guideline-on-the-management-of-blood-cholesterol 2019-03-12T01:26:26+0000 weekly 0.8 https://www.iqanda-cme.com/flexpaper/pooled-analysis-of-10-odyssey-trials-comparing-reductions-in-atherogenic-lipids-and-major-cv-events 2019-03-12T01:32:54+0000 weekly 0.8 https://www.iqanda-cme.com/flexpaper/program-agenda-and-complete-faq-list 2019-03-23T00:53:54+0000 weekly 0.8 https://www.iqanda-cme.com/flexpaper/fourier-further-cardiovascular-outcomes-research-with-pcsk9-inhibition-in-subjects-with-elevated-risk 2019-04-09T22:23:45+0000 weekly 0.8 https://www.iqanda-cme.com/flexpaper/nla-expert-panel-pcsk9-recommendations 2019-03-12T01:33:11+0000 weekly 0.8 https://www.iqanda-cme.com/flexpaper/2016-esc/eas-guidelines-for-the-management-of-dyslipidaemias 2019-03-12T01:27:02+0000 weekly 0.8 https://www.iqanda-cme.com/flexpaper/infographic-nla-expert-panel-pcsk9-recommendations 2019-03-12T01:33:27+0000 weekly 0.8